
<html lang="en"     class="pb-page"  data-request-id="fca60da8-c37d-4225-90ae-2aa5b1de59c6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2018.61.issue-10;requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.7b00969;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Relevance of Half-Life in Drug Design" /></meta><meta name="dc.Creator" content="Dennis&#xA;A.  Smith" /></meta><meta name="dc.Creator" content="Kevin  Beaumont" /></meta><meta name="dc.Creator" content="Tristan S.  Maurer" /></meta><meta name="dc.Creator" content="Li  Di" /></meta><meta name="dc.Description" content="Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state. A half-life of 12–48 h is generally ideal for once daily dosing of oral drugs. If the half..." /></meta><meta name="Description" content="Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state. A half-life of 12–48 h is generally ideal for once daily dosing of oral drugs. If the half..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 7, 2017" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00969" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00969" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00969" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00969" /></link>
        
    
    

<title>Relevance of Half-Life in Drug Design | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00969" /></meta><meta property="og:title" content="Relevance of Half-Life in Drug Design" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0008.jpeg" /></meta><meta property="og:description" content="Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state. A half-life of 12–48 h is generally ideal for once daily dosing of oral drugs. If the half-life is too short, it may require more frequent dosing in order to maintain desired exposures and avoid unnecessarily high peak concentrations. This may pose challenges to achieving optimal efficacy, safety, and patient compliance. If the half-life is too long, the time over which accumulation and subsequent elimination occur may be prolonged. This may pose problems with managing adverse effects and the design of efficient clinical trials. Half-life is a key parameter for optimization in research and development. Structural modification to affect clearance, and to a lesser extent volume of distribution, is the preferred means of modulating half-life. An effective approach to half-life optimization requires an understanding of the many pitfalls associated with its estimation and interpretation." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state. A half-life of 12–48 h is generally ideal for once daily dosing of oral drugs. If the half-life is too short, it may require more frequent dosing in order to maintain desired exposures and avoid unnecessarily high peak concentrations. This may pose challenges to achieving optimal efficacy, safety, and patient compliance. If the half-life is too long, the time over which accumulation and subsequent elimination occur may be prolonged. This may pose problems with managing adverse effects and the design of efficient clinical trials. Half-life is a key parameter for optimization in research and development. Structural modification to affect clearance, and to a lesser extent volume of distribution, is the preferred means of modulating half-life. An effective approach to half-life optimization requires an understanding of the many pitfalls associated with its estimation and interpretation." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0008.jpeg" /></meta><meta name="twitter:title" content="Relevance of Half-Life in Drug Design" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00969"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00969">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00969&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00969&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00969&amp;href=/doi/10.1021/acs.jmedchem.7b00969" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4273-4282</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.7b01120" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Relevance of Half-Life in Drug Design</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Dennis A. Smith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dennis A. Smith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Cambridge, Massachusetts 02139, United States</div><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dennis%0AA.++Smith">Dennis A. Smith</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kevin Beaumont</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kevin Beaumont</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Beaumont">Kevin Beaumont</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tristan S. Maurer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tristan S. Maurer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tristan+S.++Maurer">Tristan S. Maurer</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Li Di</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li Di</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 860-715-6172. E-mail: <a href="/cdn-cgi/l/email-protection#036f6a2d676a4373656a7966712d606c6e"><span class="__cf_email__" data-cfemail="7d11145319143d0d1b1407180f531e1210">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li++Di">Li Di</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6117-9022" title="Orcid link">http://orcid.org/0000-0001-6117-9022</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00969&amp;href=/doi/10.1021%2Facs.jmedchem.7b00969" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4273–4282</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 7, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 June 2017</li><li><span class="item_label"><b>Published</b> online</span>7 November 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 May 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00969" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00969</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4273%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDennis%250AA.%2BSmith%252C%2BKevin%2BBeaumont%252C%2BTristan%2BS.%2BMaurer%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D10%26contentID%3Dacs.jmedchem.7b00969%26title%3DRelevance%2Bof%2BHalf-Life%2Bin%2BDrug%2BDesign%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4282%26publicationDate%3DMay%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00969"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">11916</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">33</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00969" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Relevance of Half-Life in Drug Design&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Dennis\nA.&quot;,&quot;last_name&quot;:&quot;Smith&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Beaumont&quot;},{&quot;first_name&quot;:&quot;Tristan&quot;,&quot;last_name&quot;:&quot;S. Maurer&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Di&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;4273-4282&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00969&quot;},&quot;abstract&quot;:&quot;Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state. A half-life of 12–48 h is generally ideal for once daily dosing of oral drugs. If the half-life is too short, it may require more frequent dosing in order to maintain desired exposures and avoid unnecessarily high peak concentrations. This may pose challenges to achieving optimal efficacy, safety, and patient compliance. If the half-life is too long, the time over which accumulation and subsequent elimination occur may be prolonged. This may pose problems with managing adverse effects and the design of efficient clinical trials. Half-life is a key parameter for optimization in research and development. Structural modification to affect clearance, and to a lesser extent volume of distribution, is the preferred means of modulating half-life. An effective approach to half-life optimization requires an understanding of the many pitfalls associated with its estimation and interpretation.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00969&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00969" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00969&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00969" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00969&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00969" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00969&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00969&amp;href=/doi/10.1021/acs.jmedchem.7b00969" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00969" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00969" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00969%26sid%3Dliteratum%253Aachs%26pmid%3D29112446%26genre%3Darticle%26aulast%3DSmith%26date%3D2018%26atitle%3DRelevance%2Bof%2BHalf-Life%2Bin%2BDrug%2BDesign%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D10%26spage%3D4273%26epage%3D4282%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291342" title="Absorption">Absorption</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a>,</li><li><a href="/action/doSearch?ConceptID=291089" title="Plasma">Plasma</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/10" title="Go to Volume 61, Issue 10"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/jmcmar.2018.61.issue-10/20180524/jmcmar.2018.61.issue-10.largecover.jpg" alt="Go to Volume 61, Issue 10"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state. A half-life of 12–48 h is generally ideal for once daily dosing of oral drugs. If the half-life is too short, it may require more frequent dosing in order to maintain desired exposures and avoid unnecessarily high peak concentrations. This may pose challenges to achieving optimal efficacy, safety, and patient compliance. If the half-life is too long, the time over which accumulation and subsequent elimination occur may be prolonged. This may pose problems with managing adverse effects and the design of efficient clinical trials. Half-life is a key parameter for optimization in research and development. Structural modification to affect clearance, and to a lesser extent volume of distribution, is the preferred means of modulating half-life. An effective approach to half-life optimization requires an understanding of the many pitfalls associated with its estimation and interpretation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51018" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51018" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Half-life (<i>t</i><sub>1/2</sub>) is a useful parameter to put a rate of decline into an intuitive numerical context. The term was initially coined by Nobel Laureate Ernest Rutherford in the study of radioactive decay, and this area of application remains the most common in the popular press. From a drug discovery perspective, <i>t</i><sub>1/2</sub> is defined as the time required for the concentration of a drug (typically in blood or plasma) to reduce to half of its initial value when the concentrations of the drug are in simple exponential (log–linear) decline. Despite its relatively simple visualization and mathematical derivation, the role of <i>t</i><sub>1/2</sub> in drug discovery and development is surprisingly complex. In our recent review on volume of distribution,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> the importance of drug distribution in defining <i>t</i><sub>1/2</sub> was exemplified, as this is likely to be the major determinant of dosing frequency for many drugs. For ease of administration, orally delivered small molecule drugs are often required to be dosed on a once daily basis. Since the duration of pharmacodynamic (PD) effect will be determined, in part, by the duration of exposure, <i>t</i><sub>1/2</sub> is often a critical parameter in drug design. When considering a design effort to optimize <i>t</i><sub>1/2</sub>, there are several key questions that need to be understood, namely:<ul class="NLM_list-list_type-bullet" id="list1"><li><p class="inline">What is the optimal <i>t</i><sub>1/2</sub> to support once daily administration?</p></li><li><p class="inline">How can <i>t</i><sub>1/2</sub> be modulated?</p></li><li><p class="inline">What are the important considerations in measuring <i>t</i><sub>1/2</sub> during compound optimization?</p></li></ul>This manuscript will provide a review and perspective of <i>t</i><sub>1/2</sub> in the context of these generally relevant drug design questions.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Basic Concepts, Relevance to Drug Design and Optimal Space</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06712" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06712" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The classical one compartment pharmacokinetic (PK) model provides a simple and generally applicable framework within which to consider the relevance of <i>t</i><sub>1/2</sub> to drug design (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a). In this model, a dose can be administered directly via iv bolus (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b and <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>c) or absorbed via a first order rate (<i>k</i><sub>a</sub>) following oral dosing (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>d and <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>e). Drug is eliminated via another first order rate constant (<i>k</i><sub>el</sub>) which determines the <i>t</i><sub>1/2</sub> of the drug under conditions in which the rate of absorption is more rapid than the rate of elimination. Under this condition, <i>k</i><sub>el</sub> can be estimated from the slope obtained after plotting the log<sub>10</sub> of concentration versus time as indicated in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>c and <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>e. The <i>k</i><sub>el</sub> parameter determines the <i>t</i><sub>1/2</sub> of a drug according to <a class="ref internalNav" href="#eq1" aria-label="eq 1">eq 1</a>.<span class="NLM_disp-formula" id="eq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m001.gif" alt="" id="_i4" /></img><span class="labelSpan">(1)</span></span></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Basic characteristics of a one compartment PK model. Panel A illustrates the model structure shown with first order absorption and elimination rates. Panels b and c illustrate the characteristic exponential decline following iv bolus administrations. Panels d and e illustrate the absorptive phase followed by monoexponential decline that is typical following oral administration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><i>t</i><sub>1/2</sub> is an important determinant in almost every aspect of a PK profile. Given the fixed relationship between <i>t</i><sub>1/2</sub> and <i>k</i><sub>el</sub>, its relevance can be seen throughout the equations of <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> (keeping in mind that each instance of <i>k</i><sub>el</sub> is exactly equivalent to ln(2)/<i>t</i><sub>1/2</sub>). For example, dose requirements to achieve a steady-state maximum or minimum target exposure will be related to the <i>t</i><sub>1/2</sub> through <i>k</i><sub>el</sub>. In addition, as a rule of thumb, the time to steady-state exposure will require 3–5 <i>t</i><sub>1/2</sub> of multiple dosing. <i>t</i><sub>1/2</sub> is also related to the extent of steady-state accumulation through its relationship to <i>k</i><sub>el</sub>. Other determinants include the absorption rate and dosing frequency as depicted in the somewhat complex equation for <i>R</i> in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. An important concept here is that accumulation will increase as <i>t</i><sub>1/2</sub> becomes a larger fraction of the target dose interval (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). In contrast, <i>t</i><sub>1/2</sub> is not a determinant of steady-state average concentrations (<i>C</i><sub>avg,ss</sub>; see equations in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a><a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a>). However, on a practical level, <i>t</i><sub>1/2</sub> remains an important consideration even when targeting a <i>C</i><sub>avg,ss</sub>. Perhaps the most important aspect to consider in this regard is the relationship of <i>t</i><sub>1/2</sub> to steady-state peak-to-trough exposure ratio (<i>P</i>/<i>T</i><sub>ss</sub>). <i>t</i><sub>1/2</sub> values that are short relative to a desired dosing interval (Tau) will potentially incur safety risks due to large swings in exposure around the target steady-state average exposure. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B, while the <i>C</i><sub>avg,ss</sub> remains constant, <i>P</i>/<i>T</i><sub>ss</sub> increases exponentially as <i>t</i><sub>1/2</sub> becomes a smaller fraction of the Tau. This figure is semigeneralized for a one compartment model in that it is universal under the assumption that <i>k</i><sub>a</sub> is 1.8/h (providing for <i>T</i><sub>max</sub> values between 1 and 2 h). As such, a molecule dosed once daily with a <i>t</i><sub>1/2</sub> value of 4 h (<i>t</i><sub>1/2</sub>/Tau = 0.17), is expected to have a <i>P</i>/<i>T</i><sub>ss</sub> ratio greater than 40 (log P/T<sub>ss</sub> > 1.6). Such large swings in drug exposure around a target <i>C</i><sub>avg,ss</sub> bring the potential for safety-related issues (due to unnecessarily high maximal concentrations). In addition, large swings around a target <i>C</i><sub>avg,ss</sub> can result in suboptimal efficacy. This arises from the fact that target binding and modulation are inherently nonlinear processes, resulting in a disconnect between average exposure and average PD effect as <i>t</i><sub>1/2</sub> decreases. This disconnect is again illustrated in a semigeneralized way (assuming a <i>k</i><sub>a</sub> of 1.8/h and the simple sigmoidal <i>E</i><sub>max</sub> PD model) in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. In this case, the impact is greater when targeting higher EC<sub>xx</sub> values. For example, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> shows that a molecule dosed once daily with a <i>t</i><sub>1/2</sub> value of 4 h (<i>t</i><sub>1/2</sub>/Tau = 0.17) is expected to achieve an average effect of 17%, 39%, 65%, and 78% despite maintaining <i>C</i><sub>avg,ss</sub> values equivalent to EC<sub>20</sub>, EC<sub>50</sub>, EC<sub>80</sub>, and EC<sub>90</sub>, respectively. The disconnect becomes larger as <i>t</i><sub>1/2</sub> continues to decrease to 2 h, with an average effect being approximately 50% at a <i>C</i><sub>avg,ss</sub> value equivalent to the EC<sub>90</sub>. As such, regardless of whether the target exposure is <i>C</i><sub>min,ss</sub>, <i>C</i><sub>avg,ss</sub>, or <i>C</i><sub>max,ss</sub>, <i>t</i><sub>1/2</sub> is an important aspect to consider in drug design as it will influence dose requirements and therapeutic index in the manner discussed above. Although other properties (e.g., intrinsic potency and safety) preclude the establishment of absolute values, the relationships described above support a common design rule of thumb that <i>t</i><sub>1/2</sub> should be no less than 25% of the intended dose interval in order to maintain the desired PD effect and minimize <i>P</i>/<i>T</i><sub>ss</sub>. While increasing <i>t</i><sub>1/2</sub> is a common design goal, it is important to note that exceedingly long <i>t</i><sub>1/2</sub> can also have untoward implications. For example, the number of doses required to reach a specified fraction of target steady-state levels increases as <i>t</i><sub>1/2</sub> increases. As such, <i>t</i><sub>1/2</sub> values that are exceedingly long can pose issues to rapidly achieving target concentrations in clinical trials and in the therapeutic setting. Likewise, the time it takes to wash drug out (<i>T</i><sub>wash</sub>) by a specified fraction (<i>f</i><sub>el</sub>) also increases as <i>t</i><sub>1/2</sub> increases (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). For example, the time it takes to wash out (<i>T</i><sub>wash</sub>) 50%, 75%, and 90% (<i>f</i><sub>el</sub> = 0.5, 0.75, and 0.9) of a drug with a 48 h <i>t</i><sub>1/2</sub> is 48, 96, and 160 h, respectively. Here, <i>t</i><sub>1/2</sub> values that are exceedingly long can pose problems in managing adverse effects as they arise. For these reasons, it is generally desirable to target half-lives that are no more than 48 h for once daily dosing. It is also difficult to run crossover studies when the drug <i>t</i><sub>1/2</sub> is long. In some cases, however, longer terminal <i>t</i><sub>1/2</sub> may result from slow but extensive distribution into and out of particular tissues. The extreme example of prolonged <i>t</i><sub>1/2</sub> of this nature is seen with the oral bisphosphonates. These drugs avidly bind to their therapeutic target which is bone. After oral absorption, the apparent clearance from plasma is rapid by binding to bone quasi-reversibly and excretion by the kidney (20–80%). Alendronate, for example, has an initial volume of distribution excluding bone of 0.4 L/kg and a plasma clearance of 10 mL min<sup>–1</sup> kg<sup>–1</sup> indicative of active secretion in the kidney.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> After bone uptake, the return of the drug to the circulation is controlled by the resorption of the bone. This renders the terminal <i>t</i><sub>1/2</sub> of bisphosphonates very long (5–10 years). Drug is not detectable in plasma during this period, but the long <i>t</i><sub>1/2</sub> can be determined by monitoring the excretion of the drug in urine. In PK terms, the system has moderate clearance but the affinity for bone leads to a remarkably high volume of distribution (approximately 70 000 L/kg) and leading to long <i>t</i><sub>1/2</sub>. Another similar example was observed during the development of the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib; the terminal <i>t</i><sub>1/2</sub> in healthy volunteers and patients increased with increasing length of exposure.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Initially thought to have a clinical <i>t</i><sub>1/2</sub> of around 60 h, long-term studies showed residual concentrations of anacetrapib remain significantly elevated after the cessation of therapy. Twelve weeks after stopping treatment of anacetrapib, plasma concentrations were approximately half the on-treatment levels. In a small subset of patients, anacetrapib was detectable in plasma as late as 4 years after the last dose. The lipophilicity of the compound prompted further preclinical studies which illustrated that white fat retention, rather than brown fat retention, was the probable source of the long <i>t</i><sub>1/2</sub>.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Not surprisingly simple PK reveals why long-term therapy exposes the long terminal <i>t</i><sub>1/2</sub>. If 12 weeks is a broad estimate of the terminal <i>t</i><sub>1/2</sub> and it relates to redistribution from white fat, then steady state concentrations of anacetrapib will not be achieved in white fat until approximately 1 year of dosing (approximately 4-fold the terminal or white fat <i>t</i><sub>1/2</sub>). Amiodarone is another drug that accumulates into white fat and exhibits a long terminal <i>t</i><sub>1/2</sub>.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9">(6−9)</a> The difficulty of measuring the long <i>t</i><sub>1/2</sub> of multiphasic compounds in short studies (single doses) is illustrated by the variation in <i>t</i><sub>1/2</sub> values quoted. Initially values of 4 and 17 h were published for the <i>t</i><sub>1/2</sub> following iv and oral administration. Subsequent publications have described the <i>t</i><sub>1/2</sub> as 35 h before a more realistic value of around 40 days. On long-term therapy, it is probably nearer 100 days. A study after chronic dosing in rabbits showed that amiodarone total concentrations were the highest in fat tissue followed by lung, liver, and muscle, with the lowest concentration in serum and only traces in the brain.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Interestingly, the active metabolite desethylamiodarone had similar concentrations in liver, lung, and kidney to the parent drug but lower accumulation in fat tissue. The problems with <i>t</i><sub>1/2</sub> determination lead to similar huge variation in volume of distribution with values from 0.9 and 148 L/kg, with the latter probably the most accurate estimate.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Key Equations That Characterize the One-Compartment PK Model<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a><sup>,</sup><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">equation</th></tr></thead><tbody><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" align="left" valign="middle"><i>C</i>(<i>t</i>)<sub>ss</sub>, steady-state concentration at time <i>t</i></td><td class="colsep0 rowsep0" align="left" valign="middle"><span class="NLM_inline-formula"><img class="imgWithoutFigViewer inline-formula-styles" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m009.gif" alt="" id="_i6" /></img></span></td></tr><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" align="left" valign="middle"><i>C</i><sub>max,ss</sub>, steady-state maximum concentration</td><td class="colsep0 rowsep0" align="left" valign="middle"><span class="NLM_inline-formula"><img class="imgWithoutFigViewer inline-formula-styles" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m010.gif" alt="" id="_i7" /></img></span></td></tr><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" align="left" valign="middle">C<sub>min,ss</sub>, steady-state minimum concentration</td><td class="colsep0 rowsep0" align="left" valign="middle"><span class="NLM_inline-formula"><img class="imgWithoutFigViewer inline-formula-styles" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m011.gif" alt="" id="_i8" /></img></span></td></tr><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" align="left" valign="middle"><i>C</i><sub>avg,ss</sub>, steady-state average concentration</td><td class="colsep0 rowsep0" align="left" valign="middle"><span class="NLM_inline-formula"><img class="imgWithoutFigViewer inline-formula-styles" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m012.gif" alt="" id="_i9" /></img></span></td></tr><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" align="left" valign="middle"><i>t</i><sub>max,ss</sub>, steady-state postdosing time at which maximum concentration occurs</td><td class="colsep0 rowsep0" align="left" valign="middle"><span class="NLM_inline-formula"><img class="imgWithoutFigViewer inline-formula-styles" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m013.gif" alt="" id="_i10" /></img></span></td></tr><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" align="left" valign="middle"><i>R</i>, steady state accumulation at postdosing time <i>t</i></td><td class="colsep0 rowsep0" align="left" valign="middle"><span class="NLM_inline-formula"><img class="imgWithoutFigViewer inline-formula-styles" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m014.gif" alt="" id="_i11" /></img></span></td></tr><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" align="left" valign="middle"><i>P</i>/<i>T</i><sub>ss</sub>, steady-state peak-to-trough concentration ratio</td><td class="colsep0 rowsep0" align="left" valign="middle"><span class="NLM_inline-formula"><img class="imgWithoutFigViewer inline-formula-styles" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m015.gif" alt="" id="_i12" /></img></span></td></tr><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" align="left" valign="middle"><i>T</i><sub>wash</sub>, the time it takes to “wash out” a specified fraction (<i>f</i><sub>el</sub>) of the drug concentration after sessation of dosing</td><td class="colsep0 rowsep0" align="left" valign="middle"><span class="NLM_inline-formula"><img class="imgWithoutFigViewer inline-formula-styles" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m016.gif" alt="" id="_i13" /></img></span></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">All relationships correspond to a one compartment pharmacokinetic model. <i>F</i><sub>po</sub>, <i>D</i><sub>po</sub>, <i>V</i><sub>ss</sub>, CL, and Tau represent oral bioavailability, oral dose, steady-state volume of distribution, clearance rate, and dosing interval, respectively. <i>k</i><sub>el</sub> and <i>k</i><sub>a</sub> represent the first order rates of elimination and absorption.</p></div></div></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Semigeneralized relationships of the extent of steady-state accumulation (A) and peak-to-trough concentration ratio (B) (plotted as log <i>P</i>/<i>T</i><sub>ss</sub> values) to half-life-to-dose interval ratio (<i>t</i><sub>1/2</sub>/Tau). Relationships were simulated using the corresponding <i>R</i>(<i>t</i>) and <i>P</i>/<i>T</i><sub>ss</sub> equations in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and assuming an absorption rate of 1.8/h. (A) Accumulation (as calculated as the ratio of AUC at steady state to AUC following a single dose) increases as the <i>t</i><sub>1/2</sub> becomes a smaller fraction of the target dose interval. (B) While the steady-state average concentration is constant, <i>P</i>/<i>T</i><sub>ss</sub> increases exponentially as <i>t</i><sub>1/2</sub> becomes a smaller fraction of the target dose interval.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Semigeneralized relationship between average pharmacodynamics effect (expressed as a fraction of maximal) and half-life-to-dose interval ratio (<i>t</i><sub>1/2</sub>/Tau). Relationship was simulated using the <i>C</i>(<i>t</i>)<sub>ss</sub> equation of <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> assuming a <i>k</i><sub>a</sub> of 1.8/h. Simulations depict four dosing levels designed to deliver <i>C</i><sub>avg,ss</sub> values equivalent to arbitrarily selected EC<sub>20</sub>, EC<sub>50</sub>, EC<sub>80</sub>, and EC<sub>90</sub> values. Actual average effect was calculated as the dose interval normalized AUC under an effect curve defined by (100 × <i>C</i>(<i>t</i>)<sub>ss</sub>)/(<i>C</i>(<i>t</i>)<sub>ss</sub> + EC<sub>50</sub>). Volume was varied in order to affect <i>t</i><sub>1/2</sub>/Tau while maintaining a constant C<sub>avg,ss</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3-1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Optimization of Half-Life. Volume and Clearance Modulation</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12011" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12011" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Keeping with the one-compartmental model, <i>t</i><sub>1/2</sub> can be appreciated in terms of its determinants (<a class="ref internalNav" href="#eq2" aria-label="eq 2">eq 2</a>).<span class="NLM_disp-formula" id="eq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m002.gif" alt="" id="_i15" /></img><span class="labelSpan">(2)</span></span>From this relationship, it is clear that <i>t</i><sub>1/2</sub> will be proportional to volume and inversely proportional to clearance. In turn, <a class="ref internalNav" href="#eq3" aria-label="eqs 3">eqs 3</a> and <a class="ref internalNav" href="#eq4" aria-label="4">4</a> provide conceptually useful information regarding the common physiological determinants of <i>V</i><sub>ss</sub> and CL. In these equations, fu<sub>p</sub>, fu<sub>t</sub>, <i>V</i><sub>p</sub>, and <i>V</i><sub>t</sub> represent the unbound fraction in plasma, unbound fraction in tissue, volume of the plasma, and volume of the tissue, respectively. Further, in the depicted well stirred model of hepatic clearance, Qh, and CL<sub>int</sub> represent the hepatic blood flow and intrinsic clearance, respectively. As covered in our previous review, <i>V</i><sub>ss</sub> is most sensitive to ionization state with acids typically displaying low volumes (high binding to albumin in plasma, low fu<sub>p</sub>) and bases displaying higher volumes (high partitioning to acidic phospholipids in tissues, low fu<sub>t</sub>). This has important implications for design, as the requisite clearance values in order to achieve a particular <i>t</i><sub>1/2</sub> will often depend on ionization state for this reason. For example, in order to achieve a <i>t</i><sub>1/2</sub> of 12 h, acids (<i>V</i><sub>ss</sub> ≈ 0.2 L/kg), neutrals (<i>V</i><sub>ss</sub> ≈ 1 L/kg), and bases (<i>V</i><sub>ss</sub> ≈ 4 L/kg) will typically require clearances at least as low as 0.2, 1, and 4 mL min<sup>–1</sup> kg<sup>–1</sup>, respectively (1%, 5%, and 20% of human hepatic blood flow, respectively).<span class="NLM_disp-formula" id="eq3"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m003.gif" alt="" id="_i16" /></img><span class="labelSpan">(3)</span></span><span class="NLM_disp-formula" id="eq4"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m004.gif" alt="" id="_i17" /></img><span class="labelSpan">(4)</span></span></div><div class="NLM_p">Optimization of CL<sub>int</sub> is often the primary focus in design efforts to improve <i>t</i><sub>1/2.</sub> For oxidative metabolism, CL<sub>int</sub> is relatively easily measured in liver microsomes or hepatocytes in high throughput in vitro systems which facilitate an efficient development of structure–activity relationships (SARs). In addition, because it is also a determinant of <i>C</i><sub>avg,ss</sub> and hepatic extraction, optimization efforts focused on CL<sub>int</sub> are also likely to pay additional dividends with respect to dose optimization.</div><div class="NLM_p last">While tempting when looking at <i>V</i><sub>ss</sub> or CL in isolation, optimization of <i>t</i><sub>1/2</sub> through changes in plasma protein binding is not generally a productive endeavor. As can be seen in <a class="ref internalNav" href="#eq3" aria-label="eqs 3">eqs 3</a> and <a class="ref internalNav" href="#eq4" aria-label="4">4</a>, decreases in fu<sub>p</sub> may improve clearance but may also reduce <i>V</i><sub>ss</sub>. Likewise, increases in fu<sub>p</sub> may improve <i>V</i><sub>ss</sub> but will also tend to increase clearance. Consequently, modulation of plasma protein binding cannot modulate <i>t</i><sub>1/2</sub>, unless clearance is reduced or <i>V</i><sub>ss</sub> increased independent of the modulation of fraction unbound. It is a common misconception that reducing plasma protein binding can result in longer <i>t</i><sub>1/2</sub>. Generally, in order to reduce plasma protein binding, lipophilicity is reduced. It is well-known that reducing lipophilicity is likely to reduce intrinsic metabolic clearance with an overall reduction of the clearance of a molecule. It is this reduction in metabolic clearance that drives any <i>t</i><sub>1/2</sub> improvement, not the reduction in plasma protein binding. The impact of plasma protein binding on drug disposition has been thoroughly reviewed previously.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a></div></div><div id="sec3-2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Modified Release Formulations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11362" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11362" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Another option for extending <i>t</i><sub>1/2</sub> is the use of modified release formulations (MR). Such formulations can effectively extend the PK <i>t</i><sub>1/2</sub> of molecules with suboptimal values by providing for sustained release along the intestinal tract. This has been successfully used in a number of marketed drugs.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16">(13−16)</a> The principles of dose size and frequency of administration as well as the potential value of MR formulations were demonstrated early using the two calcium channel blockers nifedipine and amlodipine (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).<a onclick="showRef(event, 'ref1 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref1 ref17 ref18 ref19 ref20">(1,17−20)</a> Amlodipine exhibits <i>t</i><sub>1/2</sub> value that is amenable to once daily (QD) administration.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The short <i>t</i><sub>1/2</sub> of nifedipine necessitated a 3 times daily (TID) dose regimen. Nifedipine was eventually developed as a slow release formulation (zero order) termed nifedipine gastrointestinal therapeutic system (GITS) to allow once a day administration with doses of 30 and 60 mg.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> A more recent example of the application of modified release to extend the <i>t</i><sub>1/2</sub> and reduce dose frequency is the extended release formulation of tofacitinib.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Tofacitinib is JAK inhibitor with a human <i>t</i><sub>1/2</sub> of 3 h. It is presented as an immediate release tablet formulation with a dose of 5 mg twice daily. A modified release device using an extrudable core system (ECS) has been developed that drives similar AUC to 5 mg twice daily with an 11 mg once daily device. Although a thorough review of the practical considerations for solving <i>t</i><sub>1/2</sub> issues with this technology is beyond the scope of this manuscript, it is important to point out that there are limitations to what this technology can achieve. Generally, the compound must have a degree of aqueous solubility and relative rapid dissolution, since released drug will need to dissolve rapidly under all environments encountered in the human gastrointestinal (GI) tract. Membrane permeability also needs to be sufficient to allow for rapid absorption of dissolved compound across the GI tract wall. Finally, affinity for efflux transporters at the wall of the GI tract needs to be minimized. Generally, immediate release devices present very high drug concentrations to the upper GI tract which are capable of saturating any potential efflux mechanism. Modified release devices steadily present much lower concentration throughout the GI tract, which may be below those required to saturate efflux proteins in the GI tract. Aqueous solubility, permeability, and efflux transport are important considerations for MR, since the drug needs to be as well absorbed in the colon as it is in the small intestine. The human colon has less fluid, a lower surface area for absorption, and higher expression of efflux transporters (such as P-glycoprotein) than the small intestine. Finally, due to the need for excipients to drive MR, the drug loading (dose) for a MR device needs to be limited. Thus, potency and clearance properties of a candidate for MR need to be optimized to maintain dose requirements.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Comparison of Nifedipine and the Long <i>t</i><sub>1/2</sub> Calcium Channel Blocker Amlodipine<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>av,u</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>int,u</sub> (mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">daily dose (mg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nifedipine</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">175</td><td class="colsep0 rowsep0" align="left">10 TID</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">amlodipine</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">85</td><td class="colsep0 rowsep0" align="left">5–10 QD</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup><sup>a</sup></sup><p class="last">Daily dose size reflects the potency (IC<sub>50</sub>) and CL<sub>int,u</sub> of the drugs. Dose frequency reflects the <i>t</i><sub>1/2</sub>.</p></div></div></div></div><div id="sec3-3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Prodrug Approach</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74424" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74424" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Finally, because a number of drugs generate long-lived active metabolites and therefore act as (accidental) prodrugs, the idea of adding a promoiety to a promising molecule that lacks duration due to a short <i>t</i><sub>1/2</sub> is regularly raised. This is not likely to be successful for the following reasons:<table class="listgroup" border="0" width="95%" id="list2" list-type="label"><tr class="li1"><td valign="top">(1)</td><td colspan="5" valign="top" class="paragraph"><p class="last">The design of optimal prodrugs from a preclinical perspective is difficult. In vitro assays need to be available in preclinical species and human to examine intestinal, hepatic, and extrahepatic hydrolysis of the prodrug moiety to the active drug. Preclinical species can modulate the prodrug to a significantly different extent to humans, making extrapolation and prediction fraught with difficulty.</p></td></tr><tr class="li1"><td valign="top">(2)</td><td colspan="5" valign="top" class="paragraph"><p class="last">If the short <i>t</i><sub>1/2</sub> of the active drug is due to high unbound intrinsic clearance or total clearance, the total daily dose of the prodrug is likely to be very high, even if there is extensive conversion of the promoiety to the active drug.</p></td></tr><tr class="li1"><td valign="top">(3)</td><td colspan="5" valign="top" class="paragraph"><p class="last">The rate of metabolism of the prodrug to the active drug must be slow, and this raises the likelihood of nonproductive clearance of the prodrug by metabolism via other routes or other mechanisms leading to the need for higher doses to compensate.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></p></td></tr></table></div></div><div id="sec4-1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Pitfalls in Half-Life Optimization. “Flip-Flop” Kinetics</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74664" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74664" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Most drugs are absorbed at a rate (<i>k</i><sub>a</sub>) that exceeds the elimination rate (<i>k</i><sub>el</sub>). In this circumstance, the observed <i>t</i><sub>1/2</sub> is defined as previously described in <a class="ref internalNav" href="#eq1" aria-label="eqs 1">eqs 1</a> and <a class="ref internalNav" href="#eq2" aria-label="2">2</a>. However, in certain circumstances, the rate of absorption can be slower than the rate of elimination, resulting in a <i>t</i><sub>1/2</sub> which is determined by the rate of absorption rather than the rate of elimination. This phenomenon, known as “flip-flop” kinetics, can occur when dealing with molecules that have particularly poor permeability or solubility. In these cases, the <i>t</i><sub>1/2</sub> following oral administration may exceed that observed following iv dosing due to absorption or dissolution rate-limited absorption. This phenomenon is not uncommon in preclinical PK studies (particularly in rodents) on molecules with suboptimal PK properties in the course of research and development. There are several pitfalls that arise in this situation. For example, as a compound progresses in development, formulations may improve the dissolution rate, and hence the <i>t</i><sub>1/2</sub> value will collapse to that defined by elimination. In addition, accumulation will often be much less than predicted from an oral <i>t</i><sub>1/2</sub> in this circumstance. This results from the fact that there is a discrete window of time over which <i>k</i><sub>a</sub> is operational as determined by the physiological intestinal transit times and physiochemical drug properties. Further, this highlights the limitation of empirical compartmental PK models which do not explicitly account for such physiological limitations and may lead to erroneous expectations when these limitations are not properly considered in experimental design and interpretation. Finally, attention to oral <i>t</i><sub>1/2</sub> in this circumstance can lead to a misprioritization in favor of less soluble or poorly permeable molecules that will ultimately suffer from absorption challenges in the clinic where formulation options are more limited (e.g., limited absolute bioavailability with an associated high degree of inter and intrasubject variability). A much more appropriate use of “flip-flop” kinetics to extend <i>t</i><sub>1/2</sub> is the use of modified-release formulations.</div><div class="NLM_p">Often PK data are extrapolated to infinity using the apparent terminal <i>t</i><sub>1/2</sub>. This is an exercise in which the concentration in the last time point collected is divided by the apparent <i>k</i><sub>el</sub> value (typically determined though regression of last few data points) in order to infer the remainder of the AUC not explicitly measured through infinite collection of samples. When the oral <i>t</i><sub>1/2</sub> exceeds the iv one, there is a dilemma. Extrapolating to infinity with the oral <i>t</i><sub>1/2</sub> is using potentially the <i>k</i><sub>a</sub> and not the <i>k</i><sub>el</sub> in preclinical species, which may not be the case in the human situation leading to much shorter <i>t</i><sub>1/2</sub>.</div><div class="NLM_p last">Here, it is worth pointing out that the <i>t</i><sub>1/2</sub> of metabolite can be equally confounded by formation-rate-limited disposition (analogous to “flip-flop” kinetics) when the rate of formation from parent is slower than the rate of metabolite elimination.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Thus, a metabolite may, if administered discretely, show a shorter <i>t</i><sub>1/2</sub> than parent, but when the parent is administered, the decline of the metabolite will parallel that of the parent. Consequently, the <i>t</i><sub>1/2</sub> of a metabolite when derived from administration of a parent compound can never be shorter than that of the parent. Of course, some metabolites can possess longer <i>t</i><sub>1/2</sub> values than the parent, normally due to their being more stable than the parent to metabolic processes, or they exhibit <i>V</i><sub>ss</sub> greater than the parent. Prime examples are the N-dealkylation reactions of tertiary amines where the generated metabolites exhibit lower intrinsic clearance by subsequent metabolism combined with potentially higher <i>V</i><sub>ss</sub> values.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Dose-Dependent Half-Lives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82151" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82151" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Dose-dependent PK usually occurs due to saturation of absorption or clearance processes as doses are increased. The most common dose-dependent processes observed are saturation of clearance in preclinical toxicity studies, where doses are high. In many low dose PK studies, the unbound concentrations of drug are likely to be below the <i>K</i><sub>m</sub> (e.g., substrate concentration that gives half maximal velocity of transport or metabolism) for the clearance process. Under these conditions, the parameters of clearance and <i>t</i><sub>1/2</sub> will be dose independent (i.e., will not change with increasing doses). However, if doses are used that drive to unbound concentrations that exceed the <i>K</i><sub>m</sub>, then the PK will change from first order to zero order processes. If the dose is high enough for zero order kinetics to be observed, the plot of <i>C</i><sub>p</sub> versus time will be linear and a log<sub>10</sub> <i>C</i><sub>p</sub> against time will be curvilinear. Once concentrations fall below the <i>K</i><sub>m,</sub> the normal linear decline is observed for the log<sub>10</sub> <i>C</i><sub>p</sub> against time curve. Therefore, clearance will decrease and <i>t</i><sub>1/2</sub> will increase with increasing dose (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Consequently, it is important that PK studies which are extrapolated to the clinical situation are completed at doses that generate unbound plasma concentrations below the <i>K</i><sub>m</sub> of the rate-determining clearing process. In rare instances, nonlinear pharmacokinetics may result from saturation of plasma protein binding. In these cases, concentrations exceeding the binding capacity of plasma proteins lead to higher free fractions which, in turn, will increase clearance and increase volume of distribution (all else being equal). The potential for this phenomenon should be considered in circumstances where plasma drug concentrations approach physiological levels of the major binding proteins in plasma (e.g., ∼15 μM and 600 μM for α<sub>1</sub>-acid glycoprotein and albumin, respectively). Valproic acid is an example of a drug associated with therapeutic exposures in this range (total plasma concentrations of ∼350–700 μM) and which also exhibits saturable protein binding and nonlinear clearance. In other, more complex situations, saturable tissue binding may occur. In these cases, a decrease in volume of distribution may be seen at concentrations that begin to saturate tissue binding.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plasma concentration versus time curve for a compound following escalating oral administration exhibiting dose-dependent (nonlinear) PK due to saturation of clearance with increasing dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Multicompartmental PK Profiles</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03506" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03506" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the above discussion, a one compartmental model, which provides for a monoexponential decline in drug concentration, was assumed in order to discuss basic concepts related to the <i>t</i><sub>1/2</sub>. This one compartment situation requires essentially instantaneous (or very rapid) distribution of a compound into tissues. In the case of most acidic drugs, the majority of total drug is confined to plasma and so a single compartment model is often observed. However, for lipophilic neutral and basic compounds, this is seldom the case. The decline of plasma concentration–time course, particularly after iv injection, typically shows at least two or more discrete phases when viewed on a log<sub>10</sub> <i>C</i><sub>p</sub> against time plot (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). This is due to the rate of entry into compartment 2 from the first compartment (<i>k</i><sub>12</sub>) and from compartment 2 back to the first compartment (<i>k</i><sub>21</sub>). Consequently, <i>t</i><sub>1/2</sub> can no longer be described as the time taken for the plasma concentrations to fall by half, as there are at least two distinct phases with different rates of decline. The initial decline is often viewed as a distribution phase followed by a terminal elimination rate (β). In this model, <i>V</i><sub>ss</sub>, CL, β, and terminal <i>t</i><sub>1/2</sub> are defined by <a class="ref internalNav" href="#eq5" aria-label="eqs 5">eqs 5</a>, <a class="ref internalNav" href="#eq6" aria-label="6">6</a>, <a class="ref internalNav" href="#eq7" aria-label="7">7</a>, and <a class="ref internalNav" href="#eq8" aria-label="8">8</a> respectively.<span class="NLM_disp-formula" id="eq5"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m005.gif" alt="" id="_i24" /></img><span class="labelSpan">(5)</span></span><span class="NLM_disp-formula" id="eq6"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m006.gif" alt="" id="_i25" /></img><span class="labelSpan">(6)</span></span><span class="NLM_disp-formula" id="eq7"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m007.gif" alt="" id="_i26" /></img><span class="labelSpan">(7)</span></span><span class="NLM_disp-formula" id="eq8"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_m008.gif" alt="" id="_i27" /></img><span class="labelSpan">(8)</span></span></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Basic characteristics of a two-compartment PK model. Panel a illustrates the model structure shown with first-order rates of absorption, elimination, and distribution. Panel b illustrates the characteristic biexponential decline in plasma concentrations following iv bolus administration. β is the elimination rate constant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although the relationships appear to be much more complicated, it is important to note that β is closely approximated by CL/<i>V</i><sub>ss</sub> (i.e., another way to define <i>k</i><sub>el</sub> in the one compartment model) so long as the distributional rates exceed that of the elimination rate. As such, under most circumstances, the basic concepts for modulating terminal <i>t</i><sub>1/2</sub> according to <i>V</i><sub>ss</sub> and CL remain relevant with this more complicated profile. In addition, it is not uncommon for the multiexponential decline to be lost or attenuated following oral administration due to the relative rates of absorption versus distribution. However, in a manner analogous to “flip-flop” kinetics, these rates may be difficult to interpret once the distribution rates become slower than the elimination rate. In some cases, a prolonged terminal half-life may be observed after concentrations have declined significantly providing for a portion of the concentration–time curve containing very little of the overall area under the curve (AUC). In this case, while the terminal elimination phase <i>t</i><sub>1/2</sub> may well approach a value that would be associated with once daily administration in humans, it would not lead to significant accumulation of drug exposure at steady state owing to the fact that it contributes very little to the overall AUC and clearance of the drug. Such a drug would still need to be administered more than once daily to achieve appropriate steady state exposure. To account for this complexity in a practical way, the concept of an “effective” or “operational” <i>t</i><sub>1/2</sub> has been developed that describes <i>t</i><sub>1/2</sub> in relation to the observed or predicted degree of accumulation and shape of the concentration–time profile upon steady-state dosing.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> This is exemplified by the NK<sub>2</sub> antagonist UK-224671 [(<i>S</i>)-(1)-4-(1-H2-[1-(cyclopropylmethyl)-3-(3,4-dichlorophenyl)-6-oxo-3-piperidyl]ethylazetidin-3-yl)-1-piperazinesulfonamide].<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The PK of UK-224671 in human following iv administration is characterized by a multiple compartmental profile (at least three phases, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The terminal elimination phase <i>t</i><sub>1/2</sub> is calculated at 28 h. However, this terminal phase describes approximately 20% of the AUC. Consequently, a once daily regimen for this compound would not accumulate to an appreciable steady state trough concentration. Paradoxically, this compound would be best suited to three times daily administration, despite an apparently once daily <i>t</i><sub>1/2</sub>.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PK of UK-224,671 in human following single intravenous administration of 0.1 mg/kg: (a) overall PK profile; (b) isolated initial phase profile; (c) isolated terminal phase profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Estimation of Half-Life</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The normally quoted (terminal) <i>t</i><sub>1/2</sub> is commonly determined by estimating the final slope of the plasma concentration–time curve. This now brings error in data analysis. After an iv dose, time points will often be taken with three samplings in the first hour and then hourly up to 4 h followed by samplings at perhaps 6, 8, and 24 h. The sampling time of the later time points is mostly governed by practical reasons. The <i>t</i><sub>1/2</sub> calculation will probably use the final three or so time points that have measurable concentrations. In the estimation of <i>t</i><sub>1/2</sub>, at least three points should be used. This is an inadequate number to gain a robust estimate of <i>t</i><sub>1/2</sub>. Having any drug detectable at 24 h postdose usually significantly prolongs the apparent <i>t</i><sub>1/2</sub>, which means assay sensitivity between compounds may be a major factor in selecting compounds rather than real PK differences. The assay differences may be compounded across species. For instance rodent studies usually have a lower number of samples of the different time points with a smaller volume of plasma samples than larger species like dog. Therefore, the larger species has the potential to generate a significantly longer <i>t</i><sub>1/2</sub> than rodents simply because of analytical sensitivity. The same analytical sensitivity issue will be seen in the AUC and area under the first moment curve (AUMC) so that clearance and volume will also be defined by the analytical sensitivity issue. Clearly, these are aspects of the PK study design that may complicate the estimation of the true <i>t</i><sub>1/2</sub> of the compound being tests and affect the extrapolation to human PK.</div><div class="NLM_p last">Often oral studies use higher doses than iv studies for safety reasons (oral exposure is usually less than that for the same iv dose due to oral bioavailability). This adds to the complexity of <i>t</i><sub>1/2</sub> determination since the oral study concentrations will be higher than iv dosing in the terminal phase, assuming the same analytical method is used. Consequently, the “true” terminal <i>t</i><sub>1/2</sub> of the molecule could be exposed with the chance of therefore a significantly longer apparent <i>t</i><sub>1/2</sub> after oral administration. The difficulty in interpretation will then be whether this is a fundamental parameter of the compound or driven by slow dissolution in the GI tract (as discussed previously). The problems of detection of drug in later samples or not sampling long enough also apply to the estimation of CL and <i>V</i><sub>ss</sub>. Although model free approaches are used largely in drug discovery, there is still a need for determination of the final elimination phase to extrapolate AUC values to infinity. Underestimating the terminal <i>t</i><sub>1/2</sub> therefore results in an underestimation of <i>V</i><sub>ss</sub> and an overestimation of CL. When this is exaggerated by the low iv dose compared to the oral dose in a crossover study, overestimates (including >100%) will be made for bioavailability.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Population Variability of Half-Life</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88675" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88675" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Variability of the <i>t</i><sub>1/2</sub> across populations can be of major concern. Variability in <i>t</i><sub>1/2</sub> should be a consideration in any patient population for which a high degree of variability in CL is expected due to the known mechanisms of clearance (hepatic impairment, renal impairment, genotype, ethnicity, age, etc.). In other cases, variability can arise due to much more complicated mechanisms. For example, high variation in <i>t</i><sub>1/2</sub> is accentuated when the drug’s <i>t</i><sub>1/2</sub> is partially dependent on reversible metabolism (metabolic conversion back to parent). This is illustrated by benoxaprofen, a nonselective COX inhibitor (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Most of the drugs in this class contain a carboxylic acid moiety. It is difficult to obtain a long <i>t</i><sub>1/2</sub> with such agents due to the low <i>V</i><sub>ss</sub>. Benoxaprofen was developed because the plasma elimination <i>t</i><sub>1/2</sub> of the drug was in the range of 19–26 h,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> almost ideal for a once a day administration. However, the development studies were conducted only in younger volunteers and patients. At the time a once a day drug with a simple single dose size was commercially attractive against the many other drugs in the class. Very soon after launch, toxicity problems were noted affecting the skin and liver. With both skin toxicity and hepatotoxicity, the major proportion of effects was observed in elderly patients.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> When PK of these patients were studied, <i>t</i><sub>1/2</sub> extended out to 150 h which coincided with reduced creatinine clearance.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Acyl glucuronidation was the major clearance pathway of benoxaprofen.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Excretion of this metabolite could occur renally and hepatobiliary. Enterohepatic recirculation of this metabolite after hepatobiliary clearance and subsequent hydrolysis in the gut back to benoxaprofen were likely to be an important contributor to the long <i>t</i><sub>1/2</sub>. GI stasis leading to higher recirculation and lowered kidney function lowering the renal clearance of the acyl glucuronide contributed to accumulation of the drug in the elderly. Today, studies in the elderly would have been conducted during drug development in addition to more detailed studies to understand the clearance and metabolism. These would have probably rendered the drug much less commercially attractive. The drug illustrates that thinking and basing decisions on a single average value for <i>t</i><sub>1/2</sub> are problematic. Drugs can exhibit quite different <i>t</i><sub>1/2</sub> in different patients and populations leading to the need for different dosing regimens.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of benoxaprofen and acylglucuronidation metabolite. Oxidative metabolism is likely to be very low due the chlorine substituent and oxidazole ring leading to acylglucuronidation as the major clearance pathway.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52007" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52007" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The simplest PK definition of <i>t</i><sub>1/2</sub> as the time taken for plasma concentrations to fall by half only applies under one compartment PK following iv administration. Under other conditions, such as oral administration and multicompartmental PK, the effect of rate constants other than <i>k</i><sub>el</sub> needs to be taken into consideration; however, <i>V</i><sub>ss</sub> and CL remain important factors to consider in any approach to optimize <i>t</i><sub>1/2</sub>.</div><div class="NLM_p">We introduced this perspective by posing several important questions with respect to <i>t</i><sub>1/2</sub> during a drug discovery project.<ul class="NLM_list-list_type-bullet" id="list3"><li><p class="inline">What <i>t</i><sub>1/2</sub> is optimal to support once daily administration?</p></li></ul></div><div class="NLM_p">Deriving dose regimen from <i>t</i><sub>1/2</sub> should drive to minimize peak-to-trough ratio, which will limit the potential for <i>C</i><sub>max</sub> driven side effects and lack of efficacy at <i>C</i><sub>min</sub>. An acceptable peak-to-trough ratio is below 4, which leads to a <i>t</i><sub>1/2</sub> greater than 12 h (if the PK is one compartment). <i>t</i><sub>1/2</sub> of 24–48 h would further minimize peak-to-trough ratio and potentially allow “forgiveness” of a single missed dose in minimizing loss of steady state exposure. Compounds with <i>t</i><sub>1/2</sub> values greater than this can lead to potential issues in terms of time to achieve steady-state, washout in the event of adverse effects and longer drug development time.<ul class="NLM_list-list_type-bullet" id="list4"><li><p class="inline">How can <i>t</i><sub>1/2</sub> be modulated?</p></li></ul></div><div class="NLM_p"><i>t</i><sub>1/2</sub> is determined by the plasma CL and <i>V</i><sub>ss</sub> of a compound. To improve <i>t</i><sub>1/2</sub>, medicinal chemistry strategy should mainly focus on reducing plasma CL (e.g., increase metabolic stability, reduce renal clearance, reduce hepatic uptake by active transporters and biliary clearance) and/or second increasing <i>V</i><sub>ss</sub>.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Generally, modulation of plasma protein binding in the absence of changing CL or <i>V</i><sub>ss</sub> will not affect <i>t</i><sub>1/2</sub>. This is a consequence of the relationship of <i>t</i><sub>1/2</sub> to CL and <i>V</i><sub>ss</sub> (<a class="ref internalNav" href="#eq2" aria-label="eq 2">eq 2</a>). Changing fraction unbound in plasma will often change CL and <i>V</i><sub>ss</sub> in equal and opposite directions. Should a clinical agent not possess the appropriate <i>t</i><sub>1/2</sub> to suit its proposed dose regimen, it is possible to improve the <i>t</i><sub>1/2</sub> by modifying the delivery of the compound. Subject to appropriate properties of aqueous solubility sufficient to support dose requirements, high membrane permeability, and low efflux transport, a compound can be formulated as MR to enhance <i>t</i><sub>1/2</sub>. This formulation will constantly release the compound throughout its passage through the GI tract. Effectively, the MR formulation gives zero order delivery of the compound and results in “flip-flop” PK, meaning <i>t</i><sub>1/2</sub> in plasma will reflect the rate of delivery.<ul class="NLM_list-list_type-bullet" id="list5"><li><p class="inline">What are the important considerations for measuring <i>t</i><sub>1/2</sub> during compound optimization?</p></li></ul></div><div class="NLM_p last">Complexities related to the multiple rates (absorption, distribution, and elimination) can confound efforts to optimize <i>t</i><sub>1/2</sub> by obscuring the interpretation of preclinical and clinical data. A careful analysis of PK profiles under different dose regimens and formulations (particularly iv and oral administration) are required in order to put an observed <i>t</i><sub>1/2</sub> into a context useful to design. In addition, nonlinearities in absorption and elimination can equally confound the interpretation of <i>t</i><sub>1/2</sub>. PK studies employing a range of doses and exposure levels are often required to detect these issues. Finally, population variability in <i>t</i><sub>1/2</sub> (particularly in the clinic) can confound the interpretation of <i>t</i><sub>1/2</sub>. Here an understanding of the mechanisms of clearance and distribution specific to a molecule and how those mechanisms vary across potential patient populations is important to ensure the appropriate interpretation of observed <i>t</i><sub>1/2</sub>.</div></div><div class="NLM_back"><div class="NLM_notes" id="NOTES-d7e3471-autogenerated"><p class="first last">The authors declare no competing financial interest.</p></div><div class="NLM_notes" id="retired">†<span class="title" id="d79863370e2786">Author Status</span><p class="last">Retired.</p></div><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00969" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60716" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60716" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Di</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6117-9022" title="Orcid link">http://orcid.org/0000-0001-6117-9022</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1e7277307a775e6e7877647b6c307d7173"><span class="__cf_email__" data-cfemail="64080d4a000d2414020d1e01164a070b09">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><sup>†</sup><span class="hlFld-ContribAuthor strong">Dennis
A. Smith</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Beaumont</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tristan S. Maurer</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br><sup>†</sup>Retired.</p></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68077" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68077" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Dennis
A. Smith</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=BIO-d7e3451-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dennis A. Smith</b> worked in the pharmaceutical industry for 32 years after gaining his Ph.D. from the University of Manchester, U.K. During this period he directly helped in the discovery and development of eight marketed NCEs. More recently his roles include advisory boards or expert panels with many drug research based organizations, both industrial and academic, including Medicines for Malaria Venture and Cancer Research UK. His research interests and publications span all aspects of drug discovery and development particularly where drug metabolism knowledge can impact on the design of more efficacious and safer drugs.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Kevin Beaumont</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=BIO-d7e3456-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Kevin Beaumont</b> has worked extensively in the discovery and development drug metabolism field throughout his 30 years in the pharmaceutical industry. His major area of expertise is in the modulation of physicochemistry to affect drug disposition and prediction of human PK. He is author on over 40 peer reviewed publications. Overall, Kevin has worked on many drug discovery and development projects throughout his career. He has been responsible for the DMPK input to at least 30 FIH studies as well as 10 phase II compounds, including one marketed agent. Kevin now provides DMPK input to the Inflammation and Immunology research unit and Rare Disease research unit, based in Cambridge, MA.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Tristan S. Maurer</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=BIO-d7e3461-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tristan S. Maurer</b> received his Pharm.D. from the University of Georgia in 1993 and his Ph.D. from the University of Buffalo, State University of New York in 1999. During his 18-year tenure with Pfizer, his work has focused on the development and application of quantitatively rigorous, biologically based methods to predict human pharmacokinetics and pharmacodynamics from preclinical data. He has coauthored over 60 manuscripts illustrating the utility of these methods to drug design and early clinical development. Currently, Dr. Maurer sits on the Medicine Design leadership team responsible for scientific and operational strategies spanning from idea to loss of exclusivity. He also leads a modeling and simulation group responsible for both computational chemistry and quantitative translational pharmacology across Pfizer’s small molecule portfolio.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Li Di</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=BIO-d7e3466-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Li Di</b> has about 20 years of experience in the pharmaceutical industry including Pfizer, Wyeth, and Syntex. She is currently a research fellow at Medicine Design Department, Pfizer Global Research and Development, Groton, CT. Her research interests include the areas of drug metabolism, absorption, transporters, pharmacokinetics, blood–brain barrier, and drug–drug interactions. She has over 120 publications including two books and presented more than 80 invited lectures. She is a recipient of the Thomas Alva Edison Patent Award, the New Jersey Association for Biomedical Research Outstanding Woman in Science Award, the Wyeth President’s Award, Peer Award for Excellence and Publication Award.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00683" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00683" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors greatly appreciate the technical assistance from David Tess.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>0</sub></td><td class="NLM_def"><p class="first last">initial drug concentration</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>avg,ss</sub></td><td class="NLM_def"><p class="first last">average steady state drug concentration</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>avg,ss,u</sub></td><td class="NLM_def"><p class="first last">average unbound steady state drug concentration</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>avg,ss</sub></td><td class="NLM_def"><p class="first last">steady state average concentration</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>min,ss</sub></td><td class="NLM_def"><p class="first last">steady state minimum concentration</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max,ss</sub></td><td class="NLM_def"><p class="first last">steady state maximum concentration</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CL<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">CL<sub>int,u</sub></td><td class="NLM_def"><p class="first last">unbound intrinsic clearance</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum drug concentration</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>min</sub></td><td class="NLM_def"><p class="first last">minimum drug concentration</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>p</sub></td><td class="NLM_def"><p class="first last">drug concentration in plasma</p></td></tr><tr><td class="NLM_term">EC<sub>xx</sub></td><td class="NLM_def"><p class="first last">effective concentration at certain “xx” percentage of maximal, e.g., EC<sub>50</sub> is the concentration that causes 50% of maximum effect</p></td></tr><tr><td class="NLM_term"><i>f</i><sub>a</sub></td><td class="NLM_def"><p class="first last">fraction absorbed</p></td></tr><tr><td class="NLM_term"><i>f</i><sub>el</sub></td><td class="NLM_def"><p class="first last">fraction of drug being washed out</p></td></tr><tr><td class="NLM_term"><i>f</i><sub>g</sub></td><td class="NLM_def"><p class="first last">fraction escaped from gut</p></td></tr><tr><td class="NLM_term"><i>f</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">fraction of target steady-state level</p></td></tr><tr><td class="NLM_term">fu<sub>p</sub></td><td class="NLM_def"><p class="first last">unbound fraction in plasma</p></td></tr><tr><td class="NLM_term">fu<sub>t</sub></td><td class="NLM_def"><p class="first last">unbound fraction in tissue</p></td></tr><tr><td class="NLM_term">GITS</td><td class="NLM_def"><p class="first last">gastrointestinal therapeutic system</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term"><i>k</i><sub>a</sub></td><td class="NLM_def"><p class="first last">first-order absorption rate constant</p></td></tr><tr><td class="NLM_term"><i>k</i><sub>el</sub></td><td class="NLM_def"><p class="first last">first-order elimination rate constant</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>m</sub></td><td class="NLM_def"><p class="first last">substrate concentration that gives half maximal velocity of an enzymatic reaction</p></td></tr><tr><td class="NLM_term">MR</td><td class="NLM_def"><p class="first last">modified release formulation</p></td></tr><tr><td class="NLM_term">MRT</td><td class="NLM_def"><p class="first last">mean residence time</p></td></tr><tr><td class="NLM_term">PBPK</td><td class="NLM_def"><p class="first last">physiologically based pharmacokinetic modeling</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term"><i>P</i>/<i>T</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">steady-state peak-to-trough concentration ratio</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once daily</p></td></tr><tr><td class="NLM_term">Qh</td><td class="NLM_def"><p class="first last">hepatic plasma flow</p></td></tr><tr><td class="NLM_term"><i>t</i></td><td class="NLM_def"><p class="first last">time</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">Tau</td><td class="NLM_def"><p class="first last">dosing interval</p></td></tr><tr><td class="NLM_term">TID</td><td class="NLM_def"><p class="first last">three times daily</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time at maximum plasma drug concentration</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>wash</sub></td><td class="NLM_def"><p class="first last">the time it takes to wash drug out by a specified fraction</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>d</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">steady state volume of distribution</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>p</sub></td><td class="NLM_def"><p class="first last">volume of the plasma</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>t</sub></td><td class="NLM_def"><p class="first last">volume of the tissue</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67412" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67412" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Volume of Distribution in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5691</span>– <span class="NLM_lpage">5698</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Volume+of+Distribution+in+Drug+Design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0liF0q0QVayaYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DVolume%2520of%2520Distribution%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northam, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alway, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, O. S.</span></span> <span> </span><span class="NLM_article-title">Blood levels of drug at the equilibrium state after multiple dosing</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>207</i></span>,  <span class="NLM_fpage">1301</span>– <span class="NLM_lpage">1302</span>, <span class="refDoi"> DOI: 10.1038/2071301a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1038%2F2071301a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=5884654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A280%3ADyaF287ksVSntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=1965&pages=1301-1302&author=J.+G.+Wagnerauthor=J.+I.+Northamauthor=C.+D.+Alwayauthor=O.+S.+Carpenter&title=Blood+levels+of+drug+at+the+equilibrium+state+after+multiple+dosing&doi=10.1038%2F2071301a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Blood levels of drug at the equilibrium state after multiple dosing</span></div><div class="casAuthors">Wagner J G; Northam J I; Alway C D; Carpenter O S</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">207</span>
        (<span class="NLM_cas:issue">5003</span>),
    <span class="NLM_cas:pages">1301-2</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkXM4pbz4uL8uCWE5mhx1RfW6udTcc2eaRfEuTEN54f7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaF287ksVSntQ%253D%253D&md5=de878fcb3ee5b632be74a12d50dfcfa7</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F2071301a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F2071301a0%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DJ.%2BG.%26aulast%3DNortham%26aufirst%3DJ.%2BI.%26aulast%3DAlway%26aufirst%3DC.%2BD.%26aulast%3DCarpenter%26aufirst%3DO.%2BS.%26atitle%3DBlood%2520levels%2520of%2520drug%2520at%2520the%2520equilibrium%2520state%2520after%2520multiple%2520dosing%26jtitle%3DNature%26date%3D1965%26volume%3D207%26spage%3D1301%26epage%3D1302%26doi%3D10.1038%2F2071301a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. H.</span></span> <span> </span><span class="NLM_article-title">Bisphosphonates: A review of their pharmacokinetic properties</span>. <i>Bone (N. Y.)</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/8756-3282(95)00445-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1016%2F8756-3282%2895%2900445-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=8833200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaK28XisVGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1996&pages=75-85&author=J.+H.+Lin&title=Bisphosphonates%3A+A+review+of+their+pharmacokinetic+properties&doi=10.1016%2F8756-3282%2895%2900445-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Bisphosphonates: A review of their pharmacokinetic properties</span></div><div class="casAuthors">Lin, J. H.</div><div class="citationInfo"><span class="NLM_cas:title">Bone (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">75-85</span>CODEN:
                <span class="NLM_cas:coden">BONEDL</span>;
        ISSN:<span class="NLM_cas:issn">8756-3282</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 96 refs.  Bisphosphonates are a unique class of drugs.  As a family, they are characterized pharmacol. by their ability to inhibit bone resorption, whereas, pharmacokinetically, they are classified by their similarity in absorption, distribution, and elimination.  Although all bisphosphonates have similar physicochem. properties, their antiresorbing activities differ substantially.  Activity is dramatically increased when the amino group is contained in the aliph. carbon chain.  For example, alendronate, an aminobisphosphonate, is approx. 700-fold more potent than etidronate, both in vitro and in vivo.  In general, bisphosphonates are poorly absorbed from the gastrointestinal tract as a result of their poor lipophilicity.  In vitro and in vivo studies have shown that bisphosphonates are absorbed from the gastrointestinal tract via paracellular transport.  Systemically available bisphosphonates disappear very rapidly from plasma, and are partly taken up by the bone and partly excreted by the kidney.  The relative contribution of these two processes to overall plasma elimination differs significantly among bisphosphonates.  To date, all bisphosphonates studied show no evidence of metab.  Renal excretion is the only route of elimination.  Studies with alendronate in rats indicate that the drug is actively secreted by an uncharacterized renal transport system, and not by the anionic or cationic renal transport systems.  Bisphosphonates bind preferentially to bones which have high turnover rates, and their distribution in bone is not homogeneous.  After bone uptake, the bisphosphonates are liberated again only when the bone in which they are deposited is resorbed.  Thus, the half-life of bisphosphonates in bone is very long, ranging among different species from 1 to 10 yr, depending largely on the rate of bone turnover.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO9vCF_MXhDLVg90H21EOLACvtfcHk0lhTvt5cg8Rb4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XisVGjs7g%253D&md5=db0515b258923cf8c4819ff24ae94162</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2F8756-3282%2895%2900445-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F8756-3282%252895%252900445-9%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BH.%26atitle%3DBisphosphonates%253A%2520A%2520review%2520of%2520their%2520pharmacokinetic%2520properties%26jtitle%3DBone%2520%2528N.%2520Y.%2529%26date%3D1996%26volume%3D18%26spage%3D75%26epage%3D85%26doi%3D10.1016%2F8756-3282%2895%2900445-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadpour, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhlaghi, F.</span></span> <span> </span><span class="NLM_article-title">Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.1007/s40262-013-0071-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1007%2Fs40262-013-0071-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=23658137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=615-626&author=A.+H.+Mohammadpourauthor=F.+Akhlaghi&title=Future+of+Cholesteryl+Ester+Transfer+Protein+%28CETP%29+Inhibitors%3A+A+Pharmacological+Perspective&doi=10.1007%2Fs40262-013-0071-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective</span></div><div class="casAuthors">Mohammadpour, Amir Hooshang; Akhlaghi, Fatemeh</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">615-626</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  In almost 30 years since the introduction of HMG-CoA reductase inhibitors (statins), no other class of lipid modulators has entered the market.  Elevation of high-d. lipoprotein-cholesterol (HDL-C) via inhibiting cholesteryl ester transfer protein (CETP) is an attractive strategy for reducing the risk of cardiovascular events in high-risk patients.  Transfer of triglyceride and cholesteryl ester (CE) between lipoproteins is mediated by CETP; thus inhibition of this pathway can increase the concn. of HDL-C.  Torcetrapib was the first CETP inhibitor evaluated in phase III clin. trials.  Because of off-target effects, torcetrapib raised blood pressure and increased the concn. of serum aldosterone, leading to higher cardiovascular events and mortality.  Torcetrapib showed pos. effects on cardiovascular risk esp. in patients with a greater increase in HDL-C and apolipoprotein A-1 (apoA-1) levels.  The phase III clin. trial of dalcetrapib, the second CETP inhibitor that has entered clin. development, was terminated because of ineffectiveness.  Dalcetrapib is a CETP modulator that elevated HDL-C levels but did not reduce the concn. of low-d. lipoprotein cholesterol (LDL-C).  Both heterotypic and homotypic CE transfer between lipoproteins are mediated by some CETP inhibitors, including torcetrapib, anacetrapib, and evacetrapib, while dalcetrapib only affects the heterotypic CE transfer.  Dalcetrapib has a chem. structure that is distinct from other CETP inhibitors, with a smaller mol. wt. and a lack of trifluoride moieties.  Moreover, dalcetrapib is a pro-drug that must be hydrolyzed to a pharmacol. active thiol form.  Two other CETP inhibitors, anacetrapib and evacetrapib, are currently undergoing evaluation in phase III clin. trials.  Both mols. have shown beneficial effects by increasing HDL-C and decreasing LDL-C concn.  The success of anacetrapib and evacetrapib remains to be confirmed upon the completion of phase III clin. trials in 2017 and 2015, resp.  Generally, the concn. of HDL-C has been considered a biomarker for the activity of CETP inhibitors.  However, it is not clear whether a fundamental relationship exists between HDL-C levels and the risk of coronary artery diseases.  The most crucial role for HDL is cholesterol efflux capacity in which HDL can reverse transport cholesterol from foam cells in atherosclerotic plaques.  In view of the heterogeneity in HDL particle size, charge, and compn., the mere concn. of HDL-C may not be a good surrogate marker for HDL functionality.  Recent clin. studies have reported that increased HDL functionality inversely correlates with the development of atherosclerotic plaque.  Future development of CETP inhibitors may therefore benefit from the use of biomarkers of HDL functionality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooWA0RhZp_JLVg90H21EOLACvtfcHk0lhTvt5cg8Rb4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7vL&md5=d80f7ec7c020c674bf66c6c8856ab345</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs40262-013-0071-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-013-0071-8%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadpour%26aufirst%3DA.%2BH.%26aulast%3DAkhlaghi%26aufirst%3DF.%26atitle%3DFuture%2520of%2520Cholesteryl%2520Ester%2520Transfer%2520Protein%2520%2528CETP%2529%2520Inhibitors%253A%2520A%2520Pharmacological%2520Perspective%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2013%26volume%3D52%26spage%3D615%26epage%3D626%26doi%3D10.1007%2Fs40262-013-0071-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gheyas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lederman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez-Eng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, K.</span></span> <span> </span><span class="NLM_article-title">Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.067736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1124%2Fdmd.115.067736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=26712818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A280%3ADC%252BC28rlsVSlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=428-434&author=G.+Hartmannauthor=S.+Kumarauthor=D.+Johnsauthor=F.+Gheyasauthor=D.+Gutsteinauthor=X.+Shenauthor=A.+Burtonauthor=H.+Ledermanauthor=R.+Lutzauthor=T.+Jacksonauthor=C.+Chavez-Engauthor=K.+Mitra&title=Disposition+into+Adipose+Tissue+Determines+Accumulation+and+Elimination+Kinetics+of+the+Cholesteryl+Ester+Transfer+Protein+Inhibitor+Anacetrapib+in+Mice&doi=10.1124%2Fdmd.115.067736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice</span></div><div class="casAuthors">Hartmann Georgy; Kumar Sanjeev; Johns Douglas; Gheyas Ferdous; Gutstein David; Shen Xiaolan; Burton Aimee; Lederman Harmony; Lutz Ryan; Jackson Tonya; Chavez-Eng Cynthia; Mitra Kaushik</div><div class="citationInfo"><span class="NLM_cas:title">Drug metabolism and disposition: the biological fate of chemicals</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">428-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibits a long terminal half-life (t1/2) in humans; however, the dispositional mechanisms that lead to this long t1/2 are still being elucidated.  As it is hypothesized that disposition into adipose tissue and binding to CETP might play a role, we sought to delineate the relative importance of these factors using a preclinical animal model.  A multiple-dose pharmacokinetic study was conducted in C57BL6 wild-type (WT) lean, WT diet-induced obese (DIO), natural flanking region (NFR) CETP-transgenic lean, and NFR-DIO mice.  Mice were dosed orally with 10 mg/kg anacetrapib daily for 42 days.  Drug concentrations in blood, brown and white adipose tissue, liver, and brain were measured up to 35 weeks postdose.  During dosing, a 3- to 9-fold accumulation in 72-hour postdose blood concentrations of anacetrapib was observed.  Drug concentrations in white adipose tissue accumulated ∼20- to 40-fold, whereas 10- to 17-fold accumulation occurred in brown adipose and approximately 4-fold in liver.  Brain levels were very low (<0.1 μM), and a trend of accumulation was not seen.  The presence of CETP as well as adiposity seems to play a role in determining the blood concentrations of anacetrapib.  The highest blood concentrations were observed in NFR DIO mice, whereas the lowest concentrations were seen in WT lean mice.  In adipose and liver tissue, higher concentrations were seen in DIO mice, irrespective of the presence of CETP.  This finding suggests that white adipose tissue serves as a potential depot and that disposition into adipose tissue governs the long-term kinetics of anacetrapib in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvolMVAlekEd1QT_1O5WBYfW6udTcc2eaRfEuTEN54f7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rlsVSlsw%253D%253D&md5=889e0108f486863be71af1807c6e4f40</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.067736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.067736%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DJohns%26aufirst%3DD.%26aulast%3DGheyas%26aufirst%3DF.%26aulast%3DGutstein%26aufirst%3DD.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DBurton%26aufirst%3DA.%26aulast%3DLederman%26aufirst%3DH.%26aulast%3DLutz%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DT.%26aulast%3DChavez-Eng%26aufirst%3DC.%26aulast%3DMitra%26aufirst%3DK.%26atitle%3DDisposition%2520into%2520Adipose%2520Tissue%2520Determines%2520Accumulation%2520and%2520Elimination%2520Kinetics%2520of%2520the%2520Cholesteryl%2520Ester%2520Transfer%2520Protein%2520Inhibitor%2520Anacetrapib%2520in%2520Mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26spage%3D428%26epage%3D434%26doi%3D10.1124%2Fdmd.115.067736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holt, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storey, G. C.</span></span> <span> </span><span class="NLM_article-title">Amiodarone pharmacokinetics</span>. <i>Am. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">840</span>– <span class="NLM_lpage">847</span>, <span class="refDoi"> DOI: 10.1016/0002-8703(83)90006-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1016%2F0002-8703%2883%2990006-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=1983&pages=840-847&author=D.+W.+Holtauthor=G.+T.+Tuckerauthor=P.+R.+Jacksonauthor=G.+C.+Storey&title=Amiodarone+pharmacokinetics&doi=10.1016%2F0002-8703%2883%2990006-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2F0002-8703%2883%2990006-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-8703%252883%252990006-6%26sid%3Dliteratum%253Aachs%26aulast%3DHolt%26aufirst%3DD.%2BW.%26aulast%3DTucker%26aufirst%3DG.%2BT.%26aulast%3DJackson%26aufirst%3DP.%2BR.%26aulast%3DStorey%26aufirst%3DG.%2BC.%26atitle%3DAmiodarone%2520pharmacokinetics%26jtitle%3DAm.%2520Heart%2520J.%26date%3D1983%26volume%3D106%26spage%3D840%26epage%3D847%26doi%3D10.1016%2F0002-8703%2883%2990006-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plomp, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rossum, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robles de Medina, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Lier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, R. A. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and body distribution of amiodarone in man</span>. <i>Arzneim. Forsch.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">520</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=6540111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL2cXktFKktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1984&pages=513-520&author=T.+A.+Plompauthor=J.+M.+Van+Rossumauthor=E.+O.+Robles+de+Medinaauthor=T.+Van+Lierauthor=R.+A.+A.+Maes&title=Pharmacokinetics+and+body+distribution+of+amiodarone+in+man"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and body distribution of amiodarone in man</span></div><div class="casAuthors">Plomp, T. A.; Van Rossum, J. M.; Robles de Medina, E. O.; Van Lier, T.; Maes, R. A. A.</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">513-20</span>CODEN:
                <span class="NLM_cas:coden">ARZNAD</span>;
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    </div><div class="casAbstract">The concns. of amiodarone  [1951-25-3] and desethylamiodarone  [83409-32-9] in plasma after single oral and i.v. and long-term oral dosing were detd. in normal subjects and patients with various cardiac arrhythmias, resp.  The decline in amiodarone plasma concn. after a single i.v. 400 mg dose was described by a triexponential decay equation, with a mean terminal half-life (t1/2) of 34.5 h.  Mean values for clearance and apparent vol. of distribution were 14.7 L/h and 376 L.  Following single oral doses of 400 mg, amiodarone plasma concn. time data were fitted in a triexponential function.  The mean terminal half-life for amiodarone after oral dosage was 31.6 h.  Amiodarone peak concns. of 0.37 μg/mL were attained in 4.8 h.  The bioavailability of oral amiodarone was only 31%, in part due to 1st-pass metab.  Desethylamiodarone, the major metabolite of amiodarone, was present in plasma in very low levels of about 10 ng/mL in several volunteers after single i.v. or oral administration of amiodarone.  The mean plasma amiodarone and desethylamiodarone levels in patients (mean oral daily maintenance dosage of 440 mg for a mean period of 9.1 mo) were 1.85 μg/mL and 1.35 μg/mL, resp.  The mean elimination t1/2 of amiodarone and desethylamiodarone after discontinuation of therapy in 4 patients on long-term amiodarone treatment were 40 days and 57 days, resp.  Amiodarone and desethylamiodarone were neither detectable in urine samples of the normal subjects after single i.v. and oral administration of the drug nor in the urine of several patients on long-term oral amiodarone treatment.  There was extensive tissue accumulation of amiodarone and desethylamiodarone with particularly high levels in adipose tissue, lung, and liver and relatively lower concns. in other organs such as heart, kidney and thyroid gland.  With exception of fat, in all tissues studied the levels of the metabolite were substantially higher than those of the parent compd., probably due to differences in physicochem. properties of both drugs.  During long-term oral therapy the mean amiodarone and desethylamiodarone plasma concns. were several times higher than the values predicted from the single dose studies.  These changes may be explained by redn. in presystemic metab. of amiodarone and the possibly reduced clearances of both drugs during long-term oral use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2-gc-kQo6m7Vg90H21EOLACvtfcHk0lgQk8wob62wEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXktFKktLk%253D&md5=0f6bf736a1dd5fc0fea3c35bb22a35e1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPlomp%26aufirst%3DT.%2BA.%26aulast%3DVan%2BRossum%26aufirst%3DJ.%2BM.%26aulast%3DRobles%2Bde%2BMedina%26aufirst%3DE.%2BO.%26aulast%3DVan%2BLier%26aufirst%3DT.%26aulast%3DMaes%26aufirst%3DR.%2BA.%2BA.%26atitle%3DPharmacokinetics%2520and%2520body%2520distribution%2520of%2520amiodarone%2520in%2520man%26jtitle%3DArzneim.%2520Forsch.%26date%3D1984%26volume%3D34%26spage%3D513%26epage%3D520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastasiou-Nana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulopoulos, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of amiodarone after intravenous and oral administration</span>. <i>Int. J. Clin. Pharmacol. Ther. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">524</span>– <span class="NLM_lpage">529</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=7174155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A280%3ADyaL3s%252FotFKktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1982&pages=524-529&author=M.+Anastasiou-Nanaauthor=G.+M.+Levisauthor=S.+Moulopoulos&title=Pharmacokinetics+of+amiodarone+after+intravenous+and+oral+administration"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of amiodarone after intravenous and oral administration</span></div><div class="casAuthors">Anastasiou-Nana M; Levis G M; Moulopoulos S</div><div class="citationInfo"><span class="NLM_cas:title">International journal of clinical pharmacology, therapy, and toxicology</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">524-9</span>
        ISSN:<span class="NLM_cas:issn">0174-4879</span>.
    </div><div class="casAbstract">Pharmacokinetic studies were conducted in four subjects who received 150 mg amiodarone i.v., in nine subjects who received 200 or 400 mg amiodarone p.o., and in four subjects who received the drug by both routes of administration.  Amiodarone concentrations were determined by high pressure liquid chromatography.  Aminodarone levels after i.v. administration, with one exception, declined biphasically according to a two-compartment model.  The decline appeared to be monophasic after p.o. administration with one exception.  Plasma levels after p.o. administration varied considerably between subjects.  The biologic half-life after p.o. administration (mean 17.1 h +/- S.D.) was higher than that calculated for the second phase after i.v. administration (mean 4.3 h +/- 0.98 S.D.).  Total clearance rate during the second phase was within the range 125-288 ml/min after i.v. and 114-473 ml/min after p.o. administration.  The apparent volume of distribution in the central compartment after i.v. administration was found to be about 17.0 l and that calculated for the second elimination phase, 77 l, possibly indicating a concentration of the drug in the tissues.  The systemic availability of amiodarone varied from 23 to 50% as determined on the basis of of the ratios of areas under p.o. and i.v. serum concentration curves for four subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTPlkdhywOliBJ5E29YNGvQfW6udTcc2eY49DKD2MIBNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s%252FotFKktQ%253D%253D&md5=09ba0e2cab61433aa86b10e6d3e1042b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAnastasiou-Nana%26aufirst%3DM.%26aulast%3DLevis%26aufirst%3DG.%2BM.%26aulast%3DMoulopoulos%26aufirst%3DS.%26atitle%3DPharmacokinetics%2520of%2520amiodarone%2520after%2520intravenous%2520and%2520oral%2520administration%26jtitle%3DInt.%2520J.%2520Clin.%2520Pharmacol.%2520Ther.%2520Toxicol.%26date%3D1982%26volume%3D20%26spage%3D524%26epage%3D529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Latini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kates, R. E.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics of amiodarone</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.2165/00003088-198409020-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.2165%2F00003088-198409020-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=6370540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL2cXktVSjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1984&pages=136-156&author=R.+Latiniauthor=G.+Tognoniauthor=R.+E.+Kates&title=Clinical+pharmacokinetics+of+amiodarone&doi=10.2165%2F00003088-198409020-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of amiodarone</span></div><div class="casAuthors">Latini, Roberto; Tognoni, Gianni; Kates, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">136-56</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    </div><div class="casAbstract">A review with ∼75 refs. on the pharmacokinetics of amiodarone (I)  [1951-25-3] in humans and lab. animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6VR8HBvsdVrVg90H21EOLACvtfcHk0lhXaA0UZ-7g6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXktVSjs7Y%253D&md5=6cd8c312dedc9f69429b2eabcea8e865</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2165%2F00003088-198409020-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-198409020-00002%26sid%3Dliteratum%253Aachs%26aulast%3DLatini%26aufirst%3DR.%26aulast%3DTognoni%26aufirst%3DG.%26aulast%3DKates%26aufirst%3DR.%2BE.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520amiodarone%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1984%26volume%3D9%26spage%3D136%26epage%3D156%26doi%3D10.2165%2F00003088-198409020-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kannan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B. N.</span></span> <span> </span><span class="NLM_article-title">Tissue uptake and metabolism of amiodarone after chronic administration in rabbits</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">650</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1985&pages=646-650&author=R.+Kannanauthor=S.+Millerauthor=B.+N.+Singh&title=Tissue+uptake+and+metabolism+of+amiodarone+after+chronic+administration+in+rabbits"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKannan%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DB.%2BN.%26atitle%3DTissue%2520uptake%2520and%2520metabolism%2520of%2520amiodarone%2520after%2520chronic%2520administration%2520in%2520rabbits%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1985%26volume%3D13%26spage%3D646%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span> <span> </span><span class="NLM_article-title">The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1038/nrd3287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1038%2Fnrd3287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=21119731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=929-939&author=D.+A.+Smithauthor=L.+Diauthor=E.+H.+Kerns&title=The+effect+of+plasma+protein+binding+on+in+vivo+efficacy%3A+misconceptions+in+drug+discovery&doi=10.1038%2Fnrd3287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery</span></div><div class="casAuthors">Smith, Dennis A.; Di, Li; Kerns, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">929-939</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Data from in vitro plasma protein binding expts. that det. the fraction of protein-bound drug are frequently used in drug discovery to guide structure design and to prioritize compds. for in vivo studies.  However, we consider that these practices are usually misleading, because in vivo efficacy is detd. by the free (unbound) drug concn. surrounding the therapeutic target, not by the free drug fraction.  These practices yield no enhancement of the in vivo free drug concn.  So, decisions based on free drug fraction could result in the wrong compds. being advanced through drug discovery programs.  This Perspective provides guidance on the application of plasma protein binding information in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOa3ippodhGbVg90H21EOLACvtfcHk0lhXaA0UZ-7g6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI&md5=a45d00f68ab44580fa38a6acef49493a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd3287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3287%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DThe%2520effect%2520of%2520plasma%2520protein%2520binding%2520on%2520in%2520vivo%2520efficacy%253A%2520misconceptions%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D929%26epage%3D939%26doi%3D10.1038%2Fnrd3287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E. C. A.</span></span> <span> </span><span class="NLM_article-title">Rational Use of Plasma Protein and Tissue Binding Data in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8238</span>– <span class="NLM_lpage">8248</span>, <span class="refDoi"> DOI: 10.1021/jm5007935</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5007935" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8238-8248&author=X.+Liuauthor=M.+Wrightauthor=C.+E.+C.+A.+Hop&title=Rational+Use+of+Plasma+Protein+and+Tissue+Binding+Data+in+Drug+Design&doi=10.1021%2Fjm5007935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Use of Plasma Protein and Tissue Binding Data in Drug Design</span></div><div class="casAuthors">Liu, Xingrong; Wright, Matthew; Hop, Cornelis E. C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8238-8248</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is a commonly accepted assumption that only unbound drug mols. are available to interact with their targets.  Therefore, one of the objectives in drug design is to optimize the compd. structure to increase in vivo unbound drug concn.  In this review, theor. analyses and exptl. observations are presented to illustrate that low plasma protein binding does not necessarily lead to high in vivo unbound plasma concn.  Similarly, low brain tissue binding does not lead to high in vivo unbound brain tissue concn.  Instead, low intrinsic clearance leads to high in vivo unbound plasma concn., and low efflux transport activity at the blood-brain barrier leads to high unbound brain concn.  Plasma protein and brain tissue binding are very important parameters in understanding pharmacokinetics, pharmacodynamics, and toxicities of drugs, but these parameters should not be targeted for optimization in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKiYUz9ljIDrVg90H21EOLACvtfcHk0lhXaA0UZ-7g6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M&md5=53ffbdb88ddf500a90a0eee14b0e641f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm5007935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5007935%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DHop%26aufirst%3DC.%2BE.%2BC.%2BA.%26atitle%3DRational%2520Use%2520of%2520Plasma%2520Protein%2520and%2520Tissue%2520Binding%2520Data%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8238%26epage%3D8248%26doi%3D10.1021%2Fjm5007935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span> <span> </span><span class="NLM_article-title">Modified-Release Drug Products and Drug Devices</span> In  <i>Applied Biopharmaceutics and Pharmacokinetics</i>, <span class="NLM_edition">7</span>th ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Shargel, L.</span>, <span class="NLM_string-name">Yu, A. B. C.</span></span>, Eds.; <span class="NLM_publisher-name">McGraw-Hill Education</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2016</span>; pp  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">613</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=567-613&author=H.+Dingauthor=L.+Shargel&author=A.+B.+C.+Yu&title=Applied+Biopharmaceutics+and+Pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%26atitle%3DModified-Release%2520Drug%2520Products%2520and%2520Drug%2520Devices%26btitle%3DApplied%2520Biopharmaceutics%2520and%2520Pharmacokinetics%26aulast%3DShargel%26aufirst%3DL.%26pub%3DMcGraw-Hill%2520Education%26date%3D2016%26spage%3D567%26epage%3D613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ummadi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shravani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, N. G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, B. S.</span></span> <span> </span><span class="NLM_article-title">Overview on Controlled Release Dosage Form</span>. <i>International Journal of Pharma Sciences</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">258</span>– <span class="NLM_lpage">269</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=258-269&author=S.+Ummadiauthor=B.+Shravaniauthor=N.+G.+R.+Raoauthor=M.+S.+Reddyauthor=B.+S.+Nayak&title=Overview+on+Controlled+Release+Dosage+Form"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUmmadi%26aufirst%3DS.%26aulast%3DShravani%26aufirst%3DB.%26aulast%3DRao%26aufirst%3DN.%2BG.%2BR.%26aulast%3DReddy%26aufirst%3DM.%2BS.%26aulast%3DNayak%26aufirst%3DB.%2BS.%26atitle%3DOverview%2520on%2520Controlled%2520Release%2520Dosage%2520Form%26jtitle%3DInternational%2520Journal%2520of%2520Pharma%2520Sciences%26date%3D2013%26volume%3D3%26spage%3D258%26epage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banweer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span> <span> </span><span class="NLM_article-title">Osmotically controlled drug delivery system with associated drugs</span>. <i>J. Pharm. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">571</span>– <span class="NLM_lpage">588</span>, <span class="refDoi"> DOI: 10.18433/J38W25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.18433%2FJ38W25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=21486532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2qtr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=571-588&author=B.+P.+Guptaauthor=N.+Thakurauthor=N.+P.+Jainauthor=J.+Banweerauthor=S.+Jain&title=Osmotically+controlled+drug+delivery+system+with+associated+drugs&doi=10.18433%2FJ38W25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Osmotically controlled drug delivery system with associated drugs</span></div><div class="casAuthors">Gupta, Brahma P.; Thakur, Navneet; Jain, Nishi P.; Banweer, Jitendra; Jain, Surendra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy & Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">571-588</span>CODEN:
                <span class="NLM_cas:coden">JPPSFY</span>;
        ISSN:<span class="NLM_cas:issn">1482-1826</span>.
    
            (<span class="NLM_cas:orgname">Canadian Society for Pharmaceutical Sciences</span>)
        </div><div class="casAbstract">A review.  Conventional drug delivery systems have slight control over their drug release and almost no control over the effective concn. at the target site.  This kind of dosing pattern may result in constantly changing, unpredictable plasma concns.  Drugs can be delivered in a controlled pattern over a long period of time by the controlled or modified release drug delivery systems.  They include dosage forms for oral and transdermal administration as well as injectable and implantable systems.  For most of drugs, oral route remains as the most acceptable route of administration.  Certain mols. may have low oral bioavailability because of soly. or permeability limitations.  Development of an extended release dosage form also requires reasonable absorption throughout the gastro-intestinal tract (GIT).  Among the available techniques to improve the bioavailability of these drugs fabrication of osmotic drug delivery system is the most appropriate one.  Osmotic drug delivery systems release the drug with the zero order kinetics which does not depend on the initial concn. and the physiol. factors of GIT.  This review brings out new technologies, fabrication and recent clin. research in osmotic drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-y8WkGKkGnbVg90H21EOLACvtfcHk0ljCShGaZpGkAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2qtr%252FJ&md5=1faf14c2bcc9eebaca3f2788eb53ddca</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.18433%2FJ38W25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18433%252FJ38W25%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DB.%2BP.%26aulast%3DThakur%26aufirst%3DN.%26aulast%3DJain%26aufirst%3DN.%2BP.%26aulast%3DBanweer%26aufirst%3DJ.%26aulast%3DJain%26aufirst%3DS.%26atitle%3DOsmotically%2520controlled%2520drug%2520delivery%2520system%2520with%2520associated%2520drugs%26jtitle%3DJ.%2520Pharm.%2520Pharm.%2520Sci.%26date%3D2010%26volume%3D13%26spage%3D571%26epage%3D588%26doi%3D10.18433%2FJ38W25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keraliya, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keraliya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soni, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. M.</span></span> <span> </span><span class="NLM_article-title">Osmotic drug delivery system as a part of modified release dosage form</span>. <i>ISRN Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">528079</span>, (9 pp) <span class="refDoi"> DOI: 10.5402/2012/528079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.5402%2F2012%2F528079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=22852100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A280%3ADC%252BC38fpsl2msw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=528079&author=R.+A.+Keraliyaauthor=C.+Patelauthor=P.+Patelauthor=V.+Keraliyaauthor=T.+G.+Soniauthor=R.+C.+Patelauthor=M.+M.+Patel&title=Osmotic+drug+delivery+system+as+a+part+of+modified+release+dosage+form&doi=10.5402%2F2012%2F528079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Osmotic drug delivery system as a part of modified release dosage form</span></div><div class="casAuthors">Keraliya Rajesh A; Patel Chirag; Patel Pranav; Keraliya Vipul; Soni Tejal G; Patel Rajnikant C; Patel M M</div><div class="citationInfo"><span class="NLM_cas:title">ISRN pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">528079</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Conventional drug delivery systems are known to provide an immediate release of drug, in which one can not control the release of the drug and can not maintain effective concentration at the target site for longer time.  Controlled drug delivery systems offer spatial control over the drug release.  Osmotic pumps are most promising systems for controlled drug delivery.  These systems are used for both oral administration and implantation.  Osmotic pumps consist of an inner core containing drug and osmogens, coated with a semipermeable membrane.  As the core absorbs water, it expands in volume, which pushes the drug solution out through the delivery ports.  Osmotic pumps release drug at a rate that is independent of the pH and hydrodynamics of the dissolution medium.  The historical development of osmotic systems includes development of the Rose-Nelson pump, the Higuchi-Leeper pumps, the Alzet and Osmet systems, the elementary osmotic pump, and the push-pull system.  Recent advances include development of the controlled porosity osmotic pump, and systems based on asymmetric membranes.  This paper highlights the principle of osmosis, materials used for fabrication of pumps, types of pumps, advantages, disadvantages, and marketed products of this system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHnpGf4gD5z2K_SFaaT9INfW6udTcc2eYtN36wdCsmvLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fpsl2msw%253D%253D&md5=f26ff28b7730985addb7d2315de87b2c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.5402%2F2012%2F528079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5402%252F2012%252F528079%26sid%3Dliteratum%253Aachs%26aulast%3DKeraliya%26aufirst%3DR.%2BA.%26aulast%3DPatel%26aufirst%3DC.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DKeraliya%26aufirst%3DV.%26aulast%3DSoni%26aufirst%3DT.%2BG.%26aulast%3DPatel%26aufirst%3DR.%2BC.%26aulast%3DPatel%26aufirst%3DM.%2BM.%26atitle%3DOsmotic%2520drug%2520delivery%2520system%2520as%2520a%2520part%2520of%2520modified%2520release%2520dosage%2520form%26jtitle%3DISRN%2520Pharm.%26date%3D2012%26volume%3D2012%26spage%3D528079%26doi%3D10.5402%2F2012%2F528079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGibney, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chasseaud, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, I. W.</span></span> <span> </span><span class="NLM_article-title">The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.1986.tb02874.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1111%2Fj.1365-2125.1986.tb02874.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=2943308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL28Xlt1Kkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1986&pages=21-5&author=J.+K.+Faulknerauthor=D.+McGibneyauthor=L.+F.+Chasseaudauthor=J.+L.+Perryauthor=I.+W.+Taylor&title=The+pharmacokinetics+of+amlodipine+in+healthy+volunteers+after+single+intravenous+and+oral+doses+and+after+14+repeated+oral+doses+given+once+daily&doi=10.1111%2Fj.1365-2125.1986.tb02874.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily</span></div><div class="casAuthors">Faulkner, J. K.; McGibney, D.; Chasseaud, L. F.; Perry, J. L.; Taylor, I. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-5</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">I.v. administration of amlodipine (I)  [88150-42-9] (single dose, 10 mg) to 12 volunteers gave a mean plasma half-life of 34 h, mean clearance of 7 mL/min/kg and a mean apparent vol. of distribution of 21 L/kg.  Oral administration (single dose, 10 mg) to the same 12 volunteers gave a mean systemic availability of 64% and a mean plasma half-life of 36 h.  In a 2nd study, repeated oral administration (once daily for 14 days, 15 mg) to 28 volunteers resulted in steady state plasma drug concn. being reached after 7 doses, an accumulation of approx. 3-fold and a mean half-life of 45 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEO2GPnr6jVbVg90H21EOLACvtfcHk0ljCShGaZpGkAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xlt1Kkt7Y%253D&md5=ca5af419408e45b4e4eb16a34297129f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.1986.tb02874.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.1986.tb02874.x%26sid%3Dliteratum%253Aachs%26aulast%3DFaulkner%26aufirst%3DJ.%2BK.%26aulast%3DMcGibney%26aufirst%3DD.%26aulast%3DChasseaud%26aufirst%3DL.%2BF.%26aulast%3DPerry%26aufirst%3DJ.%2BL.%26aulast%3DTaylor%26aufirst%3DI.%2BW.%26atitle%3DThe%2520pharmacokinetics%2520of%2520amlodipine%2520in%2520healthy%2520volunteers%2520after%2520single%2520intravenous%2520and%2520oral%2520doses%2520and%2520after%252014%2520repeated%2520oral%2520doses%2520given%2520once%2520daily%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1986%26volume%3D22%26spage%3D21%26epage%3D5%26doi%3D10.1111%2Fj.1365-2125.1986.tb02874.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abernethy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. B.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of calcium antagonists under development</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.2165/00003088-198815010-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.2165%2F00003088-198815010-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=3042243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL1cXlt1Wrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1988&pages=1-14&author=D.+R.+Abernethyauthor=J.+B.+Schwartz&title=Pharmacokinetics+of+calcium+antagonists+under+development&doi=10.2165%2F00003088-198815010-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of calcium antagonists under development</span></div><div class="casAuthors">Abernethy, Darrell R.; Schwartz, Janice B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-14</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    </div><div class="casAbstract">A review with 67 refs. examg. the pharmacokinetics of the type-I Ca2+ antagonist tiapamil and those of the type II drugs amlodipine, felodipine, isradipine, nicardipine, nilvadipine, nimodipine, nisoldipine, and nitrendipine in healthy humans and those with hepatic, renal, or other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLU1Tf6sPJ07Vg90H21EOLACvtfcHk0lgAJtZIHXXcCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXlt1Wrt78%253D&md5=8648d78bde7bec42ebf40822ed68a378</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2165%2F00003088-198815010-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-198815010-00001%26sid%3Dliteratum%253Aachs%26aulast%3DAbernethy%26aufirst%3DD.%2BR.%26aulast%3DSchwartz%26aufirst%3DJ.%2BB.%26atitle%3DPharmacokinetics%2520of%2520calcium%2520antagonists%2520under%2520development%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1988%26volume%3D15%26spage%3D1%26epage%3D14%26doi%3D10.2165%2F00003088-198815010-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piascik, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, R. G.,  Jr</span></span> <span> </span><span class="NLM_article-title">Aspects of the clinical pharmacology of nifedipine, a dihydropyridine calcium-entry antagonist</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1002/bdd.2510070102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1002%2Fbdd.2510070102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=3513860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL28XhsVWmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1986&pages=1-10&author=S.+R.+Hamannauthor=M.+T.+Piascikauthor=R.+G.+McAllister&title=Aspects+of+the+clinical+pharmacology+of+nifedipine%2C+a+dihydropyridine+calcium-entry+antagonist&doi=10.1002%2Fbdd.2510070102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Aspects of the clinical pharmacology of nifedipine, a dihydropyridine calcium-entry antagonist</span></div><div class="casAuthors">Hamann, Scott R.; Piascik, Michael T.; McAllister, R. G., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    </div><div class="casAbstract">A review with 36 refs. on the clin. pharmacol. and pharmacokinetics of nifedipine  [21829-25-4].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPOu0DSht3fbVg90H21EOLACvtfcHk0lgAJtZIHXXcCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhsVWmt7g%253D&md5=deb359fa601e03cc8df5f51240c69626</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2510070102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2510070102%26sid%3Dliteratum%253Aachs%26aulast%3DHamann%26aufirst%3DS.%2BR.%26aulast%3DPiascik%26aufirst%3DM.%2BT.%26aulast%3DMcAllister%26aufirst%3DR.%2BG.%26atitle%3DAspects%2520of%2520the%2520clinical%2520pharmacology%2520of%2520nifedipine%252C%2520a%2520dihydropyridine%2520calcium-entry%2520antagonist%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D1986%26volume%3D7%26spage%3D1%26epage%3D10%26doi%3D10.1002%2Fbdd.2510070102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N. J.</span></span> <span> </span><span class="NLM_article-title">Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1385</span>– <span class="NLM_lpage">1405</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.020479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1124%2Fdmd.108.020479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=18426954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVensr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1385-1405&author=R.+S.+Obachauthor=F.+Lombardoauthor=N.+J.+Waters&title=Trend+analysis+of+a+database+of+intravenous+pharmacokinetic+parameters+in+humans+for+670+drug+compounds&doi=10.1124%2Fdmd.108.020479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds</span></div><div class="casAuthors">Obach, R. Scott; Lombardo, Franco; Waters, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1385-1405</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We present herein a compilation and trend anal. of human i.v. pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clin. pharmacokinetic data.  This data set provides the drug metab. scientist with a robust and accurate resource suitable for a no. of applications, including in silico modeling, in vitro-in vivo scaling, and physiol. based pharmacokinetic approaches.  Clearance, vol. of distribution at steady state, mean residence time, and terminal phase half-life were obtained or derived from original refs. exclusively from studies utilizing i.v. administration.  Plasma protein binding data were collected from other sources to supplement these pharmacokinetic data.  These parameters were analyzed concurrently with a range of simple physicochem. descriptors, and resultant trends and patterns within the data are presented.  Our findings with this much expanded data set were consistent with earlier described notions of trends between physicochem. properties and pharmacokinetic behavior.  These observations and analyses, along with the large database of human pharmacokinetic data, should enable future efforts aimed toward developing quant. structure-pharmacokinetic relationships and improving our understanding of the relationship between fundamental chem. characteristics and drug disposition.  0.95 1.6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9WuEgpgbrarVg90H21EOLACvtfcHk0lgAJtZIHXXcCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVensr0%253D&md5=c438c6791817201452cc3e1d6172b6bb</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.020479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.020479%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DWaters%26aufirst%3DN.%2BJ.%26atitle%3DTrend%2520analysis%2520of%2520a%2520database%2520of%2520intravenous%2520pharmacokinetic%2520parameters%2520in%2520humans%2520for%2520670%2520drug%2520compounds%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1385%26epage%3D1405%26doi%3D10.1124%2Fdmd.108.020479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, R. T.</span></span> <span> </span><span class="NLM_article-title">The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.2165/00003088-199630010-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.2165%2F00003088-199630010-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=8846626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaK28XhsFWnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1996&pages=28-51&author=J.+S.+Grundyauthor=R.+T.+Foster&title=The+nifedipine+gastrointestinal+therapeutic+system+%28GITS%29.+Evaluation+of+pharmaceutical%2C+pharmacokinetic+and+pharmacological+properties&doi=10.2165%2F00003088-199630010-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties</span></div><div class="casAuthors">Grundy, John S.; Foster, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-51</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review, with 131 refs.  Nifedipine is a short-acting calcium antagonist formulated into several different oral prepns., each of which offers a distinct drug release profile.  Of these, the nifedipine gastrointestinal therapeutic system (GITS) affords (rate)-controlled-release (CR) and once-daily administration.  Specific topics discussed in this review were: the rationale for development and marketing of the nifedipine gastrointestinal therapeutic system; formulation design; pharmacokinetic and dosage considerations; pharmacol. effects; and treatment compliance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbtE0WAeKs27Vg90H21EOLACvtfcHk0lgAJtZIHXXcCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhsFWnu70%253D&md5=b3308d0f9fd486e5a78de3670e8a153d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2165%2F00003088-199630010-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199630010-00003%26sid%3Dliteratum%253Aachs%26aulast%3DGrundy%26aufirst%3DJ.%2BS.%26aulast%3DFoster%26aufirst%3DR.%2BT.%26atitle%3DThe%2520nifedipine%2520gastrointestinal%2520therapeutic%2520system%2520%2528GITS%2529.%2520Evaluation%2520of%2520pharmaceutical%252C%2520pharmacokinetic%2520and%2520pharmacological%2520properties%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1996%26volume%3D30%26spage%3D28%26epage%3D51%26doi%3D10.2165%2F00003088-199630010-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, J. I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, T. C.</span></span> <span> </span><span class="NLM_article-title">Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1362</span>– <span class="NLM_lpage">1371</span>, <span class="refDoi"> DOI: 10.1002/jcph.734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1002%2Fjcph.734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=26970526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Wkur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=1362-1371&author=M.+Lambaauthor=R.+Wangauthor=T.+Fletcherauthor=C.+Alveyauthor=J.+I.+V.+Kushnerauthor=T.+C.+Stock&title=Extended-Release+Once-Daily+Formulation+of+Tofacitinib%3A+Evaluation+of+Pharmacokinetics+Compared+With+Immediate-Release+Tofacitinib+and+Impact+of+Food&doi=10.1002%2Fjcph.734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food</span></div><div class="casAuthors">Lamba, Manisha; Wang, Rong; Fletcher, Tracey; Alvey, Christine; Kushner, Joseph, IV; Stock, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1362-1371</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.  An extended-release (XR) formulation has been designed to provide a once-daily (QD) dosing option to patients to achieve comparable pharmacokinetic (PK) parameters to the twice-daily immediate-release (IR) formulation.  We conducted 2 randomized, open-label, phase 1 studies in healthy volunteers.  Study A characterized single-dose and steady-state PK of tofacitinib XR 11 mg QD and intended to demonstrate equivalence of exposure under single-dose and steady-state conditions to tofacitinib IR 5 mg twice daily.  Study B assessed the effect of a high-fat meal on the bioavailability of tofacitinib from the XR formulation.  Safety and tolerability were monitored in both studies.  In study A (N = 24), the XR and IR formulations achieved time to max. plasma concn. at 4 h and 0.5 h postdose, resp.; terminal half-life was 5.9 h and 3.2 h, resp.  Area under plasma concn.-time curve (AUC) and max. plasma concn. (Cmax) after single- and multiple-dose administration were equiv. between the XR and IR formulations.  In study B (N = 24), no difference in AUC was obsd. for fed vs fasted conditions.  Cmax increased by 27% under the fed state.  On repeat administration, negligible accumulation (<20%) of systemic exposures was obsd. for both formulations.  Steady state was achieved within 48 h of dosing with the XR formulation.  Tofacitinib administration as an XR or IR formulation was generally well tolerated in these studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotnOLKAQOsybVg90H21EOLACvtfcHk0lhem9ifsLKKyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Wkur3L&md5=bb46ee17ae48cec6a8fbed7840ce02d9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fjcph.734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.734%26sid%3Dliteratum%253Aachs%26aulast%3DLamba%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DFletcher%26aufirst%3DT.%26aulast%3DAlvey%26aufirst%3DC.%26aulast%3DKushner%26aufirst%3DJ.%2BI.%2BV.%26aulast%3DStock%26aufirst%3DT.%2BC.%26atitle%3DExtended-Release%2520Once-Daily%2520Formulation%2520of%2520Tofacitinib%253A%2520Evaluation%2520of%2520Pharmacokinetics%2520Compared%2520With%2520Immediate-Release%2520Tofacitinib%2520and%2520Impact%2520of%2520Food%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D56%26spage%3D1362%26epage%3D1371%26doi%3D10.1002%2Fjcph.734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutmacher, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furst, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikranian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduaka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span> <span> </span><span class="NLM_article-title">Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib</span>. <i>Clin. Pharmacol. Ther. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1002/cpt.576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1002%2Fcpt.576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=27859030" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2017&pages=745-753&author=M.+Lambaauthor=M.+M.+Hutmacherauthor=D.+E.+Furstauthor=A.+Dikranianauthor=M.+E.+Dowtyauthor=D.+Conradoauthor=T.+Stockauthor=C.+Nduakaauthor=J.+Cookauthor=S.+Krishnaswami&title=Model-Informed+Development+and+Registration+of+a+Once-Daily+Regimen+of+Extended-Release+Tofacitinib&doi=10.1002%2Fcpt.576"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcpt.576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.576%26sid%3Dliteratum%253Aachs%26aulast%3DLamba%26aufirst%3DM.%26aulast%3DHutmacher%26aufirst%3DM.%2BM.%26aulast%3DFurst%26aufirst%3DD.%2BE.%26aulast%3DDikranian%26aufirst%3DA.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DConrado%26aufirst%3DD.%26aulast%3DStock%26aufirst%3DT.%26aulast%3DNduaka%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DKrishnaswami%26aufirst%3DS.%26atitle%3DModel-Informed%2520Development%2520and%2520Registration%2520of%2520a%2520Once-Daily%2520Regimen%2520of%2520Extended-Release%2520Tofacitinib%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2017%26volume%3D101%26spage%3D745%26epage%3D753%26doi%3D10.1002%2Fcpt.576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dack, K.</span></span> <span> </span><span class="NLM_article-title">Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.2174/1389200033489253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.2174%2F1389200033489253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=14683475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpslShtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=461-485&author=K.+Beaumontauthor=R.+Websterauthor=I.+Gardnerauthor=K.+Dack&title=Design+of+ester+prodrugs+to+enhance+oral+absorption+of+poorly+permeable+compounds%3A+Challenges+to+the+discovery+scientist&doi=10.2174%2F1389200033489253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist</span></div><div class="casAuthors">Beaumont, Kevin; Webster, Robert; Gardner, Iain; Dack, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">461-485</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review and discussion.  Many drugs are administered at sites that are remote from their site of action.  The most common route of drug delivery is the oral route.  The optimal physicochem. properties to allow high transcellular absorption following oral administration are well established and include a limit on mol. size, hydrogen bonding potential and adequate lipophilicity.  For many drug targets, synthetic strategies can be devised to balance the physicochem. properties required for high transcellular absorption and the SAR for the drug target.  However, there are drug targets where the SAR requires properties at odds with good membrane permeability.  These include a requirement for significant polarity and groups that exhibit high hydrogen bonding potential such as carboxylic acids and alcs.  In such cases, prodrug strategies have been employed.  The rationale behind the prodrug strategy is to introduce lipophilicity and mask hydrogen bonding groups of an active compd. by the addn. of another moiety, most commonly an ester.  An ideal ester prodrug should exhibit the following properties:.  (1) Weak (or no) activity against any pharmacol. target,.  (2) Chem. stability across a pH range,.  (3) High aq. soly.,.  (4) Good transcellular absorption,.  (5) Resistance to hydrolysis during the absorption phase,.  (6) Rapid and quant. breakdown to yield high circulating concns. of the active component post absorption.  This paper will review the literature around marketed prodrugs and det. the most appropriate prodrug characteristics.  In addn., it will examine potential discovery approaches to optimizing prodrug delivery and recommend a strategy for prosecuting an oral prodrug approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJklGnlqCIqbVg90H21EOLACvtfcHk0lhem9ifsLKKyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpslShtLo%253D&md5=442e3b78efc2e601c688c03eeeaa6e54</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F1389200033489253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200033489253%26sid%3Dliteratum%253Aachs%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DDack%26aufirst%3DK.%26atitle%3DDesign%2520of%2520ester%2520prodrugs%2520to%2520enhance%2520oral%2520absorption%2520of%2520poorly%2520permeable%2520compounds%253A%2520Challenges%2520to%2520the%2520discovery%2520scientist%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2003%26volume%3D4%26spage%3D461%26epage%3D485%26doi%3D10.2174%2F1389200033489253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, G.</span></span> <span> </span><span class="NLM_article-title">Drug metabolite concentration-time profiles: influence of route of drug administration</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.1984.tb02362.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1111%2Fj.1365-2125.1984.tb02362.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=6721984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL2cXhvVGgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1984&pages=385-94&author=J.+B.+Houstonauthor=G.+Taylor&title=Drug+metabolite+concentration-time+profiles%3A+influence+of+route+of+drug+administration&doi=10.1111%2Fj.1365-2125.1984.tb02362.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Drug metabolite concentration-time profiles:  influence of route of drug administration</span></div><div class="casAuthors">Houston, J. B.; Taylor, G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">385-94</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">The influence of the route of drug administration on metabolite kinetics was investigated by computer simulation.  Comparisons between simulated profiles and published concn.-time data were carried out.  A route dependence in metabolite concn.-time curves is readily apparent provided that the metabolite kinetics are formation-rate limited and the hepatic clearance of drug is >25 L/h (medium to highly cleared).  Oral drug administration produces a triphasic metabolite concn.-time profile, whereas only 2 phases are discernable after i.v. drug administration.  The magnitude of the difference in max. metabolite concn. is directly proportional to the hepatic clearance of drug due to 1st-pass metabolite prodn.  The route dependence in the shape of the metabolite concn.-time curves is most dramatic when the absorption and distribution of drug and the elimination of metabolite is rapid.  A redn. in the rate of either of these processes alters the shape of the metabolite concn.-time profile such that the consequence of 1st-pass metabolite formation may be reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlVoh0NewQwbVg90H21EOLACvtfcHk0lhem9ifsLKKyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXhvVGgs78%253D&md5=0209ac06cf0d153434903b8e9a2b0c09</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.1984.tb02362.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.1984.tb02362.x%26sid%3Dliteratum%253Aachs%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26aulast%3DTaylor%26aufirst%3DG.%26atitle%3DDrug%2520metabolite%2520concentration-time%2520profiles%253A%2520influence%2520of%2520route%2520of%2520drug%2520administration%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1984%26volume%3D17%26spage%3D385%26epage%3D94%26doi%3D10.1111%2Fj.1365-2125.1984.tb02362.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">The Operational Multiple Dosing Half-life: A Key to Defining Drug Accumulation in Patients and to Designing Extended Release Dosage Forms</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2869</span>– <span class="NLM_lpage">2877</span>, <span class="refDoi"> DOI: 10.1007/s11095-008-9787-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1007%2Fs11095-008-9787-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2008&pages=2869-2877&author=S.+Sahinauthor=L.+Z.+Benet&title=The+Operational+Multiple+Dosing+Half-life%3A+A+Key+to+Defining+Drug+Accumulation+in+Patients+and+to+Designing+Extended+Release+Dosage+Forms&doi=10.1007%2Fs11095-008-9787-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs11095-008-9787-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-008-9787-9%26sid%3Dliteratum%253Aachs%26aulast%3DSahin%26aufirst%3DS.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DThe%2520Operational%2520Multiple%2520Dosing%2520Half-life%253A%2520A%2520Key%2520to%2520Defining%2520Drug%2520Accumulation%2520in%2520Patients%2520and%2520to%2520Designing%2520Extended%2520Release%2520Dosage%2520Forms%26jtitle%3DPharm.%2520Res.%26date%3D2008%26volume%3D25%26spage%3D2869%26epage%3D2877%26doi%3D10.1007%2Fs11095-008-9787-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boxenbaum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battle, M.</span></span> <span> </span><span class="NLM_article-title">Effective half-life in clinical pharmacology</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">763</span>– <span class="NLM_lpage">766</span>, <span class="refDoi"> DOI: 10.1002/j.1552-4604.1995.tb04117.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1002%2Fj.1552-4604.1995.tb04117.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=8522631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaK2MXpsVaju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1995&pages=763-766&author=H.+Boxenbaumauthor=M.+Battle&title=Effective+half-life+in+clinical+pharmacology&doi=10.1002%2Fj.1552-4604.1995.tb04117.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Effective half-life in clinical pharmacology</span></div><div class="casAuthors">Boxenbaum, Harold; Battle, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">763-6</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">A commentary discussing effective half-life in simple math. terms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHvhmW6PGswrVg90H21EOLACvtfcHk0ljlpN51piy9wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpsVaju7k%253D&md5=33e8048bcc0487154567862ebed7169b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fj.1552-4604.1995.tb04117.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1552-4604.1995.tb04117.x%26sid%3Dliteratum%253Aachs%26aulast%3DBoxenbaum%26aufirst%3DH.%26aulast%3DBattle%26aufirst%3DM.%26atitle%3DEffective%2520half-life%2520in%2520clinical%2520pharmacology%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1995%26volume%3D35%26spage%3D763%26epage%3D766%26doi%3D10.1002%2Fj.1552-4604.1995.tb04117.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and metabolism of a sulphamide NK2 antagonist in rat, dog and human</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">642</span>, <span class="refDoi"> DOI: 10.1080/004982500406453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1080%2F004982500406453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10923864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvFCltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2000&pages=627-642&author=K.+Beaumontauthor=A.+Harperauthor=D.+A.+Smithauthor=S.+Abel&title=Pharmacokinetics+and+metabolism+of+a+sulphamide+NK2+antagonist+in+rat%2C+dog+and+human&doi=10.1080%2F004982500406453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and metabolism of a sulphamide NK2 antagonist in rat, dog and human</span></div><div class="casAuthors">Beaumont, K.; Harper, A.; Smith, D. A.; Abel, S.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">627-642</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">1. UK-224,671 is a sulfamide-contg. NK2 antagonist with moderate lipophilicity and basicity.  2. The physicochem. properties of UK-224,671 are reflected in its pharmacokinetics following i.v. administration.  The compd. partitioned extensively into red blood cells in all species examd. and the blood clearance was moderate to low with respect to liver blood flow and distribution into tissues was extensive.  3. UK-224,671 exhibited species differences in oral bioavailability.  In dog, the compd. exhibited moderate bioavailability (55%), whereas in rat and man oral bioavailability was < 10%.  4. In rat and dog, the major excreted form after i.v. administration was unchanged UK-224,671 in both urine and feces.  In addn., of three metabolites obsd., the most abundant was the N-descyclopropylmethyl (UK-280,045).  5. The profile of radioactivity in rat following oral administration of [14C]-UK-224,671 was not consistent with a 10% absorbed compd. with 40% of the dose present as metabolites.  This suggests that the low bioavailability of UK-224,671 in rat is due to a combination of moderate intestinal permeability and extensive first-pass metab. by the gut and does not result from poor gastrointestinal absorption per se.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpns74iTwf5PbVg90H21EOLACvtfcHk0ljlpN51piy9wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvFCltL4%253D&md5=5d6a03b5b2b7060be7e6c4c6fb0f1af0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1080%2F004982500406453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F004982500406453%26sid%3Dliteratum%253Aachs%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DHarper%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DAbel%26aufirst%3DS.%26atitle%3DPharmacokinetics%2520and%2520metabolism%2520of%2520a%2520sulphamide%2520NK2%2520antagonist%2520in%2520rat%252C%2520dog%2520and%2520human%26jtitle%3DXenobiotica%26date%3D2000%26volume%3D30%26spage%3D627%26epage%3D642%26doi%3D10.1080%2F004982500406453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nash, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridolfo, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spradlin, C. T.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetic and metabolic studies</span>. <i>J. Rheumatol., Suppl.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">19</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=6930483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL3cXlsVartLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1980&pages=12-19&author=J.+F.+Nashauthor=R.+H.+Carmichaelauthor=A.+S.+Ridolfoauthor=C.+T.+Spradlin&title=Pharmacokinetic+studies+of+benoxaprofen+after+therapeutic+doses+with+a+review+of+related+pharmacokinetic+and+metabolic+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetic and metabolic studies</span></div><div class="casAuthors">Nash, J. Frank; Carmichael, Ralph H.; Ridolfo, Anthony S.; Spradlin, C. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology, Supplement</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Proc. Int. Symp. Benoxaprofen, 1979</span>),
    <span class="NLM_cas:pages">12-19</span>CODEN:
                <span class="NLM_cas:coden">JRSUDX</span>;
        ISSN:<span class="NLM_cas:issn">0380-0903</span>.
    </div><div class="casAbstract">The pharmacokinetics of benoxaprofen (I)  [51234-28-7] in therapeutic doses of 400 or 600 mg as a soln., capsule or tablet were detd. in 44 men after single or multiple doses.  The plasma levels of the drug after oral administration of a soln. best fitted a 2-compartment open pharmacokinetic model, whereas the levels after the solid dosage forms more appropriately fitted the simple 1-compartment open model.  The plasma elimination half-life of the drug, when in solid dosage form, was in the range of 19-26 h, justifying once-a-day dosage.  Steady state levels of benoxaprofen were obtained after the 5th dose of a 400 mg capsule every 24 h.  A review of the related pharmacokinetic and metabolic studies is also given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreCo6wn6XChLVg90H21EOLACvtfcHk0ljlpN51piy9wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXlsVartLg%253D&md5=4421a99f3f7f9812cf4154caa7dd096c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNash%26aufirst%3DJ.%2BF.%26aulast%3DCarmichael%26aufirst%3DR.%2BH.%26aulast%3DRidolfo%26aufirst%3DA.%2BS.%26aulast%3DSpradlin%26aufirst%3DC.%2BT.%26atitle%3DPharmacokinetic%2520studies%2520of%2520benoxaprofen%2520after%2520therapeutic%2520doses%2520with%2520a%2520review%2520of%2520related%2520pharmacokinetic%2520and%2520metabolic%2520studies%26jtitle%3DJ.%2520Rheumatol.%252C%2520Suppl.%26date%3D1980%26volume%3D6%26spage%3D12%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halsey, J.
P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoe, N.</span></span> <span> </span><span class="NLM_article-title">Benoxaprofen: side-effect profile in 300 patients</span>. <i>Br. Med. J. (Clin. Res. Ed.)</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">1365</span>– <span class="NLM_lpage">1368</span>, <span class="refDoi"> DOI: 10.1136/bmj.284.6326.1365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1136%2Fbmj.284.6326.1365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=6803978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A280%3ADyaL387otlGmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=1982&pages=1365-1368&author=J.%0AP.+Halseyauthor=N.+Cardoe&title=Benoxaprofen%3A+side-effect+profile+in+300+patients&doi=10.1136%2Fbmj.284.6326.1365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Benoxaprofen: side-effect profile in 300 patients</span></div><div class="casAuthors">Halsey J P; Cardoe N</div><div class="citationInfo"><span class="NLM_cas:title">British medical journal (Clinical research ed.)</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">6326</span>),
    <span class="NLM_cas:pages">1365-8</span>
        ISSN:<span class="NLM_cas:issn">0267-0623</span>.
    </div><div class="casAbstract">Out of 300 patients who had taken benoxaprofen for a mean of 6.4 months, 196 (65.3%) reported side effects, resulting in 104 patients (34.6%) having the drug withdrawn.  Out of 42 patients aged over 70, 35 (83.3%) had side effects and 29 (69.0%) had the drug withdrawn because of them. cutaneous side effects accounted for 180 (69.5%) of all 259 side effects reported.  The commonest cutaneous side effect was photosensitivity, which occurred in 86 patients (28.6%).  Photosensitivity, which occurred in half of the patients treated in the summer, resulted in withdrawal of benoxaprofen in 26 (30.2%) of the patients who experienced it.  Onycholysis was observed in 38 patients (12.6%) and was frequently unnoticed by patients.  The overall incidence of gastric side effects was 12.6% (38 patients), and the figure rose to 40.5% (17 cases) in patients over 70.  During treatment with benoxaprofen one patient developed an active duodenal ulcer but no cases of major gastrointestinal haemorrhage occurred.  Multiple subepidermal cysts (milia) were observed in 16 patients, who had been treated for a mean of 10.8 months.  These findings show that benoxaprofen is a potent phototoxic drug and that the manufacturers' recommended dosage of 600 mg daily is associated with an unacceptable incidence of side effects in the elderly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQv83-g_m4FW8rRqEXsZufAfW6udTcc2ebHW5wvcGd6q7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL387otlGmuw%253D%253D&md5=dbed090d696d9e4604e645aa69036bb2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1136%2Fbmj.284.6326.1365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.284.6326.1365%26sid%3Dliteratum%253Aachs%26aulast%3DHalsey%26aufirst%3DJ.%2BP.%26aulast%3DCardoe%26aufirst%3DN.%26atitle%3DBenoxaprofen%253A%2520side-effect%2520profile%2520in%2520300%2520patients%26jtitle%3DBr.%2520Med.%2520J.%2520%2528Clin.%2520Res.%2520Ed.%2529%26date%3D1982%26volume%3D284%26spage%3D1365%26epage%3D1368%26doi%3D10.1136%2Fbmj.284.6326.1365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murnane, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodcock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, I. M.</span></span> <span> </span><span class="NLM_article-title">The pharmacokinetics of benoxaprofen in elderly subjects</span>. <i>Eur. J. Rheumatol. Inflammation</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">75</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=7084284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL38Xktleju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1982&pages=69-75&author=R.+C.+Hamdyauthor=B.+Murnaneauthor=N.+Pereraauthor=K.+Woodcockauthor=I.+M.+Koch&title=The+pharmacokinetics+of+benoxaprofen+in+elderly+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacokinetics of benoxaprofen in elderly subjects</span></div><div class="casAuthors">Hamdy, R. C.; Murnane, B.; Perera, N.; Woodcock, K.; Koch, I. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Rheumatology and Inflammation</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-75</span>CODEN:
                <span class="NLM_cas:coden">EJRIDH</span>;
        ISSN:<span class="NLM_cas:issn">0140-1610</span>.
    </div><div class="casAbstract">benoxaprofen (I)  [51234-28-7] plasma profiles were obtained in 2 groups of elderly female patients.  A single dose of benoxaprofen, either 600 mg or 300 mg, was given and blood levels were measured daily up to 120 h.  Mean peak plasma levels were reached at 5 h following the 600-mg dose and at 7 h after the 300-mg dose.  Elimination half-lives calcd. from levels during 36-120 h resulted in means of 111 h and 86.4 h for the 600-mg and 300-mg doses, resp., whereas the elimination half-lives for younger subjects was 30-35 h.  Because of these extended half-lives, a further study was conducted following a single 600-mg dose to 4 more patients.  Blood levels were measured up to 504 h (21 days).  This resulted in a mean half-life of 147.9 h calcd. from levels during 168-504 h.  Although serum creatinine levels were not generally above the normal for this age group, calcd. creatinine clearances were considerably reduced.  Thus, the high plasma benoxaprofen levels achieved, combined with the slow clearance rates and long half-lives, indicate that it may be possible to administer benoxaprofen less frequently or at lower doses to elderly patients.  More work is needed to det. whether this prolonged half-life is matched by an equally prolonged therapeutic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRdUJcahrmBrVg90H21EOLACvtfcHk0li4JEv4MH_sGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38Xktleju7g%253D&md5=df7a5412beff405fc8fe0a4109dc9a8e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamdy%26aufirst%3DR.%2BC.%26aulast%3DMurnane%26aufirst%3DB.%26aulast%3DPerera%26aufirst%3DN.%26aulast%3DWoodcock%26aufirst%3DK.%26aulast%3DKoch%26aufirst%3DI.%2BM.%26atitle%3DThe%2520pharmacokinetics%2520of%2520benoxaprofen%2520in%2520elderly%2520subjects%26jtitle%3DEur.%2520J.%2520Rheumatol.%2520Inflammation%26date%3D1982%26volume%3D5%26spage%3D69%26epage%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatfield, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. N.</span></span> <span> </span><span class="NLM_article-title">Disposition and metabolism of benoxaprofen in laboratory animals and man</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.3109/00498257809060392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.3109%2F00498257809060392" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1978&pages=133-144&author=D.+H.+Chatfieldauthor=J.+N.+Green&title=Disposition+and+metabolism+of+benoxaprofen+in+laboratory+animals+and+man&doi=10.3109%2F00498257809060392"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3109%2F00498257809060392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498257809060392%26sid%3Dliteratum%253Aachs%26aulast%3DChatfield%26aufirst%3DD.%2BH.%26aulast%3DGreen%26aufirst%3DJ.%2BN.%26atitle%3DDisposition%2520and%2520metabolism%2520of%2520benoxaprofen%2520in%2520laboratory%2520animals%2520and%2520man%26jtitle%3DXenobiotica%26date%3D1978%26volume%3D8%26spage%3D133%26epage%3D144%26doi%3D10.3109%2F00498257809060392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 33 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Tristan S. Maurer, Dennis Smith, Kevin Beaumont, <span class="NLM_string-name hlFld-ContribAuthor">Li Di</span>. </span><span class="cited-content_cbyCitation_article-title">Dose Predictions for Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (12)
                                     , 6423-6435. <a href="https://doi.org/10.1021/acs.jmedchem.9b01365" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01365</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01365%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDose%252BPredictions%252Bfor%252BDrug%252BDesign%26aulast%3DMaurer%26aufirst%3DTristan%2BS.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D18082019%26date%3D22012020%26date%3D08012020%26volume%3D63%26issue%3D12%26spage%3D6423%26epage%3D6435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mayuri Gupta, Thomas Bogdanowicz, Mark A. Reed, Christopher J. Barden, <span class="NLM_string-name hlFld-ContribAuthor">Donald F. Weaver</span>. </span><span class="cited-content_cbyCitation_article-title">The Brain Exposure Efficiency (BEE) Score. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (2)
                                     , 205-224. <a href="https://doi.org/10.1021/acschemneuro.9b00650" title="DOI URL">https://doi.org/10.1021/acschemneuro.9b00650</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.9b00650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.9b00650%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DThe%252BBrain%252BExposure%252BEfficiency%252B%252528BEE%252529%252BScore%26aulast%3DGupta%26aufirst%3DMayuri%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D04122019%26date%3D09122019%26date%3D27122019%26date%3D09122019%26volume%3D11%26issue%3D2%26spage%3D205%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Carl A. Brooks, Linda S. Barton, David J. Behm, Edward J. Brnardic, Melissa H. Costell, Dennis A. Holt, Larry J. Jolivette, Jay M. Matthews, John J. McAtee, Brent W. McCleland, Jaclyn R. Patterson, Joseph E. Pero, Ralph A. Rivero, Theresa J. Roethke, Robert M. Sanchez, Raynold Shenje, Lamont R. Terrell, <span class="NLM_string-name hlFld-ContribAuthor">Brian G. Lawhorn</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of GSK3527497: A Candidate for the Inhibition of Transient Receptor Potential Vanilloid-4 (TRPV4). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 9270-9280. <a href="https://doi.org/10.1021/acs.jmedchem.9b01247" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01247</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01247%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BGSK3527497%25253A%252BA%252BCandidate%252Bfor%252Bthe%252BInhibition%252Bof%252BTransient%252BReceptor%252BPotential%252BVanilloid-4%252B%252528TRPV4%252529%26aulast%3DBrooks%26aufirst%3DCarl%2BA.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D31072019%26date%3D09102019%26date%3D18092019%26volume%3D62%26issue%3D20%26spage%3D9270%26epage%3D9280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Youchao Deng, Xiang Weng, Yuling Li, Meng Su, Zhongqing Wen, Xinxin Ji, Nan Ren, Ben Shen, Yanwen Duan, <span class="NLM_string-name hlFld-ContribAuthor">Yong Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (14)
                                     , 6682-6693. <a href="https://doi.org/10.1021/acs.jmedchem.9b00616" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00616</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00616%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLate-Stage%252BFunctionalization%252Bof%252BPlatensimycin%252BLeading%252Bto%252BMultiple%252BAnalogues%252Bwith%252BImproved%252BAntibacterial%252BActivity%252Bin%252BVitro%252Band%252Bin%252BVivo%26aulast%3DDeng%26aufirst%3DYouchao%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D10042019%26date%3D02072019%26date%3D18062019%26volume%3D62%26issue%3D14%26spage%3D6682%26epage%3D6693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dennis
A. Smith, Kevin Beaumont, Tristan S. Maurer, <span class="NLM_string-name hlFld-ContribAuthor">Li Di</span>. </span><span class="cited-content_cbyCitation_article-title">Clearance in Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (5)
                                     , 2245-2255. <a href="https://doi.org/10.1021/acs.jmedchem.8b01263" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01263%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DClearance%252Bin%252BDrug%252BDesign%26aulast%3DSmith%26aufirst%3DDennis%2BA.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D09082018%26date%3D17102018%26date%3D03102018%26volume%3D62%26issue%3D5%26spage%3D2245%26epage%3D2255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Brian Raymer, <span class="NLM_string-name hlFld-ContribAuthor">Samit K. Bhattacharya</span>. </span><span class="cited-content_cbyCitation_article-title">Lead-like Drugs: A Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (23)
                                     , 10375-10384. <a href="https://doi.org/10.1021/acs.jmedchem.8b00407" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00407%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLead-like%252BDrugs%25253A%252BA%252BPerspective%26aulast%3DRaymer%26aufirst%3DBrian%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D13032018%26date%3D27072018%26volume%3D61%26issue%3D23%26spage%3D10375%26epage%3D10384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Paul W. Smith, Fabio Zuccotto, Robert H. Bates, Maria Santos Martinez-Martinez, Kevin D. Read, Caroline Peet, <span class="NLM_string-name hlFld-ContribAuthor">Ola Epemolu</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetics of β-Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2018,</strong> <em>4 </em>
                                    (10)
                                     , 1439-1447. <a href="https://doi.org/10.1021/acsinfecdis.8b00160" title="DOI URL">https://doi.org/10.1021/acsinfecdis.8b00160</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.8b00160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.8b00160%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DPharmacokinetics%252Bof%252B%2525CE%2525B2-Lactam%252BAntibiotics%25253A%252BClues%252Bfrom%252Bthe%252BPast%252BTo%252BHelp%252BDiscover%252BLong-Acting%252BOral%252BDrugs%252Bin%252Bthe%252BFuture%26aulast%3DSmith%26aufirst%3DPaul%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D04072018%26date%3D10092018%26date%3D24082018%26volume%3D4%26issue%3D10%26spage%3D1439%26epage%3D1447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hakan Gunaydin, Michael D. Altman, J. Michael Ellis, Peter Fuller, Scott A. Johnson, Brian Lahue, <span class="NLM_string-name hlFld-ContribAuthor">Blair Lapointe</span>. </span><span class="cited-content_cbyCitation_article-title">Strategy for Extending Half-life in Drug Design and Its Significance. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (6)
                                     , 528-533. <a href="https://doi.org/10.1021/acsmedchemlett.8b00018" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00018%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStrategy%252Bfor%252BExtending%252BHalf-life%252Bin%252BDrug%252BDesign%252Band%252BIts%252BSignificance%26aulast%3DGunaydin%26aufirst%3DHakan%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D12012018%26date%3D02042018%26date%3D04042018%26date%3D02042018%26volume%3D9%26issue%3D6%26spage%3D528%26epage%3D533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam J.  Plaunt</span>, <span class="hlFld-ContribAuthor ">Sasha J.  Rose</span>, <span class="hlFld-ContribAuthor ">Jeong Yeon  Kang</span>, <span class="hlFld-ContribAuthor ">Kuan-Ju  Chen</span>, <span class="hlFld-ContribAuthor ">Daniel  LaSala</span>, <span class="hlFld-ContribAuthor ">Ryan P.  Heckler</span>, <span class="hlFld-ContribAuthor ">Arielle  Dorfman</span>, <span class="hlFld-ContribAuthor ">Barrett T.  Smith</span>, <span class="hlFld-ContribAuthor ">Donald  Chun</span>, <span class="hlFld-ContribAuthor ">Veronica  Viramontes</span>, <span class="hlFld-ContribAuthor ">Antonio  Macaluso</span>, <span class="hlFld-ContribAuthor ">Zhili  Li</span>, <span class="hlFld-ContribAuthor ">Yuchen  Zhou</span>, <span class="hlFld-ContribAuthor ">Lilly  Mark</span>, <span class="hlFld-ContribAuthor ">Jessica  Basso</span>, <span class="hlFld-ContribAuthor ">Franziska G.  Leifer</span>, <span class="hlFld-ContribAuthor ">Michel R.  Corboz</span>, <span class="hlFld-ContribAuthor ">Richard W.  Chapman</span>, <span class="hlFld-ContribAuthor ">David  Cipolla</span>, <span class="hlFld-ContribAuthor ">Walter R.  Perkins</span>, <span class="hlFld-ContribAuthor ">Vladimir S.  Malinin</span>, <span class="hlFld-ContribAuthor ">Donna M.  Konicek</span>. </span><span class="cited-content_cbyCitation_article-title">Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2021,</strong> <em>65 </em>
                                    (7)
                                     <a href="https://doi.org/10.1128/AAC.00316-21" title="DOI URL">https://doi.org/10.1128/AAC.00316-21</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/AAC.00316-21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FAAC.00316-21%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3DDevelopment%252Band%252BPreclinical%252BEvaluation%252Bof%252BNew%252BInhaled%252BLipoglycopeptides%252Bfor%252Bthe%252BTreatment%252Bof%252BPersistent%252BPulmonary%252BMethicillin-Resistant%252BStaphylococcus%252Baureus%252BInfections%26aulast%3DPlaunt%26aufirst%3DAdam%2BJ.%26date%3D2021%26volume%3D65%26issue%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hidehiko  Maruyama</span>, <span class="hlFld-ContribAuthor ">Ayano  Tanzawa</span>, <span class="hlFld-ContribAuthor ">Takanori  Funaki</span>, <span class="hlFld-ContribAuthor ">Yushi  Ito</span>, <span class="hlFld-ContribAuthor ">Tetsuya  Isayama</span>. </span><span class="cited-content_cbyCitation_article-title">Low vancomycin trough concentration in neonates and young infants. </span><span class="cited-content_cbyCitation_journal-name">Pediatrics International</span><span> <strong>2021,</strong> <em>63 </em>
                                    (5)
                                     , 556-560. <a href="https://doi.org/10.1111/ped.14459" title="DOI URL">https://doi.org/10.1111/ped.14459</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/ped.14459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fped.14459%26sid%3Dliteratum%253Aachs%26jtitle%3DPediatrics%2520International%26atitle%3DLow%252Bvancomycin%252Btrough%252Bconcentration%252Bin%252Bneonates%252Band%252Byoung%252Binfants%26aulast%3DMaruyama%26aufirst%3DHidehiko%26date%3D2021%26date%3D2021%26volume%3D63%26issue%3D5%26spage%3D556%26epage%3D560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Van Thi Khanh  Nguyen</span>, <span class="hlFld-ContribAuthor ">Preecha  Montakantikul</span>, <span class="hlFld-ContribAuthor ">Pramote  Tragulpiankit</span>, <span class="hlFld-ContribAuthor ">Jantana  Houngsaitong</span>, <span class="hlFld-ContribAuthor ">Mohd Fazli  Shuib</span>. </span><span class="cited-content_cbyCitation_article-title">Colistin Dosing Regimens against Pseudomonas aeruginosa in Critically Ill Patients: An Application of Monte Carlo Simulation. </span><span class="cited-content_cbyCitation_journal-name">Antibiotics</span><span> <strong>2021,</strong> <em>10 </em>
                                    (5)
                                     , 595. <a href="https://doi.org/10.3390/antibiotics10050595" title="DOI URL">https://doi.org/10.3390/antibiotics10050595</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antibiotics10050595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantibiotics10050595%26sid%3Dliteratum%253Aachs%26jtitle%3DAntibiotics%26atitle%3DColistin%252BDosing%252BRegimens%252Bagainst%252BPseudomonas%252Baeruginosa%252Bin%252BCritically%252BIll%252BPatients%25253A%252BAn%252BApplication%252Bof%252BMonte%252BCarlo%252BSimulation%26aulast%3DNguyen%26aufirst%3DVan%2BThi%2BKhanh%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D5%26spage%3D595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edward H.  Kerns</span>, <span class="hlFld-ContribAuthor ">Xun  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Di</span>. </span><span class="cited-content_cbyCitation_article-title">ADMET
              In
              Vitro
              Profiling – Utility and Applications in Lead Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-31. <a href="https://doi.org/10.1002/0471266949.bmc118.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc118.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc118.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc118.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DADMET%252BIn%252BVitro%252BProfiling%252B%2525E2%252580%252593%252BUtility%252Band%252BApplications%252Bin%252BLead%252BDiscovery%26aulast%3DKerns%26aufirst%3DEdward%2BH.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D31%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Qiuyue  Zhang</span>, <span class="hlFld-ContribAuthor ">Qidong  You</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the HSP90–CDC37–kinase chaperone cycle: A promising therapeutic strategy for cancer. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2021,</strong> <em>95 </em><a href="https://doi.org/10.1002/med.21807" title="DOI URL">https://doi.org/10.1002/med.21807</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21807%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252Bthe%252BHSP90%2525E2%252580%252593CDC37%2525E2%252580%252593kinase%252Bchaperone%252Bcycle%25253A%252BA%252Bpromising%252Btherapeutic%252Bstrategy%252Bfor%252Bcancer%26aulast%3DWang%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nurul A  Abdullah</span>, <span class="hlFld-ContribAuthor ">Martyn  Inman</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Moody</span>, <span class="hlFld-ContribAuthor ">Sarah J  Storr</span>, <span class="hlFld-ContribAuthor ">Stewart G  Martin</span>. </span><span class="cited-content_cbyCitation_article-title">Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Investigational New Drugs</span><span> <strong>2021,</strong> <em>68 </em><a href="https://doi.org/10.1007/s10637-021-01106-5" title="DOI URL">https://doi.org/10.1007/s10637-021-01106-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10637-021-01106-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10637-021-01106-5%26sid%3Dliteratum%253Aachs%26jtitle%3DInvestigational%2520New%2520Drugs%26atitle%3DCytotoxic%252Band%252Bradiosensitising%252Beffects%252Bof%252Ba%252Bnovel%252Bthioredoxin%252Breductase%252Binhibitor%252Bin%252Bbreast%252Bcancer%26aulast%3DAbdullah%26aufirst%3DNurul%2BA%26date%3D2021%26date%3D2021%26volume%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Keumhan  Noh</span>, <span class="hlFld-ContribAuthor ">Alicia  Pietrasiewicz</span>, <span class="hlFld-ContribAuthor ">Xingrong  Liu</span>, <span class="hlFld-ContribAuthor ">Cong  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">Use of Intravenous Infusion Study Design to Simultaneously Determine Brain Penetration and Systemic Pharmacokinetic Parameters in Rats. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2021,</strong> <em>49 </em>
                                    (2)
                                     , 142-151. <a href="https://doi.org/10.1124/dmd.120.000242" title="DOI URL">https://doi.org/10.1124/dmd.120.000242</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.120.000242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.120.000242%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DUse%252Bof%252BIntravenous%252BInfusion%252BStudy%252BDesign%252Bto%252BSimultaneously%252BDetermine%252BBrain%252BPenetration%252Band%252BSystemic%252BPharmacokinetic%252BParameters%252Bin%252BRats%26aulast%3DNoh%26aufirst%3DKeumhan%26date%3D2021%26date%3D2020%26volume%3D49%26issue%3D2%26spage%3D142%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark P.  Grillo</span>, <span class="hlFld-ContribAuthor ">Svetlana  Markova</span>, <span class="hlFld-ContribAuthor ">Marc  Evanchik</span>, <span class="hlFld-ContribAuthor ">Marc  Trellu</span>, <span class="hlFld-ContribAuthor ">Patricia  Moliner</span>, <span class="hlFld-ContribAuthor ">Priscilla  Brun</span>, <span class="hlFld-ContribAuthor ">Anne  Perreard-Dumaine</span>, <span class="hlFld-ContribAuthor ">Pascale  Vicat</span>, <span class="hlFld-ContribAuthor ">Chun  Yang</span>, <span class="hlFld-ContribAuthor ">James P.  Driscoll</span>, <span class="hlFld-ContribAuthor ">Tim J.  Carlson</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical
              in vitro
              and
              in vivo
              pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy. </span><span class="cited-content_cbyCitation_journal-name">Xenobiotica</span><span> <strong>2021,</strong> <em>51 </em>
                                    (2)
                                     , 222-238. <a href="https://doi.org/10.1080/00498254.2020.1839982" title="DOI URL">https://doi.org/10.1080/00498254.2020.1839982</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00498254.2020.1839982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00498254.2020.1839982%26sid%3Dliteratum%253Aachs%26jtitle%3DXenobiotica%26atitle%3DPreclinical%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bpharmacokinetic%252Bproperties%252Bof%252Bdanicamtiv%25252C%252Ba%252Bnew%252Btargeted%252Bmyosin%252Bactivator%252Bfor%252Bthe%252Btreatment%252Bof%252Bdilated%252Bcardiomyopathy%26aulast%3DGrillo%26aufirst%3DMark%2BP.%26date%3D2021%26date%3D2020%26volume%3D51%26issue%3D2%26spage%3D222%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">C. A.  de Araújo Vitor</span>, <span class="hlFld-ContribAuthor ">A.  de Oliveira Lira Ortega</span>, <span class="hlFld-ContribAuthor ">A. C. F. M.  Ferreira</span>, <span class="hlFld-ContribAuthor ">C. A.-A. L.  da Silva</span>, <span class="hlFld-ContribAuthor ">M. H. C.  Gallottini</span>, <span class="hlFld-ContribAuthor ">M. T. B. R.  Santos</span>. </span><span class="cited-content_cbyCitation_article-title">Pressure pain threshold of masticatory muscles in children and adolescents with and without intellectual disability: a pilot study. </span><span class="cited-content_cbyCitation_journal-name">European Archives of Paediatric Dentistry</span><span> <strong>2021,</strong> <em>49 </em><a href="https://doi.org/10.1007/s40368-020-00593-z" title="DOI URL">https://doi.org/10.1007/s40368-020-00593-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40368-020-00593-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40368-020-00593-z%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Archives%2520of%2520Paediatric%2520Dentistry%26atitle%3DPressure%252Bpain%252Bthreshold%252Bof%252Bmasticatory%252Bmuscles%252Bin%252Bchildren%252Band%252Badolescents%252Bwith%252Band%252Bwithout%252Bintellectual%252Bdisability%25253A%252Ba%252Bpilot%252Bstudy%26aulast%3Dde%2BAra%25C3%25BAjo%2BVitor%26aufirst%3DC.%2BA.%26date%3D2021%26date%3D2021%26volume%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael R.  Kilbourn</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Diagnostic Radiopharmaceuticals: Design Options for Small‐Molecule Radiotracers. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-21. <a href="https://doi.org/10.1002/9781119500575.ch1" title="DOI URL">https://doi.org/10.1002/9781119500575.ch1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119500575.ch1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119500575.ch1%26sid%3Dliteratum%253Aachs%26atitle%3DTargeted%252BDiagnostic%252BRadiopharmaceuticals%25253A%252BDesign%252BOptions%252Bfor%252BSmall%2525E2%252580%252590Molecule%252BRadiotracers%26aulast%3DKilbourn%26aufirst%3DMichael%2BR.%26date%3D2020%26date%3D2021%26spage%3D1%26epage%3D21%26pub%3DWiley%26atitle%3DHandbook%252Bof%252BRadiopharmaceuticals%26aulast%3DScott%26aufirst%3DPeter%26date%3D2020%26date%3D2021%26volume%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Denise A.  Cobb</span>, <span class="hlFld-ContribAuthor ">Nathan A.  Smith</span>, <span class="hlFld-ContribAuthor ">Benson J.  Edagwa</span>, <span class="hlFld-ContribAuthor ">JoEllyn M.  McMillan</span>. </span><span class="cited-content_cbyCitation_article-title">Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Delivery</span><span> <strong>2020,</strong> <em>17 </em>
                                    (9)
                                     , 1227-1238. <a href="https://doi.org/10.1080/17425247.2020.1783233" title="DOI URL">https://doi.org/10.1080/17425247.2020.1783233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17425247.2020.1783233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17425247.2020.1783233%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Delivery%26atitle%3DLong-acting%252Bapproaches%252Bfor%252Bdelivery%252Bof%252Bantiretroviral%252Bdrugs%252Bfor%252Bprevention%252Band%252Btreatment%252Bof%252BHIV%25253A%252Ba%252Breview%252Bof%252Brecent%252Bresearch%26aulast%3DCobb%26aufirst%3DDenise%2BA.%26date%3D2020%26date%3D2020%26volume%3D17%26issue%3D9%26spage%3D1227%26epage%3D1238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Meng</span>, <span class="hlFld-ContribAuthor ">Yangyang  Ge</span>, <span class="hlFld-ContribAuthor ">Haiyan  Xing</span>, <span class="hlFld-ContribAuthor ">Hui  Wei</span>, <span class="hlFld-ContribAuthor ">Shilin  Xu</span>, <span class="hlFld-ContribAuthor ">Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Doudou  Yan</span>, <span class="hlFld-ContribAuthor ">Tao  Wen</span>, <span class="hlFld-ContribAuthor ">Min  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaocui  Fang</span>, <span class="hlFld-ContribAuthor ">Lilusi  Ma</span>, <span class="hlFld-ContribAuthor ">Yanlian  Yang</span>, <span class="hlFld-ContribAuthor ">Chen  Wang</span>, <span class="hlFld-ContribAuthor ">Jianxiang  Wang</span>, <span class="hlFld-ContribAuthor ">Haiyan  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Small</span><span> <strong>2020,</strong> <em>16 </em>
                                    (31)
                                     , 2001890. <a href="https://doi.org/10.1002/smll.202001890" title="DOI URL">https://doi.org/10.1002/smll.202001890</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/smll.202001890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fsmll.202001890%26sid%3Dliteratum%253Aachs%26jtitle%3DSmall%26atitle%3DSynthetic%252BCXCR4%252BAntagonistic%252BPeptide%252BAssembling%252Bwith%252BNanoscaled%252BMicelles%252BCombat%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DMeng%26aufirst%3DJie%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D31%26spage%3D2001890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reece G.  Kenny</span>, <span class="hlFld-ContribAuthor ">Ziga  Ude</span>, <span class="hlFld-ContribAuthor ">James R.  Docherty</span>, <span class="hlFld-ContribAuthor ">Celine J.  Marmion</span>. </span><span class="cited-content_cbyCitation_article-title">Vorinostat and Belinostat, hydroxamate-based anti-cancer agents, are nitric oxide donors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Inorganic Biochemistry</span><span> <strong>2020,</strong> <em>206 </em>, 110981. <a href="https://doi.org/10.1016/j.jinorgbio.2019.110981" title="DOI URL">https://doi.org/10.1016/j.jinorgbio.2019.110981</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jinorgbio.2019.110981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jinorgbio.2019.110981%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Inorganic%2520Biochemistry%26atitle%3DVorinostat%252Band%252BBelinostat%25252C%252Bhydroxamate-based%252Banti-cancer%252Bagents%25252C%252Bare%252Bnitric%252Boxide%252Bdonors%26aulast%3DKenny%26aufirst%3DReece%2BG.%26date%3D2020%26volume%3D206%26spage%3D110981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mojtaba  Abbasian</span>, <span class="hlFld-ContribAuthor ">Parisa  Hasanzadeh</span>, <span class="hlFld-ContribAuthor ">Farideh  Mahmoodzadeh</span>, <span class="hlFld-ContribAuthor ">Roya  Salehi</span>. </span><span class="cited-content_cbyCitation_article-title">Novel cationic cellulose-based nanocomposites for targeted delivery of methotrexate to breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Macromolecular Science, Part A</span><span> <strong>2020,</strong> <em>57 </em>
                                    (2)
                                     , 99-115. <a href="https://doi.org/10.1080/10601325.2019.1673174" title="DOI URL">https://doi.org/10.1080/10601325.2019.1673174</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10601325.2019.1673174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10601325.2019.1673174%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Macromolecular%2520Science%252C%2520Part%2520A%26atitle%3DNovel%252Bcationic%252Bcellulose-based%252Bnanocomposites%252Bfor%252Btargeted%252Bdelivery%252Bof%252Bmethotrexate%252Bto%252Bbreast%252Bcancer%252Bcells%26aulast%3DAbbasian%26aufirst%3DMojtaba%26date%3D2020%26date%3D2019%26volume%3D57%26issue%3D2%26spage%3D99%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaxuan  Chen</span>, <span class="hlFld-ContribAuthor ">Carolyn A.  Haller</span>, <span class="hlFld-ContribAuthor ">Finith E.  Jernigan</span>, <span class="hlFld-ContribAuthor ">Steffi K.  Koerner</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Wong</span>, <span class="hlFld-ContribAuthor ">Yiqiang  Wang</span>, <span class="hlFld-ContribAuthor ">Jae Eun  Cheong</span>, <span class="hlFld-ContribAuthor ">Revanth  Kosaraju</span>, <span class="hlFld-ContribAuthor ">Julian  Kwan</span>, <span class="hlFld-ContribAuthor ">Diane D.  Park</span>, <span class="hlFld-ContribAuthor ">Beena  Thomas</span>, <span class="hlFld-ContribAuthor ">Swati  Bhasin</span>, <span class="hlFld-ContribAuthor ">Roberto C.  De La Rosa</span>, <span class="hlFld-ContribAuthor ">Alykhan M.  Premji</span>, <span class="hlFld-ContribAuthor ">Liying  Liu</span>, <span class="hlFld-ContribAuthor ">Eden  Park</span>, <span class="hlFld-ContribAuthor ">Alan C.  Moss</span>, <span class="hlFld-ContribAuthor ">Andrew  Emili</span>, <span class="hlFld-ContribAuthor ">Manoj  Bhasin</span>, <span class="hlFld-ContribAuthor ">Lijun  Sun</span>, <span class="hlFld-ContribAuthor ">Elliot L.  Chaikof</span>. </span><span class="cited-content_cbyCitation_article-title">Modulation of lymphocyte-mediated tissue repair by rational design of heterocyclic aryl hydrocarbon receptor agonists. </span><span class="cited-content_cbyCitation_journal-name">Science Advances</span><span> <strong>2020,</strong> <em>6 </em>
                                    (3)
                                     , eaay8230. <a href="https://doi.org/10.1126/sciadv.aay8230" title="DOI URL">https://doi.org/10.1126/sciadv.aay8230</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/sciadv.aay8230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fsciadv.aay8230%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Advances%26atitle%3DModulation%252Bof%252Blymphocyte-mediated%252Btissue%252Brepair%252Bby%252Brational%252Bdesign%252Bof%252Bheterocyclic%252Baryl%252Bhydrocarbon%252Breceptor%252Bagonists%26aulast%3DChen%26aufirst%3DJiaxuan%26date%3D2020%26date%3D2020%26volume%3D6%26issue%3D3%26spage%3Deaay8230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yordan  Yordanov</span>. </span><span class="cited-content_cbyCitation_article-title">Caffeic acid phenethyl ester (CAPE): cornerstone pharmacological studies and drug delivery systems. </span><span class="cited-content_cbyCitation_journal-name">Pharmacia</span><span> <strong>2019,</strong> <em>66 </em>
                                    (4)
                                     , 223-231. <a href="https://doi.org/10.3897/pharmacia.66.e38571" title="DOI URL">https://doi.org/10.3897/pharmacia.66.e38571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3897/pharmacia.66.e38571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3897%2Fpharmacia.66.e38571%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacia%26atitle%3DCaffeic%252Bacid%252Bphenethyl%252Bester%252B%252528CAPE%252529%25253A%252Bcornerstone%252Bpharmacological%252Bstudies%252Band%252Bdrug%252Bdelivery%252Bsystems%26aulast%3DYordanov%26aufirst%3DYordan%26date%3D2019%26date%3D2019%26volume%3D66%26issue%3D4%26spage%3D223%26epage%3D231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martine  Keenan</span>, <span class="hlFld-ContribAuthor ">Eric  Chatelain</span>. </span><span class="cited-content_cbyCitation_article-title">Designing Drugs to Target
              Trypanosoma cruzi
              , the Etiological Agent of Chagas Disease: When Chemistry needs Biology. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 93-113. <a href="https://doi.org/10.1002/9783527808656.ch4" title="DOI URL">https://doi.org/10.1002/9783527808656.ch4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527808656.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527808656.ch4%26sid%3Dliteratum%253Aachs%26atitle%3DDesigning%252BDrugs%252Bto%252BTarget%252BTrypanosoma%252Bcruzi%252B%25252C%252Bthe%252BEtiological%252BAgent%252Bof%252BChagas%252BDisease%25253A%252BWhen%252BChemistry%252Bneeds%252BBiology%26aulast%3DKeenan%26aufirst%3DMartine%26date%3D2019%26date%3D2019%26spage%3D93%26epage%3D113%26pub%3DWiley%26atitle%3DNeglected%252BTropical%252BDiseases%26aulast%3DSwinney%26aufirst%3DDavid%26date%3D2019%26date%3D2019%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Clément  Ghiazza</span>, <span class="hlFld-ContribAuthor ">Thierry  Billard</span>, <span class="hlFld-ContribAuthor ">Callum  Dickson</span>, <span class="hlFld-ContribAuthor ">Anis  Tlili</span>, <span class="hlFld-ContribAuthor ">Christian M.  Gampe</span>. </span><span class="cited-content_cbyCitation_article-title">Chalcogen OCF
              3
              Isosteres Modulate Drug Properties without Introducing Inherent Liabilities. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2019,</strong> <em>14 </em>
                                    (17)
                                     , 1586-1589. <a href="https://doi.org/10.1002/cmdc.201900452" title="DOI URL">https://doi.org/10.1002/cmdc.201900452</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900452%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DChalcogen%252BOCF%252B3%252BIsosteres%252BModulate%252BDrug%252BProperties%252Bwithout%252BIntroducing%252BInherent%252BLiabilities%26aulast%3DGhiazza%26aufirst%3DCl%25C3%25A9ment%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D17%26spage%3D1586%26epage%3D1589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael B.  Lowinger</span>, <span class="hlFld-ContribAuthor ">James D.  Ormes</span>, <span class="hlFld-ContribAuthor ">Yongchao  Su</span>, <span class="hlFld-ContribAuthor ">James H.  Small</span>, <span class="hlFld-ContribAuthor ">Robert O.  Williams</span>, <span class="hlFld-ContribAuthor ">Feng  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">How broadly can poly(urethane)-based implants be applied to drugs of varied properties?. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Pharmaceutics</span><span> <strong>2019,</strong> <em>568 </em>, 118550. <a href="https://doi.org/10.1016/j.ijpharm.2019.118550" title="DOI URL">https://doi.org/10.1016/j.ijpharm.2019.118550</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpharm.2019.118550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpharm.2019.118550%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Pharmaceutics%26atitle%3DHow%252Bbroadly%252Bcan%252Bpoly%252528urethane%252529-based%252Bimplants%252Bbe%252Bapplied%252Bto%252Bdrugs%252Bof%252Bvaried%252Bproperties%25253F%26aulast%3DLowinger%26aufirst%3DMichael%2BB.%26date%3D2019%26volume%3D568%26spage%3D118550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark P.  Grillo</span>, <span class="hlFld-ContribAuthor ">John C. L.  Erve</span>, <span class="hlFld-ContribAuthor ">Ryan  Dick</span>, <span class="hlFld-ContribAuthor ">James P.  Driscoll</span>, <span class="hlFld-ContribAuthor ">Nicole  Haste</span>, <span class="hlFld-ContribAuthor ">Svetlana  Markova</span>, <span class="hlFld-ContribAuthor ">Priscilla  Brun</span>, <span class="hlFld-ContribAuthor ">Timothy J.  Carlson</span>, <span class="hlFld-ContribAuthor ">Marc  Evanchik</span>. </span><span class="cited-content_cbyCitation_article-title">In vitro
              and
              in vivo
              pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. </span><span class="cited-content_cbyCitation_journal-name">Xenobiotica</span><span> <strong>2019,</strong> <em>49 </em>
                                    (6)
                                     , 718-733. <a href="https://doi.org/10.1080/00498254.2018.1495856" title="DOI URL">https://doi.org/10.1080/00498254.2018.1495856</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00498254.2018.1495856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00498254.2018.1495856%26sid%3Dliteratum%253Aachs%26jtitle%3DXenobiotica%26atitle%3DIn%252Bvitro%252Band%252Bin%252Bvivo%252Bpharmacokinetic%252Bcharacterization%252Bof%252Bmavacamten%25252C%252Ba%252Bfirst-in-class%252Bsmall%252Bmolecule%252Ballosteric%252Bmodulator%252Bof%252Bbeta%252Bcardiac%252Bmyosin%26aulast%3DGrillo%26aufirst%3DMark%2BP.%26date%3D2019%26date%3D2018%26volume%3D49%26issue%3D6%26spage%3D718%26epage%3D733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Veera C. S. R.  Chittepu</span>, <span class="hlFld-ContribAuthor ">Poonam  Kalhotra</span>, <span class="hlFld-ContribAuthor ">Tzayhri  Osorio-Gallardo</span>, <span class="hlFld-ContribAuthor ">Tzayhri  Gallardo-Velázquez</span>, <span class="hlFld-ContribAuthor ">Guillermo  Osorio-Revilla</span>. </span><span class="cited-content_cbyCitation_article-title">Repurposing of FDA-Approved NSAIDs for DPP-4 Inhibition as an Alternative for Diabetes Mellitus Treatment: Computational and in Vitro Study. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2019,</strong> <em>11 </em>
                                    (5)
                                     , 238. <a href="https://doi.org/10.3390/pharmaceutics11050238" title="DOI URL">https://doi.org/10.3390/pharmaceutics11050238</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics11050238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics11050238%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DRepurposing%252Bof%252BFDA-Approved%252BNSAIDs%252Bfor%252BDPP-4%252BInhibition%252Bas%252Ban%252BAlternative%252Bfor%252BDiabetes%252BMellitus%252BTreatment%25253A%252BComputational%252Band%252Bin%252BVitro%252BStudy%26aulast%3DChittepu%26aufirst%3DVeera%2BC.%2BS.%2BR.%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D5%26spage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabio  Broccatelli</span>, <span class="hlFld-ContribAuthor ">Cornelis  E.C.A Hop</span>, <span class="hlFld-ContribAuthor ">Matthew  Wright</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies to optimize drug half-life in lead candidate identification. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2019,</strong> <em>14 </em>
                                    (3)
                                     , 221-230. <a href="https://doi.org/10.1080/17460441.2019.1569625" title="DOI URL">https://doi.org/10.1080/17460441.2019.1569625</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2019.1569625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2019.1569625%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DStrategies%252Bto%252Boptimize%252Bdrug%252Bhalf-life%252Bin%252Blead%252Bcandidate%252Bidentification%26aulast%3DBroccatelli%26aufirst%3DFabio%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D3%26spage%3D221%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of dosing schedule in animal experiments on compound progression decisions. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2019,</strong> <em>24 </em>
                                    (2)
                                     , 371-376. <a href="https://doi.org/10.1016/j.drudis.2018.11.006" title="DOI URL">https://doi.org/10.1016/j.drudis.2018.11.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2018.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2018.11.006%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DImpact%252Bof%252Bdosing%252Bschedule%252Bin%252Banimal%252Bexperiments%252Bon%252Bcompound%252Bprogression%252Bdecisions%26aulast%3DChen%26aufirst%3DChao%26date%3D2019%26volume%3D24%26issue%3D2%26spage%3D371%26epage%3D376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaoyi  Sun</span>, <span class="hlFld-ContribAuthor ">Jianmin  Fu</span>. </span><span class="cited-content_cbyCitation_article-title">Methyl-containing pharmaceuticals: Methylation in drug design. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (20)
                                     , 3283-3289. <a href="https://doi.org/10.1016/j.bmcl.2018.09.016" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.09.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.09.016%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMethyl-containing%252Bpharmaceuticals%25253A%252BMethylation%252Bin%252Bdrug%252Bdesign%26aulast%3DSun%26aufirst%3DShaoyi%26date%3D2018%26volume%3D28%26issue%3D20%26spage%3D3283%26epage%3D3289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amro K. F.  Dyab</span>, <span class="hlFld-ContribAuthor ">Mohamed A.  Mohamed</span>, <span class="hlFld-ContribAuthor ">Noha M.  Meligi</span>, <span class="hlFld-ContribAuthor ">Shaaban K.  Mohamed</span>. </span><span class="cited-content_cbyCitation_article-title">Encapsulation of erythromycin and bacitracin antibiotics into natural sporopollenin microcapsules: antibacterial, cytotoxicity,
              in vitro
              and
              in vivo
              release studies for enhanced bioavailability. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (58)
                                     , 33432-33444. <a href="https://doi.org/10.1039/C8RA05499A" title="DOI URL">https://doi.org/10.1039/C8RA05499A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA05499A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA05499A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DEncapsulation%252Bof%252Berythromycin%252Band%252Bbacitracin%252Bantibiotics%252Binto%252Bnatural%252Bsporopollenin%252Bmicrocapsules%25253A%252Bantibacterial%25252C%252Bcytotoxicity%25252C%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252Brelease%252Bstudies%252Bfor%252Benhanced%252Bbioavailability%26aulast%3DDyab%26aufirst%3DAmro%2BK.%2BF.%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D58%26spage%3D33432%26epage%3D33444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Basic characteristics of a one compartment PK model. Panel A illustrates the model structure shown with first order absorption and elimination rates. Panels b and c illustrate the characteristic exponential decline following iv bolus administrations. Panels d and e illustrate the absorptive phase followed by monoexponential decline that is typical following oral administration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Semigeneralized relationships of the extent of steady-state accumulation (A) and peak-to-trough concentration ratio (B) (plotted as log <i>P</i>/<i>T</i><sub>ss</sub> values) to half-life-to-dose interval ratio (<i>t</i><sub>1/2</sub>/Tau). Relationships were simulated using the corresponding <i>R</i>(<i>t</i>) and <i>P</i>/<i>T</i><sub>ss</sub> equations in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and assuming an absorption rate of 1.8/h. (A) Accumulation (as calculated as the ratio of AUC at steady state to AUC following a single dose) increases as the <i>t</i><sub>1/2</sub> becomes a smaller fraction of the target dose interval. (B) While the steady-state average concentration is constant, <i>P</i>/<i>T</i><sub>ss</sub> increases exponentially as <i>t</i><sub>1/2</sub> becomes a smaller fraction of the target dose interval.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Semigeneralized relationship between average pharmacodynamics effect (expressed as a fraction of maximal) and half-life-to-dose interval ratio (<i>t</i><sub>1/2</sub>/Tau). Relationship was simulated using the <i>C</i>(<i>t</i>)<sub>ss</sub> equation of <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> assuming a <i>k</i><sub>a</sub> of 1.8/h. Simulations depict four dosing levels designed to deliver <i>C</i><sub>avg,ss</sub> values equivalent to arbitrarily selected EC<sub>20</sub>, EC<sub>50</sub>, EC<sub>80</sub>, and EC<sub>90</sub> values. Actual average effect was calculated as the dose interval normalized AUC under an effect curve defined by (100 × <i>C</i>(<i>t</i>)<sub>ss</sub>)/(<i>C</i>(<i>t</i>)<sub>ss</sub> + EC<sub>50</sub>). Volume was varied in order to affect <i>t</i><sub>1/2</sub>/Tau while maintaining a constant C<sub>avg,ss</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plasma concentration versus time curve for a compound following escalating oral administration exhibiting dose-dependent (nonlinear) PK due to saturation of clearance with increasing dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Basic characteristics of a two-compartment PK model. Panel a illustrates the model structure shown with first-order rates of absorption, elimination, and distribution. Panel b illustrates the characteristic biexponential decline in plasma concentrations following iv bolus administration. β is the elimination rate constant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PK of UK-224,671 in human following single intravenous administration of 0.1 mg/kg: (a) overall PK profile; (b) isolated initial phase profile; (c) isolated terminal phase profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/medium/jm-2017-00969y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of benoxaprofen and acylglucuronidation metabolite. Oxidative metabolism is likely to be very low due the chlorine substituent and oxidazole ring leading to acylglucuronidation as the major clearance pathway.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b00969/20180517/images/large/jm-2017-00969y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00969&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17411" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17411" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Volume of Distribution in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5691</span>– <span class="NLM_lpage">5698</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Volume+of+Distribution+in+Drug+Design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0libah9Z-jYzmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DVolume%2520of%2520Distribution%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northam, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alway, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, O. S.</span></span> <span> </span><span class="NLM_article-title">Blood levels of drug at the equilibrium state after multiple dosing</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>207</i></span>,  <span class="NLM_fpage">1301</span>– <span class="NLM_lpage">1302</span>, <span class="refDoi"> DOI: 10.1038/2071301a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1038%2F2071301a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=5884654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A280%3ADyaF287ksVSntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=1965&pages=1301-1302&author=J.+G.+Wagnerauthor=J.+I.+Northamauthor=C.+D.+Alwayauthor=O.+S.+Carpenter&title=Blood+levels+of+drug+at+the+equilibrium+state+after+multiple+dosing&doi=10.1038%2F2071301a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Blood levels of drug at the equilibrium state after multiple dosing</span></div><div class="casAuthors">Wagner J G; Northam J I; Alway C D; Carpenter O S</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">207</span>
        (<span class="NLM_cas:issue">5003</span>),
    <span class="NLM_cas:pages">1301-2</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkXM4pbz4uL8uCWE5mhx1RfW6udTcc2eb8rffKS9mUC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaF287ksVSntQ%253D%253D&md5=de878fcb3ee5b632be74a12d50dfcfa7</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F2071301a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F2071301a0%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DJ.%2BG.%26aulast%3DNortham%26aufirst%3DJ.%2BI.%26aulast%3DAlway%26aufirst%3DC.%2BD.%26aulast%3DCarpenter%26aufirst%3DO.%2BS.%26atitle%3DBlood%2520levels%2520of%2520drug%2520at%2520the%2520equilibrium%2520state%2520after%2520multiple%2520dosing%26jtitle%3DNature%26date%3D1965%26volume%3D207%26spage%3D1301%26epage%3D1302%26doi%3D10.1038%2F2071301a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. H.</span></span> <span> </span><span class="NLM_article-title">Bisphosphonates: A review of their pharmacokinetic properties</span>. <i>Bone (N. Y.)</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/8756-3282(95)00445-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1016%2F8756-3282%2895%2900445-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=8833200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaK28XisVGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1996&pages=75-85&author=J.+H.+Lin&title=Bisphosphonates%3A+A+review+of+their+pharmacokinetic+properties&doi=10.1016%2F8756-3282%2895%2900445-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Bisphosphonates: A review of their pharmacokinetic properties</span></div><div class="casAuthors">Lin, J. H.</div><div class="citationInfo"><span class="NLM_cas:title">Bone (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">75-85</span>CODEN:
                <span class="NLM_cas:coden">BONEDL</span>;
        ISSN:<span class="NLM_cas:issn">8756-3282</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 96 refs.  Bisphosphonates are a unique class of drugs.  As a family, they are characterized pharmacol. by their ability to inhibit bone resorption, whereas, pharmacokinetically, they are classified by their similarity in absorption, distribution, and elimination.  Although all bisphosphonates have similar physicochem. properties, their antiresorbing activities differ substantially.  Activity is dramatically increased when the amino group is contained in the aliph. carbon chain.  For example, alendronate, an aminobisphosphonate, is approx. 700-fold more potent than etidronate, both in vitro and in vivo.  In general, bisphosphonates are poorly absorbed from the gastrointestinal tract as a result of their poor lipophilicity.  In vitro and in vivo studies have shown that bisphosphonates are absorbed from the gastrointestinal tract via paracellular transport.  Systemically available bisphosphonates disappear very rapidly from plasma, and are partly taken up by the bone and partly excreted by the kidney.  The relative contribution of these two processes to overall plasma elimination differs significantly among bisphosphonates.  To date, all bisphosphonates studied show no evidence of metab.  Renal excretion is the only route of elimination.  Studies with alendronate in rats indicate that the drug is actively secreted by an uncharacterized renal transport system, and not by the anionic or cationic renal transport systems.  Bisphosphonates bind preferentially to bones which have high turnover rates, and their distribution in bone is not homogeneous.  After bone uptake, the bisphosphonates are liberated again only when the bone in which they are deposited is resorbed.  Thus, the half-life of bisphosphonates in bone is very long, ranging among different species from 1 to 10 yr, depending largely on the rate of bone turnover.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO9vCF_MXhDLVg90H21EOLACvtfcHk0lgSxQDADBQggg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XisVGjs7g%253D&md5=db0515b258923cf8c4819ff24ae94162</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2F8756-3282%2895%2900445-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F8756-3282%252895%252900445-9%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BH.%26atitle%3DBisphosphonates%253A%2520A%2520review%2520of%2520their%2520pharmacokinetic%2520properties%26jtitle%3DBone%2520%2528N.%2520Y.%2529%26date%3D1996%26volume%3D18%26spage%3D75%26epage%3D85%26doi%3D10.1016%2F8756-3282%2895%2900445-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadpour, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhlaghi, F.</span></span> <span> </span><span class="NLM_article-title">Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.1007/s40262-013-0071-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1007%2Fs40262-013-0071-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=23658137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=615-626&author=A.+H.+Mohammadpourauthor=F.+Akhlaghi&title=Future+of+Cholesteryl+Ester+Transfer+Protein+%28CETP%29+Inhibitors%3A+A+Pharmacological+Perspective&doi=10.1007%2Fs40262-013-0071-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective</span></div><div class="casAuthors">Mohammadpour, Amir Hooshang; Akhlaghi, Fatemeh</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">615-626</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  In almost 30 years since the introduction of HMG-CoA reductase inhibitors (statins), no other class of lipid modulators has entered the market.  Elevation of high-d. lipoprotein-cholesterol (HDL-C) via inhibiting cholesteryl ester transfer protein (CETP) is an attractive strategy for reducing the risk of cardiovascular events in high-risk patients.  Transfer of triglyceride and cholesteryl ester (CE) between lipoproteins is mediated by CETP; thus inhibition of this pathway can increase the concn. of HDL-C.  Torcetrapib was the first CETP inhibitor evaluated in phase III clin. trials.  Because of off-target effects, torcetrapib raised blood pressure and increased the concn. of serum aldosterone, leading to higher cardiovascular events and mortality.  Torcetrapib showed pos. effects on cardiovascular risk esp. in patients with a greater increase in HDL-C and apolipoprotein A-1 (apoA-1) levels.  The phase III clin. trial of dalcetrapib, the second CETP inhibitor that has entered clin. development, was terminated because of ineffectiveness.  Dalcetrapib is a CETP modulator that elevated HDL-C levels but did not reduce the concn. of low-d. lipoprotein cholesterol (LDL-C).  Both heterotypic and homotypic CE transfer between lipoproteins are mediated by some CETP inhibitors, including torcetrapib, anacetrapib, and evacetrapib, while dalcetrapib only affects the heterotypic CE transfer.  Dalcetrapib has a chem. structure that is distinct from other CETP inhibitors, with a smaller mol. wt. and a lack of trifluoride moieties.  Moreover, dalcetrapib is a pro-drug that must be hydrolyzed to a pharmacol. active thiol form.  Two other CETP inhibitors, anacetrapib and evacetrapib, are currently undergoing evaluation in phase III clin. trials.  Both mols. have shown beneficial effects by increasing HDL-C and decreasing LDL-C concn.  The success of anacetrapib and evacetrapib remains to be confirmed upon the completion of phase III clin. trials in 2017 and 2015, resp.  Generally, the concn. of HDL-C has been considered a biomarker for the activity of CETP inhibitors.  However, it is not clear whether a fundamental relationship exists between HDL-C levels and the risk of coronary artery diseases.  The most crucial role for HDL is cholesterol efflux capacity in which HDL can reverse transport cholesterol from foam cells in atherosclerotic plaques.  In view of the heterogeneity in HDL particle size, charge, and compn., the mere concn. of HDL-C may not be a good surrogate marker for HDL functionality.  Recent clin. studies have reported that increased HDL functionality inversely correlates with the development of atherosclerotic plaque.  Future development of CETP inhibitors may therefore benefit from the use of biomarkers of HDL functionality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooWA0RhZp_JLVg90H21EOLACvtfcHk0lgSxQDADBQggg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7vL&md5=d80f7ec7c020c674bf66c6c8856ab345</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs40262-013-0071-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-013-0071-8%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadpour%26aufirst%3DA.%2BH.%26aulast%3DAkhlaghi%26aufirst%3DF.%26atitle%3DFuture%2520of%2520Cholesteryl%2520Ester%2520Transfer%2520Protein%2520%2528CETP%2529%2520Inhibitors%253A%2520A%2520Pharmacological%2520Perspective%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2013%26volume%3D52%26spage%3D615%26epage%3D626%26doi%3D10.1007%2Fs40262-013-0071-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gheyas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lederman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez-Eng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, K.</span></span> <span> </span><span class="NLM_article-title">Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.067736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1124%2Fdmd.115.067736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=26712818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A280%3ADC%252BC28rlsVSlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=428-434&author=G.+Hartmannauthor=S.+Kumarauthor=D.+Johnsauthor=F.+Gheyasauthor=D.+Gutsteinauthor=X.+Shenauthor=A.+Burtonauthor=H.+Ledermanauthor=R.+Lutzauthor=T.+Jacksonauthor=C.+Chavez-Engauthor=K.+Mitra&title=Disposition+into+Adipose+Tissue+Determines+Accumulation+and+Elimination+Kinetics+of+the+Cholesteryl+Ester+Transfer+Protein+Inhibitor+Anacetrapib+in+Mice&doi=10.1124%2Fdmd.115.067736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice</span></div><div class="casAuthors">Hartmann Georgy; Kumar Sanjeev; Johns Douglas; Gheyas Ferdous; Gutstein David; Shen Xiaolan; Burton Aimee; Lederman Harmony; Lutz Ryan; Jackson Tonya; Chavez-Eng Cynthia; Mitra Kaushik</div><div class="citationInfo"><span class="NLM_cas:title">Drug metabolism and disposition: the biological fate of chemicals</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">428-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibits a long terminal half-life (t1/2) in humans; however, the dispositional mechanisms that lead to this long t1/2 are still being elucidated.  As it is hypothesized that disposition into adipose tissue and binding to CETP might play a role, we sought to delineate the relative importance of these factors using a preclinical animal model.  A multiple-dose pharmacokinetic study was conducted in C57BL6 wild-type (WT) lean, WT diet-induced obese (DIO), natural flanking region (NFR) CETP-transgenic lean, and NFR-DIO mice.  Mice were dosed orally with 10 mg/kg anacetrapib daily for 42 days.  Drug concentrations in blood, brown and white adipose tissue, liver, and brain were measured up to 35 weeks postdose.  During dosing, a 3- to 9-fold accumulation in 72-hour postdose blood concentrations of anacetrapib was observed.  Drug concentrations in white adipose tissue accumulated ∼20- to 40-fold, whereas 10- to 17-fold accumulation occurred in brown adipose and approximately 4-fold in liver.  Brain levels were very low (<0.1 μM), and a trend of accumulation was not seen.  The presence of CETP as well as adiposity seems to play a role in determining the blood concentrations of anacetrapib.  The highest blood concentrations were observed in NFR DIO mice, whereas the lowest concentrations were seen in WT lean mice.  In adipose and liver tissue, higher concentrations were seen in DIO mice, irrespective of the presence of CETP.  This finding suggests that white adipose tissue serves as a potential depot and that disposition into adipose tissue governs the long-term kinetics of anacetrapib in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvolMVAlekEd1QT_1O5WBYfW6udTcc2eZ7sq7j_E4RJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rlsVSlsw%253D%253D&md5=889e0108f486863be71af1807c6e4f40</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.067736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.067736%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DJohns%26aufirst%3DD.%26aulast%3DGheyas%26aufirst%3DF.%26aulast%3DGutstein%26aufirst%3DD.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DBurton%26aufirst%3DA.%26aulast%3DLederman%26aufirst%3DH.%26aulast%3DLutz%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DT.%26aulast%3DChavez-Eng%26aufirst%3DC.%26aulast%3DMitra%26aufirst%3DK.%26atitle%3DDisposition%2520into%2520Adipose%2520Tissue%2520Determines%2520Accumulation%2520and%2520Elimination%2520Kinetics%2520of%2520the%2520Cholesteryl%2520Ester%2520Transfer%2520Protein%2520Inhibitor%2520Anacetrapib%2520in%2520Mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26spage%3D428%26epage%3D434%26doi%3D10.1124%2Fdmd.115.067736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holt, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storey, G. C.</span></span> <span> </span><span class="NLM_article-title">Amiodarone pharmacokinetics</span>. <i>Am. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">840</span>– <span class="NLM_lpage">847</span>, <span class="refDoi"> DOI: 10.1016/0002-8703(83)90006-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1016%2F0002-8703%2883%2990006-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=1983&pages=840-847&author=D.+W.+Holtauthor=G.+T.+Tuckerauthor=P.+R.+Jacksonauthor=G.+C.+Storey&title=Amiodarone+pharmacokinetics&doi=10.1016%2F0002-8703%2883%2990006-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2F0002-8703%2883%2990006-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-8703%252883%252990006-6%26sid%3Dliteratum%253Aachs%26aulast%3DHolt%26aufirst%3DD.%2BW.%26aulast%3DTucker%26aufirst%3DG.%2BT.%26aulast%3DJackson%26aufirst%3DP.%2BR.%26aulast%3DStorey%26aufirst%3DG.%2BC.%26atitle%3DAmiodarone%2520pharmacokinetics%26jtitle%3DAm.%2520Heart%2520J.%26date%3D1983%26volume%3D106%26spage%3D840%26epage%3D847%26doi%3D10.1016%2F0002-8703%2883%2990006-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plomp, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rossum, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robles de Medina, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Lier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, R. A. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and body distribution of amiodarone in man</span>. <i>Arzneim. Forsch.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">520</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=6540111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL2cXktFKktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1984&pages=513-520&author=T.+A.+Plompauthor=J.+M.+Van+Rossumauthor=E.+O.+Robles+de+Medinaauthor=T.+Van+Lierauthor=R.+A.+A.+Maes&title=Pharmacokinetics+and+body+distribution+of+amiodarone+in+man"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and body distribution of amiodarone in man</span></div><div class="casAuthors">Plomp, T. A.; Van Rossum, J. M.; Robles de Medina, E. O.; Van Lier, T.; Maes, R. A. A.</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">513-20</span>CODEN:
                <span class="NLM_cas:coden">ARZNAD</span>;
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    </div><div class="casAbstract">The concns. of amiodarone  [1951-25-3] and desethylamiodarone  [83409-32-9] in plasma after single oral and i.v. and long-term oral dosing were detd. in normal subjects and patients with various cardiac arrhythmias, resp.  The decline in amiodarone plasma concn. after a single i.v. 400 mg dose was described by a triexponential decay equation, with a mean terminal half-life (t1/2) of 34.5 h.  Mean values for clearance and apparent vol. of distribution were 14.7 L/h and 376 L.  Following single oral doses of 400 mg, amiodarone plasma concn. time data were fitted in a triexponential function.  The mean terminal half-life for amiodarone after oral dosage was 31.6 h.  Amiodarone peak concns. of 0.37 μg/mL were attained in 4.8 h.  The bioavailability of oral amiodarone was only 31%, in part due to 1st-pass metab.  Desethylamiodarone, the major metabolite of amiodarone, was present in plasma in very low levels of about 10 ng/mL in several volunteers after single i.v. or oral administration of amiodarone.  The mean plasma amiodarone and desethylamiodarone levels in patients (mean oral daily maintenance dosage of 440 mg for a mean period of 9.1 mo) were 1.85 μg/mL and 1.35 μg/mL, resp.  The mean elimination t1/2 of amiodarone and desethylamiodarone after discontinuation of therapy in 4 patients on long-term amiodarone treatment were 40 days and 57 days, resp.  Amiodarone and desethylamiodarone were neither detectable in urine samples of the normal subjects after single i.v. and oral administration of the drug nor in the urine of several patients on long-term oral amiodarone treatment.  There was extensive tissue accumulation of amiodarone and desethylamiodarone with particularly high levels in adipose tissue, lung, and liver and relatively lower concns. in other organs such as heart, kidney and thyroid gland.  With exception of fat, in all tissues studied the levels of the metabolite were substantially higher than those of the parent compd., probably due to differences in physicochem. properties of both drugs.  During long-term oral therapy the mean amiodarone and desethylamiodarone plasma concns. were several times higher than the values predicted from the single dose studies.  These changes may be explained by redn. in presystemic metab. of amiodarone and the possibly reduced clearances of both drugs during long-term oral use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2-gc-kQo6m7Vg90H21EOLACvtfcHk0lgs-LzUjEuGwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXktFKktLk%253D&md5=0f6bf736a1dd5fc0fea3c35bb22a35e1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPlomp%26aufirst%3DT.%2BA.%26aulast%3DVan%2BRossum%26aufirst%3DJ.%2BM.%26aulast%3DRobles%2Bde%2BMedina%26aufirst%3DE.%2BO.%26aulast%3DVan%2BLier%26aufirst%3DT.%26aulast%3DMaes%26aufirst%3DR.%2BA.%2BA.%26atitle%3DPharmacokinetics%2520and%2520body%2520distribution%2520of%2520amiodarone%2520in%2520man%26jtitle%3DArzneim.%2520Forsch.%26date%3D1984%26volume%3D34%26spage%3D513%26epage%3D520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastasiou-Nana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulopoulos, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of amiodarone after intravenous and oral administration</span>. <i>Int. J. Clin. Pharmacol. Ther. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">524</span>– <span class="NLM_lpage">529</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=7174155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A280%3ADyaL3s%252FotFKktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1982&pages=524-529&author=M.+Anastasiou-Nanaauthor=G.+M.+Levisauthor=S.+Moulopoulos&title=Pharmacokinetics+of+amiodarone+after+intravenous+and+oral+administration"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of amiodarone after intravenous and oral administration</span></div><div class="casAuthors">Anastasiou-Nana M; Levis G M; Moulopoulos S</div><div class="citationInfo"><span class="NLM_cas:title">International journal of clinical pharmacology, therapy, and toxicology</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">524-9</span>
        ISSN:<span class="NLM_cas:issn">0174-4879</span>.
    </div><div class="casAbstract">Pharmacokinetic studies were conducted in four subjects who received 150 mg amiodarone i.v., in nine subjects who received 200 or 400 mg amiodarone p.o., and in four subjects who received the drug by both routes of administration.  Amiodarone concentrations were determined by high pressure liquid chromatography.  Aminodarone levels after i.v. administration, with one exception, declined biphasically according to a two-compartment model.  The decline appeared to be monophasic after p.o. administration with one exception.  Plasma levels after p.o. administration varied considerably between subjects.  The biologic half-life after p.o. administration (mean 17.1 h +/- S.D.) was higher than that calculated for the second phase after i.v. administration (mean 4.3 h +/- 0.98 S.D.).  Total clearance rate during the second phase was within the range 125-288 ml/min after i.v. and 114-473 ml/min after p.o. administration.  The apparent volume of distribution in the central compartment after i.v. administration was found to be about 17.0 l and that calculated for the second elimination phase, 77 l, possibly indicating a concentration of the drug in the tissues.  The systemic availability of amiodarone varied from 23 to 50% as determined on the basis of of the ratios of areas under p.o. and i.v. serum concentration curves for four subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTPlkdhywOliBJ5E29YNGvQfW6udTcc2eYTrX1NhHRC8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s%252FotFKktQ%253D%253D&md5=09ba0e2cab61433aa86b10e6d3e1042b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAnastasiou-Nana%26aufirst%3DM.%26aulast%3DLevis%26aufirst%3DG.%2BM.%26aulast%3DMoulopoulos%26aufirst%3DS.%26atitle%3DPharmacokinetics%2520of%2520amiodarone%2520after%2520intravenous%2520and%2520oral%2520administration%26jtitle%3DInt.%2520J.%2520Clin.%2520Pharmacol.%2520Ther.%2520Toxicol.%26date%3D1982%26volume%3D20%26spage%3D524%26epage%3D529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Latini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kates, R. E.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics of amiodarone</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.2165/00003088-198409020-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.2165%2F00003088-198409020-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=6370540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL2cXktVSjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1984&pages=136-156&author=R.+Latiniauthor=G.+Tognoniauthor=R.+E.+Kates&title=Clinical+pharmacokinetics+of+amiodarone&doi=10.2165%2F00003088-198409020-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of amiodarone</span></div><div class="casAuthors">Latini, Roberto; Tognoni, Gianni; Kates, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">136-56</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    </div><div class="casAbstract">A review with ∼75 refs. on the pharmacokinetics of amiodarone (I)  [1951-25-3] in humans and lab. animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6VR8HBvsdVrVg90H21EOLACvtfcHk0lgs-LzUjEuGwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXktVSjs7Y%253D&md5=6cd8c312dedc9f69429b2eabcea8e865</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2165%2F00003088-198409020-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-198409020-00002%26sid%3Dliteratum%253Aachs%26aulast%3DLatini%26aufirst%3DR.%26aulast%3DTognoni%26aufirst%3DG.%26aulast%3DKates%26aufirst%3DR.%2BE.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520amiodarone%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1984%26volume%3D9%26spage%3D136%26epage%3D156%26doi%3D10.2165%2F00003088-198409020-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kannan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B. N.</span></span> <span> </span><span class="NLM_article-title">Tissue uptake and metabolism of amiodarone after chronic administration in rabbits</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">650</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1985&pages=646-650&author=R.+Kannanauthor=S.+Millerauthor=B.+N.+Singh&title=Tissue+uptake+and+metabolism+of+amiodarone+after+chronic+administration+in+rabbits"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKannan%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DB.%2BN.%26atitle%3DTissue%2520uptake%2520and%2520metabolism%2520of%2520amiodarone%2520after%2520chronic%2520administration%2520in%2520rabbits%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1985%26volume%3D13%26spage%3D646%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span> <span> </span><span class="NLM_article-title">The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1038/nrd3287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1038%2Fnrd3287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=21119731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=929-939&author=D.+A.+Smithauthor=L.+Diauthor=E.+H.+Kerns&title=The+effect+of+plasma+protein+binding+on+in+vivo+efficacy%3A+misconceptions+in+drug+discovery&doi=10.1038%2Fnrd3287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery</span></div><div class="casAuthors">Smith, Dennis A.; Di, Li; Kerns, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">929-939</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Data from in vitro plasma protein binding expts. that det. the fraction of protein-bound drug are frequently used in drug discovery to guide structure design and to prioritize compds. for in vivo studies.  However, we consider that these practices are usually misleading, because in vivo efficacy is detd. by the free (unbound) drug concn. surrounding the therapeutic target, not by the free drug fraction.  These practices yield no enhancement of the in vivo free drug concn.  So, decisions based on free drug fraction could result in the wrong compds. being advanced through drug discovery programs.  This Perspective provides guidance on the application of plasma protein binding information in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOa3ippodhGbVg90H21EOLACvtfcHk0lgs-LzUjEuGwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI&md5=a45d00f68ab44580fa38a6acef49493a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd3287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3287%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DThe%2520effect%2520of%2520plasma%2520protein%2520binding%2520on%2520in%2520vivo%2520efficacy%253A%2520misconceptions%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D929%26epage%3D939%26doi%3D10.1038%2Fnrd3287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E. C. A.</span></span> <span> </span><span class="NLM_article-title">Rational Use of Plasma Protein and Tissue Binding Data in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8238</span>– <span class="NLM_lpage">8248</span>, <span class="refDoi"> DOI: 10.1021/jm5007935</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5007935" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8238-8248&author=X.+Liuauthor=M.+Wrightauthor=C.+E.+C.+A.+Hop&title=Rational+Use+of+Plasma+Protein+and+Tissue+Binding+Data+in+Drug+Design&doi=10.1021%2Fjm5007935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Use of Plasma Protein and Tissue Binding Data in Drug Design</span></div><div class="casAuthors">Liu, Xingrong; Wright, Matthew; Hop, Cornelis E. C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8238-8248</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is a commonly accepted assumption that only unbound drug mols. are available to interact with their targets.  Therefore, one of the objectives in drug design is to optimize the compd. structure to increase in vivo unbound drug concn.  In this review, theor. analyses and exptl. observations are presented to illustrate that low plasma protein binding does not necessarily lead to high in vivo unbound plasma concn.  Similarly, low brain tissue binding does not lead to high in vivo unbound brain tissue concn.  Instead, low intrinsic clearance leads to high in vivo unbound plasma concn., and low efflux transport activity at the blood-brain barrier leads to high unbound brain concn.  Plasma protein and brain tissue binding are very important parameters in understanding pharmacokinetics, pharmacodynamics, and toxicities of drugs, but these parameters should not be targeted for optimization in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKiYUz9ljIDrVg90H21EOLACvtfcHk0lg4qaiOFNDuBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M&md5=53ffbdb88ddf500a90a0eee14b0e641f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm5007935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5007935%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DHop%26aufirst%3DC.%2BE.%2BC.%2BA.%26atitle%3DRational%2520Use%2520of%2520Plasma%2520Protein%2520and%2520Tissue%2520Binding%2520Data%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8238%26epage%3D8248%26doi%3D10.1021%2Fjm5007935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span> <span> </span><span class="NLM_article-title">Modified-Release Drug Products and Drug Devices</span> In  <i>Applied Biopharmaceutics and Pharmacokinetics</i>, <span class="NLM_edition">7</span>th ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Shargel, L.</span>, <span class="NLM_string-name">Yu, A. B. C.</span></span>, Eds.; <span class="NLM_publisher-name">McGraw-Hill Education</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2016</span>; pp  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">613</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=567-613&author=H.+Dingauthor=L.+Shargel&author=A.+B.+C.+Yu&title=Applied+Biopharmaceutics+and+Pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%26atitle%3DModified-Release%2520Drug%2520Products%2520and%2520Drug%2520Devices%26btitle%3DApplied%2520Biopharmaceutics%2520and%2520Pharmacokinetics%26aulast%3DShargel%26aufirst%3DL.%26pub%3DMcGraw-Hill%2520Education%26date%3D2016%26spage%3D567%26epage%3D613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ummadi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shravani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, N. G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, B. S.</span></span> <span> </span><span class="NLM_article-title">Overview on Controlled Release Dosage Form</span>. <i>International Journal of Pharma Sciences</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">258</span>– <span class="NLM_lpage">269</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=258-269&author=S.+Ummadiauthor=B.+Shravaniauthor=N.+G.+R.+Raoauthor=M.+S.+Reddyauthor=B.+S.+Nayak&title=Overview+on+Controlled+Release+Dosage+Form"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUmmadi%26aufirst%3DS.%26aulast%3DShravani%26aufirst%3DB.%26aulast%3DRao%26aufirst%3DN.%2BG.%2BR.%26aulast%3DReddy%26aufirst%3DM.%2BS.%26aulast%3DNayak%26aufirst%3DB.%2BS.%26atitle%3DOverview%2520on%2520Controlled%2520Release%2520Dosage%2520Form%26jtitle%3DInternational%2520Journal%2520of%2520Pharma%2520Sciences%26date%3D2013%26volume%3D3%26spage%3D258%26epage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banweer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span> <span> </span><span class="NLM_article-title">Osmotically controlled drug delivery system with associated drugs</span>. <i>J. Pharm. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">571</span>– <span class="NLM_lpage">588</span>, <span class="refDoi"> DOI: 10.18433/J38W25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.18433%2FJ38W25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=21486532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2qtr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=571-588&author=B.+P.+Guptaauthor=N.+Thakurauthor=N.+P.+Jainauthor=J.+Banweerauthor=S.+Jain&title=Osmotically+controlled+drug+delivery+system+with+associated+drugs&doi=10.18433%2FJ38W25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Osmotically controlled drug delivery system with associated drugs</span></div><div class="casAuthors">Gupta, Brahma P.; Thakur, Navneet; Jain, Nishi P.; Banweer, Jitendra; Jain, Surendra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy & Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">571-588</span>CODEN:
                <span class="NLM_cas:coden">JPPSFY</span>;
        ISSN:<span class="NLM_cas:issn">1482-1826</span>.
    
            (<span class="NLM_cas:orgname">Canadian Society for Pharmaceutical Sciences</span>)
        </div><div class="casAbstract">A review.  Conventional drug delivery systems have slight control over their drug release and almost no control over the effective concn. at the target site.  This kind of dosing pattern may result in constantly changing, unpredictable plasma concns.  Drugs can be delivered in a controlled pattern over a long period of time by the controlled or modified release drug delivery systems.  They include dosage forms for oral and transdermal administration as well as injectable and implantable systems.  For most of drugs, oral route remains as the most acceptable route of administration.  Certain mols. may have low oral bioavailability because of soly. or permeability limitations.  Development of an extended release dosage form also requires reasonable absorption throughout the gastro-intestinal tract (GIT).  Among the available techniques to improve the bioavailability of these drugs fabrication of osmotic drug delivery system is the most appropriate one.  Osmotic drug delivery systems release the drug with the zero order kinetics which does not depend on the initial concn. and the physiol. factors of GIT.  This review brings out new technologies, fabrication and recent clin. research in osmotic drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-y8WkGKkGnbVg90H21EOLACvtfcHk0lg4qaiOFNDuBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2qtr%252FJ&md5=1faf14c2bcc9eebaca3f2788eb53ddca</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.18433%2FJ38W25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18433%252FJ38W25%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DB.%2BP.%26aulast%3DThakur%26aufirst%3DN.%26aulast%3DJain%26aufirst%3DN.%2BP.%26aulast%3DBanweer%26aufirst%3DJ.%26aulast%3DJain%26aufirst%3DS.%26atitle%3DOsmotically%2520controlled%2520drug%2520delivery%2520system%2520with%2520associated%2520drugs%26jtitle%3DJ.%2520Pharm.%2520Pharm.%2520Sci.%26date%3D2010%26volume%3D13%26spage%3D571%26epage%3D588%26doi%3D10.18433%2FJ38W25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keraliya, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keraliya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soni, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. M.</span></span> <span> </span><span class="NLM_article-title">Osmotic drug delivery system as a part of modified release dosage form</span>. <i>ISRN Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">528079</span>, (9 pp) <span class="refDoi"> DOI: 10.5402/2012/528079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.5402%2F2012%2F528079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=22852100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A280%3ADC%252BC38fpsl2msw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=528079&author=R.+A.+Keraliyaauthor=C.+Patelauthor=P.+Patelauthor=V.+Keraliyaauthor=T.+G.+Soniauthor=R.+C.+Patelauthor=M.+M.+Patel&title=Osmotic+drug+delivery+system+as+a+part+of+modified+release+dosage+form&doi=10.5402%2F2012%2F528079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Osmotic drug delivery system as a part of modified release dosage form</span></div><div class="casAuthors">Keraliya Rajesh A; Patel Chirag; Patel Pranav; Keraliya Vipul; Soni Tejal G; Patel Rajnikant C; Patel M M</div><div class="citationInfo"><span class="NLM_cas:title">ISRN pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">528079</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Conventional drug delivery systems are known to provide an immediate release of drug, in which one can not control the release of the drug and can not maintain effective concentration at the target site for longer time.  Controlled drug delivery systems offer spatial control over the drug release.  Osmotic pumps are most promising systems for controlled drug delivery.  These systems are used for both oral administration and implantation.  Osmotic pumps consist of an inner core containing drug and osmogens, coated with a semipermeable membrane.  As the core absorbs water, it expands in volume, which pushes the drug solution out through the delivery ports.  Osmotic pumps release drug at a rate that is independent of the pH and hydrodynamics of the dissolution medium.  The historical development of osmotic systems includes development of the Rose-Nelson pump, the Higuchi-Leeper pumps, the Alzet and Osmet systems, the elementary osmotic pump, and the push-pull system.  Recent advances include development of the controlled porosity osmotic pump, and systems based on asymmetric membranes.  This paper highlights the principle of osmosis, materials used for fabrication of pumps, types of pumps, advantages, disadvantages, and marketed products of this system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHnpGf4gD5z2K_SFaaT9INfW6udTcc2eaMc1LeUDDo97ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fpsl2msw%253D%253D&md5=f26ff28b7730985addb7d2315de87b2c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.5402%2F2012%2F528079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5402%252F2012%252F528079%26sid%3Dliteratum%253Aachs%26aulast%3DKeraliya%26aufirst%3DR.%2BA.%26aulast%3DPatel%26aufirst%3DC.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DKeraliya%26aufirst%3DV.%26aulast%3DSoni%26aufirst%3DT.%2BG.%26aulast%3DPatel%26aufirst%3DR.%2BC.%26aulast%3DPatel%26aufirst%3DM.%2BM.%26atitle%3DOsmotic%2520drug%2520delivery%2520system%2520as%2520a%2520part%2520of%2520modified%2520release%2520dosage%2520form%26jtitle%3DISRN%2520Pharm.%26date%3D2012%26volume%3D2012%26spage%3D528079%26doi%3D10.5402%2F2012%2F528079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGibney, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chasseaud, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, I. W.</span></span> <span> </span><span class="NLM_article-title">The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.1986.tb02874.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1111%2Fj.1365-2125.1986.tb02874.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=2943308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL28Xlt1Kkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1986&pages=21-5&author=J.+K.+Faulknerauthor=D.+McGibneyauthor=L.+F.+Chasseaudauthor=J.+L.+Perryauthor=I.+W.+Taylor&title=The+pharmacokinetics+of+amlodipine+in+healthy+volunteers+after+single+intravenous+and+oral+doses+and+after+14+repeated+oral+doses+given+once+daily&doi=10.1111%2Fj.1365-2125.1986.tb02874.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily</span></div><div class="casAuthors">Faulkner, J. K.; McGibney, D.; Chasseaud, L. F.; Perry, J. L.; Taylor, I. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-5</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">I.v. administration of amlodipine (I)  [88150-42-9] (single dose, 10 mg) to 12 volunteers gave a mean plasma half-life of 34 h, mean clearance of 7 mL/min/kg and a mean apparent vol. of distribution of 21 L/kg.  Oral administration (single dose, 10 mg) to the same 12 volunteers gave a mean systemic availability of 64% and a mean plasma half-life of 36 h.  In a 2nd study, repeated oral administration (once daily for 14 days, 15 mg) to 28 volunteers resulted in steady state plasma drug concn. being reached after 7 doses, an accumulation of approx. 3-fold and a mean half-life of 45 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEO2GPnr6jVbVg90H21EOLACvtfcHk0ljUZ37caqoDvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xlt1Kkt7Y%253D&md5=ca5af419408e45b4e4eb16a34297129f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.1986.tb02874.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.1986.tb02874.x%26sid%3Dliteratum%253Aachs%26aulast%3DFaulkner%26aufirst%3DJ.%2BK.%26aulast%3DMcGibney%26aufirst%3DD.%26aulast%3DChasseaud%26aufirst%3DL.%2BF.%26aulast%3DPerry%26aufirst%3DJ.%2BL.%26aulast%3DTaylor%26aufirst%3DI.%2BW.%26atitle%3DThe%2520pharmacokinetics%2520of%2520amlodipine%2520in%2520healthy%2520volunteers%2520after%2520single%2520intravenous%2520and%2520oral%2520doses%2520and%2520after%252014%2520repeated%2520oral%2520doses%2520given%2520once%2520daily%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1986%26volume%3D22%26spage%3D21%26epage%3D5%26doi%3D10.1111%2Fj.1365-2125.1986.tb02874.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abernethy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. B.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of calcium antagonists under development</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.2165/00003088-198815010-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.2165%2F00003088-198815010-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=3042243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL1cXlt1Wrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1988&pages=1-14&author=D.+R.+Abernethyauthor=J.+B.+Schwartz&title=Pharmacokinetics+of+calcium+antagonists+under+development&doi=10.2165%2F00003088-198815010-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of calcium antagonists under development</span></div><div class="casAuthors">Abernethy, Darrell R.; Schwartz, Janice B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-14</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    </div><div class="casAbstract">A review with 67 refs. examg. the pharmacokinetics of the type-I Ca2+ antagonist tiapamil and those of the type II drugs amlodipine, felodipine, isradipine, nicardipine, nilvadipine, nimodipine, nisoldipine, and nitrendipine in healthy humans and those with hepatic, renal, or other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLU1Tf6sPJ07Vg90H21EOLACvtfcHk0ljUZ37caqoDvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXlt1Wrt78%253D&md5=8648d78bde7bec42ebf40822ed68a378</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2165%2F00003088-198815010-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-198815010-00001%26sid%3Dliteratum%253Aachs%26aulast%3DAbernethy%26aufirst%3DD.%2BR.%26aulast%3DSchwartz%26aufirst%3DJ.%2BB.%26atitle%3DPharmacokinetics%2520of%2520calcium%2520antagonists%2520under%2520development%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1988%26volume%3D15%26spage%3D1%26epage%3D14%26doi%3D10.2165%2F00003088-198815010-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piascik, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, R. G.,  Jr</span></span> <span> </span><span class="NLM_article-title">Aspects of the clinical pharmacology of nifedipine, a dihydropyridine calcium-entry antagonist</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1002/bdd.2510070102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1002%2Fbdd.2510070102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=3513860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL28XhsVWmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1986&pages=1-10&author=S.+R.+Hamannauthor=M.+T.+Piascikauthor=R.+G.+McAllister&title=Aspects+of+the+clinical+pharmacology+of+nifedipine%2C+a+dihydropyridine+calcium-entry+antagonist&doi=10.1002%2Fbdd.2510070102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Aspects of the clinical pharmacology of nifedipine, a dihydropyridine calcium-entry antagonist</span></div><div class="casAuthors">Hamann, Scott R.; Piascik, Michael T.; McAllister, R. G., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    </div><div class="casAbstract">A review with 36 refs. on the clin. pharmacol. and pharmacokinetics of nifedipine  [21829-25-4].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPOu0DSht3fbVg90H21EOLACvtfcHk0ljUZ37caqoDvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhsVWmt7g%253D&md5=deb359fa601e03cc8df5f51240c69626</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2510070102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2510070102%26sid%3Dliteratum%253Aachs%26aulast%3DHamann%26aufirst%3DS.%2BR.%26aulast%3DPiascik%26aufirst%3DM.%2BT.%26aulast%3DMcAllister%26aufirst%3DR.%2BG.%26atitle%3DAspects%2520of%2520the%2520clinical%2520pharmacology%2520of%2520nifedipine%252C%2520a%2520dihydropyridine%2520calcium-entry%2520antagonist%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D1986%26volume%3D7%26spage%3D1%26epage%3D10%26doi%3D10.1002%2Fbdd.2510070102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N. J.</span></span> <span> </span><span class="NLM_article-title">Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1385</span>– <span class="NLM_lpage">1405</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.020479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1124%2Fdmd.108.020479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=18426954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVensr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1385-1405&author=R.+S.+Obachauthor=F.+Lombardoauthor=N.+J.+Waters&title=Trend+analysis+of+a+database+of+intravenous+pharmacokinetic+parameters+in+humans+for+670+drug+compounds&doi=10.1124%2Fdmd.108.020479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds</span></div><div class="casAuthors">Obach, R. Scott; Lombardo, Franco; Waters, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1385-1405</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We present herein a compilation and trend anal. of human i.v. pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clin. pharmacokinetic data.  This data set provides the drug metab. scientist with a robust and accurate resource suitable for a no. of applications, including in silico modeling, in vitro-in vivo scaling, and physiol. based pharmacokinetic approaches.  Clearance, vol. of distribution at steady state, mean residence time, and terminal phase half-life were obtained or derived from original refs. exclusively from studies utilizing i.v. administration.  Plasma protein binding data were collected from other sources to supplement these pharmacokinetic data.  These parameters were analyzed concurrently with a range of simple physicochem. descriptors, and resultant trends and patterns within the data are presented.  Our findings with this much expanded data set were consistent with earlier described notions of trends between physicochem. properties and pharmacokinetic behavior.  These observations and analyses, along with the large database of human pharmacokinetic data, should enable future efforts aimed toward developing quant. structure-pharmacokinetic relationships and improving our understanding of the relationship between fundamental chem. characteristics and drug disposition.  0.95 1.6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9WuEgpgbrarVg90H21EOLACvtfcHk0lgy7LgQ1RTGVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVensr0%253D&md5=c438c6791817201452cc3e1d6172b6bb</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.020479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.020479%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DWaters%26aufirst%3DN.%2BJ.%26atitle%3DTrend%2520analysis%2520of%2520a%2520database%2520of%2520intravenous%2520pharmacokinetic%2520parameters%2520in%2520humans%2520for%2520670%2520drug%2520compounds%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1385%26epage%3D1405%26doi%3D10.1124%2Fdmd.108.020479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, R. T.</span></span> <span> </span><span class="NLM_article-title">The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.2165/00003088-199630010-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.2165%2F00003088-199630010-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=8846626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaK28XhsFWnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1996&pages=28-51&author=J.+S.+Grundyauthor=R.+T.+Foster&title=The+nifedipine+gastrointestinal+therapeutic+system+%28GITS%29.+Evaluation+of+pharmaceutical%2C+pharmacokinetic+and+pharmacological+properties&doi=10.2165%2F00003088-199630010-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties</span></div><div class="casAuthors">Grundy, John S.; Foster, Robert T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-51</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review, with 131 refs.  Nifedipine is a short-acting calcium antagonist formulated into several different oral prepns., each of which offers a distinct drug release profile.  Of these, the nifedipine gastrointestinal therapeutic system (GITS) affords (rate)-controlled-release (CR) and once-daily administration.  Specific topics discussed in this review were: the rationale for development and marketing of the nifedipine gastrointestinal therapeutic system; formulation design; pharmacokinetic and dosage considerations; pharmacol. effects; and treatment compliance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbtE0WAeKs27Vg90H21EOLACvtfcHk0lgy7LgQ1RTGVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhsFWnu70%253D&md5=b3308d0f9fd486e5a78de3670e8a153d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2165%2F00003088-199630010-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199630010-00003%26sid%3Dliteratum%253Aachs%26aulast%3DGrundy%26aufirst%3DJ.%2BS.%26aulast%3DFoster%26aufirst%3DR.%2BT.%26atitle%3DThe%2520nifedipine%2520gastrointestinal%2520therapeutic%2520system%2520%2528GITS%2529.%2520Evaluation%2520of%2520pharmaceutical%252C%2520pharmacokinetic%2520and%2520pharmacological%2520properties%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1996%26volume%3D30%26spage%3D28%26epage%3D51%26doi%3D10.2165%2F00003088-199630010-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, J. I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, T. C.</span></span> <span> </span><span class="NLM_article-title">Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1362</span>– <span class="NLM_lpage">1371</span>, <span class="refDoi"> DOI: 10.1002/jcph.734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1002%2Fjcph.734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=26970526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Wkur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=1362-1371&author=M.+Lambaauthor=R.+Wangauthor=T.+Fletcherauthor=C.+Alveyauthor=J.+I.+V.+Kushnerauthor=T.+C.+Stock&title=Extended-Release+Once-Daily+Formulation+of+Tofacitinib%3A+Evaluation+of+Pharmacokinetics+Compared+With+Immediate-Release+Tofacitinib+and+Impact+of+Food&doi=10.1002%2Fjcph.734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food</span></div><div class="casAuthors">Lamba, Manisha; Wang, Rong; Fletcher, Tracey; Alvey, Christine; Kushner, Joseph, IV; Stock, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1362-1371</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.  An extended-release (XR) formulation has been designed to provide a once-daily (QD) dosing option to patients to achieve comparable pharmacokinetic (PK) parameters to the twice-daily immediate-release (IR) formulation.  We conducted 2 randomized, open-label, phase 1 studies in healthy volunteers.  Study A characterized single-dose and steady-state PK of tofacitinib XR 11 mg QD and intended to demonstrate equivalence of exposure under single-dose and steady-state conditions to tofacitinib IR 5 mg twice daily.  Study B assessed the effect of a high-fat meal on the bioavailability of tofacitinib from the XR formulation.  Safety and tolerability were monitored in both studies.  In study A (N = 24), the XR and IR formulations achieved time to max. plasma concn. at 4 h and 0.5 h postdose, resp.; terminal half-life was 5.9 h and 3.2 h, resp.  Area under plasma concn.-time curve (AUC) and max. plasma concn. (Cmax) after single- and multiple-dose administration were equiv. between the XR and IR formulations.  In study B (N = 24), no difference in AUC was obsd. for fed vs fasted conditions.  Cmax increased by 27% under the fed state.  On repeat administration, negligible accumulation (<20%) of systemic exposures was obsd. for both formulations.  Steady state was achieved within 48 h of dosing with the XR formulation.  Tofacitinib administration as an XR or IR formulation was generally well tolerated in these studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotnOLKAQOsybVg90H21EOLACvtfcHk0lgy7LgQ1RTGVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Wkur3L&md5=bb46ee17ae48cec6a8fbed7840ce02d9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fjcph.734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.734%26sid%3Dliteratum%253Aachs%26aulast%3DLamba%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DFletcher%26aufirst%3DT.%26aulast%3DAlvey%26aufirst%3DC.%26aulast%3DKushner%26aufirst%3DJ.%2BI.%2BV.%26aulast%3DStock%26aufirst%3DT.%2BC.%26atitle%3DExtended-Release%2520Once-Daily%2520Formulation%2520of%2520Tofacitinib%253A%2520Evaluation%2520of%2520Pharmacokinetics%2520Compared%2520With%2520Immediate-Release%2520Tofacitinib%2520and%2520Impact%2520of%2520Food%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D56%26spage%3D1362%26epage%3D1371%26doi%3D10.1002%2Fjcph.734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutmacher, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furst, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikranian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduaka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span> <span> </span><span class="NLM_article-title">Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib</span>. <i>Clin. Pharmacol. Ther. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1002/cpt.576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1002%2Fcpt.576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=27859030" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2017&pages=745-753&author=M.+Lambaauthor=M.+M.+Hutmacherauthor=D.+E.+Furstauthor=A.+Dikranianauthor=M.+E.+Dowtyauthor=D.+Conradoauthor=T.+Stockauthor=C.+Nduakaauthor=J.+Cookauthor=S.+Krishnaswami&title=Model-Informed+Development+and+Registration+of+a+Once-Daily+Regimen+of+Extended-Release+Tofacitinib&doi=10.1002%2Fcpt.576"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcpt.576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.576%26sid%3Dliteratum%253Aachs%26aulast%3DLamba%26aufirst%3DM.%26aulast%3DHutmacher%26aufirst%3DM.%2BM.%26aulast%3DFurst%26aufirst%3DD.%2BE.%26aulast%3DDikranian%26aufirst%3DA.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DConrado%26aufirst%3DD.%26aulast%3DStock%26aufirst%3DT.%26aulast%3DNduaka%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DKrishnaswami%26aufirst%3DS.%26atitle%3DModel-Informed%2520Development%2520and%2520Registration%2520of%2520a%2520Once-Daily%2520Regimen%2520of%2520Extended-Release%2520Tofacitinib%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2017%26volume%3D101%26spage%3D745%26epage%3D753%26doi%3D10.1002%2Fcpt.576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dack, K.</span></span> <span> </span><span class="NLM_article-title">Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.2174/1389200033489253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.2174%2F1389200033489253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=14683475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpslShtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=461-485&author=K.+Beaumontauthor=R.+Websterauthor=I.+Gardnerauthor=K.+Dack&title=Design+of+ester+prodrugs+to+enhance+oral+absorption+of+poorly+permeable+compounds%3A+Challenges+to+the+discovery+scientist&doi=10.2174%2F1389200033489253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist</span></div><div class="casAuthors">Beaumont, Kevin; Webster, Robert; Gardner, Iain; Dack, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">461-485</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review and discussion.  Many drugs are administered at sites that are remote from their site of action.  The most common route of drug delivery is the oral route.  The optimal physicochem. properties to allow high transcellular absorption following oral administration are well established and include a limit on mol. size, hydrogen bonding potential and adequate lipophilicity.  For many drug targets, synthetic strategies can be devised to balance the physicochem. properties required for high transcellular absorption and the SAR for the drug target.  However, there are drug targets where the SAR requires properties at odds with good membrane permeability.  These include a requirement for significant polarity and groups that exhibit high hydrogen bonding potential such as carboxylic acids and alcs.  In such cases, prodrug strategies have been employed.  The rationale behind the prodrug strategy is to introduce lipophilicity and mask hydrogen bonding groups of an active compd. by the addn. of another moiety, most commonly an ester.  An ideal ester prodrug should exhibit the following properties:.  (1) Weak (or no) activity against any pharmacol. target,.  (2) Chem. stability across a pH range,.  (3) High aq. soly.,.  (4) Good transcellular absorption,.  (5) Resistance to hydrolysis during the absorption phase,.  (6) Rapid and quant. breakdown to yield high circulating concns. of the active component post absorption.  This paper will review the literature around marketed prodrugs and det. the most appropriate prodrug characteristics.  In addn., it will examine potential discovery approaches to optimizing prodrug delivery and recommend a strategy for prosecuting an oral prodrug approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJklGnlqCIqbVg90H21EOLACvtfcHk0lglgVYZ4GiAxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpslShtLo%253D&md5=442e3b78efc2e601c688c03eeeaa6e54</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F1389200033489253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200033489253%26sid%3Dliteratum%253Aachs%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DDack%26aufirst%3DK.%26atitle%3DDesign%2520of%2520ester%2520prodrugs%2520to%2520enhance%2520oral%2520absorption%2520of%2520poorly%2520permeable%2520compounds%253A%2520Challenges%2520to%2520the%2520discovery%2520scientist%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2003%26volume%3D4%26spage%3D461%26epage%3D485%26doi%3D10.2174%2F1389200033489253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, G.</span></span> <span> </span><span class="NLM_article-title">Drug metabolite concentration-time profiles: influence of route of drug administration</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.1984.tb02362.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1111%2Fj.1365-2125.1984.tb02362.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=6721984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL2cXhvVGgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1984&pages=385-94&author=J.+B.+Houstonauthor=G.+Taylor&title=Drug+metabolite+concentration-time+profiles%3A+influence+of+route+of+drug+administration&doi=10.1111%2Fj.1365-2125.1984.tb02362.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Drug metabolite concentration-time profiles:  influence of route of drug administration</span></div><div class="casAuthors">Houston, J. B.; Taylor, G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">385-94</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">The influence of the route of drug administration on metabolite kinetics was investigated by computer simulation.  Comparisons between simulated profiles and published concn.-time data were carried out.  A route dependence in metabolite concn.-time curves is readily apparent provided that the metabolite kinetics are formation-rate limited and the hepatic clearance of drug is >25 L/h (medium to highly cleared).  Oral drug administration produces a triphasic metabolite concn.-time profile, whereas only 2 phases are discernable after i.v. drug administration.  The magnitude of the difference in max. metabolite concn. is directly proportional to the hepatic clearance of drug due to 1st-pass metabolite prodn.  The route dependence in the shape of the metabolite concn.-time curves is most dramatic when the absorption and distribution of drug and the elimination of metabolite is rapid.  A redn. in the rate of either of these processes alters the shape of the metabolite concn.-time profile such that the consequence of 1st-pass metabolite formation may be reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlVoh0NewQwbVg90H21EOLACvtfcHk0lglgVYZ4GiAxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXhvVGgs78%253D&md5=0209ac06cf0d153434903b8e9a2b0c09</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.1984.tb02362.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.1984.tb02362.x%26sid%3Dliteratum%253Aachs%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26aulast%3DTaylor%26aufirst%3DG.%26atitle%3DDrug%2520metabolite%2520concentration-time%2520profiles%253A%2520influence%2520of%2520route%2520of%2520drug%2520administration%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1984%26volume%3D17%26spage%3D385%26epage%3D94%26doi%3D10.1111%2Fj.1365-2125.1984.tb02362.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">The Operational Multiple Dosing Half-life: A Key to Defining Drug Accumulation in Patients and to Designing Extended Release Dosage Forms</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2869</span>– <span class="NLM_lpage">2877</span>, <span class="refDoi"> DOI: 10.1007/s11095-008-9787-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1007%2Fs11095-008-9787-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2008&pages=2869-2877&author=S.+Sahinauthor=L.+Z.+Benet&title=The+Operational+Multiple+Dosing+Half-life%3A+A+Key+to+Defining+Drug+Accumulation+in+Patients+and+to+Designing+Extended+Release+Dosage+Forms&doi=10.1007%2Fs11095-008-9787-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs11095-008-9787-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-008-9787-9%26sid%3Dliteratum%253Aachs%26aulast%3DSahin%26aufirst%3DS.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DThe%2520Operational%2520Multiple%2520Dosing%2520Half-life%253A%2520A%2520Key%2520to%2520Defining%2520Drug%2520Accumulation%2520in%2520Patients%2520and%2520to%2520Designing%2520Extended%2520Release%2520Dosage%2520Forms%26jtitle%3DPharm.%2520Res.%26date%3D2008%26volume%3D25%26spage%3D2869%26epage%3D2877%26doi%3D10.1007%2Fs11095-008-9787-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boxenbaum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battle, M.</span></span> <span> </span><span class="NLM_article-title">Effective half-life in clinical pharmacology</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">763</span>– <span class="NLM_lpage">766</span>, <span class="refDoi"> DOI: 10.1002/j.1552-4604.1995.tb04117.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1002%2Fj.1552-4604.1995.tb04117.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=8522631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaK2MXpsVaju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1995&pages=763-766&author=H.+Boxenbaumauthor=M.+Battle&title=Effective+half-life+in+clinical+pharmacology&doi=10.1002%2Fj.1552-4604.1995.tb04117.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Effective half-life in clinical pharmacology</span></div><div class="casAuthors">Boxenbaum, Harold; Battle, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">763-6</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">A commentary discussing effective half-life in simple math. terms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHvhmW6PGswrVg90H21EOLACvtfcHk0lglgVYZ4GiAxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpsVaju7k%253D&md5=33e8048bcc0487154567862ebed7169b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fj.1552-4604.1995.tb04117.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1552-4604.1995.tb04117.x%26sid%3Dliteratum%253Aachs%26aulast%3DBoxenbaum%26aufirst%3DH.%26aulast%3DBattle%26aufirst%3DM.%26atitle%3DEffective%2520half-life%2520in%2520clinical%2520pharmacology%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1995%26volume%3D35%26spage%3D763%26epage%3D766%26doi%3D10.1002%2Fj.1552-4604.1995.tb04117.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and metabolism of a sulphamide NK2 antagonist in rat, dog and human</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">642</span>, <span class="refDoi"> DOI: 10.1080/004982500406453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1080%2F004982500406453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10923864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvFCltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2000&pages=627-642&author=K.+Beaumontauthor=A.+Harperauthor=D.+A.+Smithauthor=S.+Abel&title=Pharmacokinetics+and+metabolism+of+a+sulphamide+NK2+antagonist+in+rat%2C+dog+and+human&doi=10.1080%2F004982500406453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and metabolism of a sulphamide NK2 antagonist in rat, dog and human</span></div><div class="casAuthors">Beaumont, K.; Harper, A.; Smith, D. A.; Abel, S.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">627-642</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">1. UK-224,671 is a sulfamide-contg. NK2 antagonist with moderate lipophilicity and basicity.  2. The physicochem. properties of UK-224,671 are reflected in its pharmacokinetics following i.v. administration.  The compd. partitioned extensively into red blood cells in all species examd. and the blood clearance was moderate to low with respect to liver blood flow and distribution into tissues was extensive.  3. UK-224,671 exhibited species differences in oral bioavailability.  In dog, the compd. exhibited moderate bioavailability (55%), whereas in rat and man oral bioavailability was < 10%.  4. In rat and dog, the major excreted form after i.v. administration was unchanged UK-224,671 in both urine and feces.  In addn., of three metabolites obsd., the most abundant was the N-descyclopropylmethyl (UK-280,045).  5. The profile of radioactivity in rat following oral administration of [14C]-UK-224,671 was not consistent with a 10% absorbed compd. with 40% of the dose present as metabolites.  This suggests that the low bioavailability of UK-224,671 in rat is due to a combination of moderate intestinal permeability and extensive first-pass metab. by the gut and does not result from poor gastrointestinal absorption per se.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpns74iTwf5PbVg90H21EOLACvtfcHk0lgE6gQ73lxjHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvFCltL4%253D&md5=5d6a03b5b2b7060be7e6c4c6fb0f1af0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1080%2F004982500406453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F004982500406453%26sid%3Dliteratum%253Aachs%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DHarper%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DAbel%26aufirst%3DS.%26atitle%3DPharmacokinetics%2520and%2520metabolism%2520of%2520a%2520sulphamide%2520NK2%2520antagonist%2520in%2520rat%252C%2520dog%2520and%2520human%26jtitle%3DXenobiotica%26date%3D2000%26volume%3D30%26spage%3D627%26epage%3D642%26doi%3D10.1080%2F004982500406453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nash, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridolfo, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spradlin, C. T.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetic and metabolic studies</span>. <i>J. Rheumatol., Suppl.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">19</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=6930483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL3cXlsVartLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1980&pages=12-19&author=J.+F.+Nashauthor=R.+H.+Carmichaelauthor=A.+S.+Ridolfoauthor=C.+T.+Spradlin&title=Pharmacokinetic+studies+of+benoxaprofen+after+therapeutic+doses+with+a+review+of+related+pharmacokinetic+and+metabolic+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetic and metabolic studies</span></div><div class="casAuthors">Nash, J. Frank; Carmichael, Ralph H.; Ridolfo, Anthony S.; Spradlin, C. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology, Supplement</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Proc. Int. Symp. Benoxaprofen, 1979</span>),
    <span class="NLM_cas:pages">12-19</span>CODEN:
                <span class="NLM_cas:coden">JRSUDX</span>;
        ISSN:<span class="NLM_cas:issn">0380-0903</span>.
    </div><div class="casAbstract">The pharmacokinetics of benoxaprofen (I)  [51234-28-7] in therapeutic doses of 400 or 600 mg as a soln., capsule or tablet were detd. in 44 men after single or multiple doses.  The plasma levels of the drug after oral administration of a soln. best fitted a 2-compartment open pharmacokinetic model, whereas the levels after the solid dosage forms more appropriately fitted the simple 1-compartment open model.  The plasma elimination half-life of the drug, when in solid dosage form, was in the range of 19-26 h, justifying once-a-day dosage.  Steady state levels of benoxaprofen were obtained after the 5th dose of a 400 mg capsule every 24 h.  A review of the related pharmacokinetic and metabolic studies is also given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreCo6wn6XChLVg90H21EOLACvtfcHk0lgE6gQ73lxjHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXlsVartLg%253D&md5=4421a99f3f7f9812cf4154caa7dd096c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNash%26aufirst%3DJ.%2BF.%26aulast%3DCarmichael%26aufirst%3DR.%2BH.%26aulast%3DRidolfo%26aufirst%3DA.%2BS.%26aulast%3DSpradlin%26aufirst%3DC.%2BT.%26atitle%3DPharmacokinetic%2520studies%2520of%2520benoxaprofen%2520after%2520therapeutic%2520doses%2520with%2520a%2520review%2520of%2520related%2520pharmacokinetic%2520and%2520metabolic%2520studies%26jtitle%3DJ.%2520Rheumatol.%252C%2520Suppl.%26date%3D1980%26volume%3D6%26spage%3D12%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halsey, J.
P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoe, N.</span></span> <span> </span><span class="NLM_article-title">Benoxaprofen: side-effect profile in 300 patients</span>. <i>Br. Med. J. (Clin. Res. Ed.)</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">1365</span>– <span class="NLM_lpage">1368</span>, <span class="refDoi"> DOI: 10.1136/bmj.284.6326.1365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.1136%2Fbmj.284.6326.1365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=6803978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A280%3ADyaL387otlGmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=1982&pages=1365-1368&author=J.%0AP.+Halseyauthor=N.+Cardoe&title=Benoxaprofen%3A+side-effect+profile+in+300+patients&doi=10.1136%2Fbmj.284.6326.1365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Benoxaprofen: side-effect profile in 300 patients</span></div><div class="casAuthors">Halsey J P; Cardoe N</div><div class="citationInfo"><span class="NLM_cas:title">British medical journal (Clinical research ed.)</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">6326</span>),
    <span class="NLM_cas:pages">1365-8</span>
        ISSN:<span class="NLM_cas:issn">0267-0623</span>.
    </div><div class="casAbstract">Out of 300 patients who had taken benoxaprofen for a mean of 6.4 months, 196 (65.3%) reported side effects, resulting in 104 patients (34.6%) having the drug withdrawn.  Out of 42 patients aged over 70, 35 (83.3%) had side effects and 29 (69.0%) had the drug withdrawn because of them. cutaneous side effects accounted for 180 (69.5%) of all 259 side effects reported.  The commonest cutaneous side effect was photosensitivity, which occurred in 86 patients (28.6%).  Photosensitivity, which occurred in half of the patients treated in the summer, resulted in withdrawal of benoxaprofen in 26 (30.2%) of the patients who experienced it.  Onycholysis was observed in 38 patients (12.6%) and was frequently unnoticed by patients.  The overall incidence of gastric side effects was 12.6% (38 patients), and the figure rose to 40.5% (17 cases) in patients over 70.  During treatment with benoxaprofen one patient developed an active duodenal ulcer but no cases of major gastrointestinal haemorrhage occurred.  Multiple subepidermal cysts (milia) were observed in 16 patients, who had been treated for a mean of 10.8 months.  These findings show that benoxaprofen is a potent phototoxic drug and that the manufacturers' recommended dosage of 600 mg daily is associated with an unacceptable incidence of side effects in the elderly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQv83-g_m4FW8rRqEXsZufAfW6udTcc2eZXb8Z3FrQ-vLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL387otlGmuw%253D%253D&md5=dbed090d696d9e4604e645aa69036bb2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1136%2Fbmj.284.6326.1365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.284.6326.1365%26sid%3Dliteratum%253Aachs%26aulast%3DHalsey%26aufirst%3DJ.%2BP.%26aulast%3DCardoe%26aufirst%3DN.%26atitle%3DBenoxaprofen%253A%2520side-effect%2520profile%2520in%2520300%2520patients%26jtitle%3DBr.%2520Med.%2520J.%2520%2528Clin.%2520Res.%2520Ed.%2529%26date%3D1982%26volume%3D284%26spage%3D1365%26epage%3D1368%26doi%3D10.1136%2Fbmj.284.6326.1365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murnane, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodcock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, I. M.</span></span> <span> </span><span class="NLM_article-title">The pharmacokinetics of benoxaprofen in elderly subjects</span>. <i>Eur. J. Rheumatol. Inflammation</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">75</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=7084284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=1%3ACAS%3A528%3ADyaL38Xktleju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1982&pages=69-75&author=R.+C.+Hamdyauthor=B.+Murnaneauthor=N.+Pereraauthor=K.+Woodcockauthor=I.+M.+Koch&title=The+pharmacokinetics+of+benoxaprofen+in+elderly+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacokinetics of benoxaprofen in elderly subjects</span></div><div class="casAuthors">Hamdy, R. C.; Murnane, B.; Perera, N.; Woodcock, K.; Koch, I. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Rheumatology and Inflammation</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-75</span>CODEN:
                <span class="NLM_cas:coden">EJRIDH</span>;
        ISSN:<span class="NLM_cas:issn">0140-1610</span>.
    </div><div class="casAbstract">benoxaprofen (I)  [51234-28-7] plasma profiles were obtained in 2 groups of elderly female patients.  A single dose of benoxaprofen, either 600 mg or 300 mg, was given and blood levels were measured daily up to 120 h.  Mean peak plasma levels were reached at 5 h following the 600-mg dose and at 7 h after the 300-mg dose.  Elimination half-lives calcd. from levels during 36-120 h resulted in means of 111 h and 86.4 h for the 600-mg and 300-mg doses, resp., whereas the elimination half-lives for younger subjects was 30-35 h.  Because of these extended half-lives, a further study was conducted following a single 600-mg dose to 4 more patients.  Blood levels were measured up to 504 h (21 days).  This resulted in a mean half-life of 147.9 h calcd. from levels during 168-504 h.  Although serum creatinine levels were not generally above the normal for this age group, calcd. creatinine clearances were considerably reduced.  Thus, the high plasma benoxaprofen levels achieved, combined with the slow clearance rates and long half-lives, indicate that it may be possible to administer benoxaprofen less frequently or at lower doses to elderly patients.  More work is needed to det. whether this prolonged half-life is matched by an equally prolonged therapeutic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRdUJcahrmBrVg90H21EOLACvtfcHk0lgE6gQ73lxjHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38Xktleju7g%253D&md5=df7a5412beff405fc8fe0a4109dc9a8e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamdy%26aufirst%3DR.%2BC.%26aulast%3DMurnane%26aufirst%3DB.%26aulast%3DPerera%26aufirst%3DN.%26aulast%3DWoodcock%26aufirst%3DK.%26aulast%3DKoch%26aufirst%3DI.%2BM.%26atitle%3DThe%2520pharmacokinetics%2520of%2520benoxaprofen%2520in%2520elderly%2520subjects%26jtitle%3DEur.%2520J.%2520Rheumatol.%2520Inflammation%26date%3D1982%26volume%3D5%26spage%3D69%26epage%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatfield, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. N.</span></span> <span> </span><span class="NLM_article-title">Disposition and metabolism of benoxaprofen in laboratory animals and man</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.3109/00498257809060392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;key=10.3109%2F00498257809060392" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1978&pages=133-144&author=D.+H.+Chatfieldauthor=J.+N.+Green&title=Disposition+and+metabolism+of+benoxaprofen+in+laboratory+animals+and+man&doi=10.3109%2F00498257809060392"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3109%2F00498257809060392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498257809060392%26sid%3Dliteratum%253Aachs%26aulast%3DChatfield%26aufirst%3DD.%2BH.%26aulast%3DGreen%26aufirst%3DJ.%2BN.%26atitle%3DDisposition%2520and%2520metabolism%2520of%2520benoxaprofen%2520in%2520laboratory%2520animals%2520and%2520man%26jtitle%3DXenobiotica%26date%3D1978%26volume%3D8%26spage%3D133%26epage%3D144%26doi%3D10.3109%2F00498257809060392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-10%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00969%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00969" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667987ae09abd932","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
